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Polymeric nanoparticles are small objects that are promising candidates for the delivery of drugs to 
subcellular compartments. Since nanomaterials contact biological systems in these biomedical 
applications, it is absolutely necessary to study their interplay with cellular components. The previous 
research on the nano-bio-interface already revealed a large number of diverse interactions (e. g. 
nanotoxicity, drug delivery mechanisms). In terms of drug delivery applications it is so far well 
accepted that a successful cellular delivery of drugs mainly depends on the nanoparticle uptake and a 
subsequent endosomal release of the cargo. Therefore, we examine (1) the drug delivery mechanism of 
biodegradable iron-containing poly-L-lactide nanoparticles (PLLA-Fe-PMI) and study (2) the uptake 
mechanisms and the intracellular trafficking pathways of nondegradable superparamagnetic iron oxide 
polystyrene nanoparticles (SPIOPSN).  
In this study, we identify an unknown and non-invasive drug delivery mechanism. We show that the 
successful subcellular delivery of nanoparticulate cargo does not necessarily depend on the 
internalization of nanomedicines. Our findings indicate that the release of nanoparticulate cargo is 
simply triggered by the physicochemical interaction of hydrophobic poly-L-lactide nanoparticles with 
a hydrophobic surface. In vitro, the membrane-mediated release of nanoparticulate cargo results in its 




 lipid droplets. The release mechanism (“kiss-and-run”) 
can be blocked by the covalent attachment of the nanoparticulate cargo molecule to the polymer, 
highlighting the importance of material properties in drug delivery applications.  
Further on, long-term studies reveal that an atypical macropinocytic mechanism mediates the uptake 
of PLLA-Fe-PMI and SPIOPSN. We characterize this pathway and identify several factors that 
influence the uptake of SPIOPSN. These include the small GTPases Rac1 and ARF1. Based on the 
gained knowledge about the portal of entry, we investigate the intracellular trafficking of the 
nanoparticles in more detail. Therefore, we dissect the intravesicular endolysosomal milieu of 
magnetically isolated SPIOPSN-containing vesicles by mass spectrometry. Intensive research on this 
project identifies markers of early endosomes, late endosomes/multivesicular bodies, Rab11
+
 
endosomes, flotillin vesicles, lysosomes and COP vesicles. Finally, we analyze the effect of the 
lysosomal milieu on the nanoparticulate protein corona. Here, it is shown that the nanoparticulate 





 lysosomes.  
These findings indicate that one has to reconsider the classical strategy of the invasive nanoparticulate 
drug delivery. Further on, the data show that polymeric nanoparticles underlie a macropinocytic-like 
uptake mechanism. This results in an intracellular trafficking of the investigated nanoparticles from 




VII. Deutsche Zusammenfassung 
Polymere Nanopartikel sind kleine Teilchen, die vielseitige Einsatzmöglichkeiten für den Transport 
von Wirkstoffen bieten. Da Nanomaterialien in diesen biomedizinischen Anwendungen oft mit 
biologischen Systemen in Berührung kommen, erfordert das eine genaue Untersuchung ihrer 
gegenseitigen Wechselwirkungen. In diesem speziellen Forschungsgebiet, welches sich auf die 
Interaktionen von Nanomaterialien mit biologischen Komponenten konzentriert, wurde bereits eine 
Vielzahl verschiedener Nanopartikel-Zell-Interaktionen (z. B. Nanotoxizität, Wirkstofftransport-
mechanismen) analysiert. Bezüglich der Untersuchungen zu nanopartikulären Wirkstofftransport-
mechanismen ist es im Allgemeinen akzeptiert, dass ein erfolgreicher zellulärer Transport 
hauptsächlich von der Aufnahme des Nanotransporters abhängt. Deshalb analysieren wir in dieser 
Arbeit (1) den Wirkstofftransportmechanismus für biologisch-abbaubare eisenhaltige Poly-L-
Milchsäure Nanopartikel (PLLA-Fe-PMI) sowie (2) die Aufnahmemechanismen und die 
intrazellulären Transportwege von nicht-abbaubaren superparamagnetischen Polystyrolnanopartikeln 
(SPIOPSN).  
In dieser Arbeit identifizieren wir einen bisher unbekannten und nicht-invasiven Wirkstoff-
transportmechanismus. Dabei zeigt diese Studie, dass der subzelluläre Transport der nanopartikulärer 
Fracht nicht unbedingt von einer Aufnahme der Nanotransporter abhängt. Der identifizierte 
Arzneimitteltransportmechanismus basiert auf einem einfachen physikochemischen Kontakt des 
hydrophoben Poly-L-Milchsäure-Nanopartikels mit einer hydrophoben Oberfläche, wodurch die 
Freisetzung der nanopartikulären Fracht ausgelöst wird. In Zellexperimenten führt die 





- Lipidtröpfchen. Der Freisetzungsmechanismus („kiss-and-run") kann durch die kovalente 
Einbindung des Frachtmoleküls in das Polymer des Nanopartikels blockiert werden. 
Weiterhin wird in Langzeitversuchen gezeigt, dass die Aufnahme der untersuchten polymeren 
Nanopartikel von einem Makropinozytose-ähnlichen Mechanismus gesteuert wird. Im Laufe dieser 
Arbeit werden mehrere Faktoren identifiziert, die in diesem Aufnahmemechanismus eine Rolle 
spielen. Darunter fallen unter anderem die kleinen GTPasen Rac1 und ARF1, die die Aufnahme von 
SPIOPSN beeinflussen. Darauffolgend werden die intrazellulären Transportwege der Nanopartikel 
untersucht. Mit Hilfe eines neuartigen Massenspektrometrieansatzes wird der intrazelluläre Transport 
von nanopartikelhaltigen endozytotischen Vesikeln rekonstruiert. Intensive Untersuchungen 
identifizieren Marker von frühen Endosomen, späten Endosomen/ multivesikulären Körpern, Rab11
+
- 
Endosomen, Flotillin-Vesikeln, Lysosomen und COP-Vesikeln. Schließlich wird der Einfluss des 
lysosomalen Milieus auf die Proteinhülle der Nanopartikel untersucht. Hier wird gezeigt, dass die 
adsorbierte Proteinhülle auf den Nanopartikeln in die Zelle transportiert wird und anschließend im 




Insgesamt verdeutlicht diese Arbeit, dass die klassische Strategie des nanopartikulären und invasiven 
Wirkstofftransportmechanismuses überdacht werden muss. Weiterhin lässt sich aus den Daten 
schlussfolgern, dass polymere Nanopartikel einem atypischen Makropinozytose-ähnlichen 
Aufnahmemechanismus unterliegen. Dies resultiert in einem intrazellulären Transport der 
Nanopartikel von Makropinosomen über multivesikuläre Körperchen zu Lysosomen. 































1. Introduction to nanobiotechnology 
Nanobiotechnology is a rapidly growing field with a large number of newly synthesized materials that 
have already been implemented in our daily life. The omnipresence of these nanomaterials raises 
several issues about nanosafety and the likelihood of interactions with biological systems (1). 
Especially, their administration in biomedical applications places high demands on the quality and 
safety of such nanomaterials. Fortunately, there is a way to achieve these high requirements. The 
improvement of nanoparticles mainly profits from the huge variety of possible synthesis protocols that 
can be applied to properly adapt nanomaterials for the desired applications. The tremendous number of 
synthesis routes provides a huge freedom to vary fundamental features such as drug release efficiency, 
blood circulation half-life or the size of the nanomaterial (1). However, the manifoldness of the diverse 
materials challenges life scientists to obtain a detailed view about nano-bio-interactions (1). To 
guarantee safe nanoproducts in the future, it is therefore absolutely necessary to gain knowledge about 
nano-bio-interactions. These include i. a. nanoparticulate cytotoxicity, cellular uptake mechanisms, 
their environmental disposition and nanoparticle-membrane interactions.  
One of the primary goals in biomedical nanotechnology is to understand these interactions and to 
exploit them also for the development of novel drug delivery systems. A major hallmark of these 
systems is that the nanoparticulate matrix serves as a protective carrier for the encapsulated 
hydrophobic or hydrophilic effector molecules shielding them from environmental degradation (2). 
The first attempts to design drug delivery systems range back into the 1980s, where scientists already 
synthesized pH-responsive liposomes for the delivery of drugs (3). Nowadays, these applications are 
highly customized for in vivo studies even applying lipid nanoparticles for a tissue-specific silencing 
of proteins (4). Besides, also non-lipidic formulations are in the spotlight. At least since the FDA 
approval of the albumin-based nanocarrier Abraxane
®
 for breast cancer treatment, one has to realize 
the huge financial interest behind drug delivery systems (5). However, not only the industry but also 
the scientific community starts to gain deep knowledge about interaction of nanoparticles with cellular 
systems and even with complete organisms (6). Especially in the field of nanoparticle-membrane 
interactions and intracellular trafficking mechanisms of nanoparticles, a large progress has been made. 
The scientific world starts to realize that the understanding of these interactions is a major prerequisite 
for an efficient design of nanocarriers for future applications. Taking all of this into account, it is 
realistic to assume that nanocarriers someday might play an indispensable role in biomedical 
applications.  
1.1  Nanomaterials – Synthesis of polymeric nanoparticles 
Polymeric nanospheres are frequently defined as colloidal particles in a size range of 10-1000 nm (7, 




Nanocapsules are hollow-body spheres with a solid material shell that allow the encapsulation of 
distinct hydrophobic or hydrophilic molecules inside the lumen (9, 10). In contrast, polymeric 
nanoparticles (PNPs) are solid full-body particles. Distinct desired molecules may be adsorbed to their 
surface or encapsulated within the polymeric matrix (6). Depending on the synthesized particle, PNPs 
are either generated from presynthesized polymers or by direct polymerization (8). To obtain particles 
by direct polymerization, techniques such as miniemulsion or microemulsion are utilized (11). 
Miniemulsion polymerization (MEP) is a popular technique to synthesize a large number of stable and 
monodisperse nanospheres (12). MEP provides a broad platform to generate nanospheres with 
different reaction types (e. g. polyaddition, polycondensation, anionic/cationic polymerization, 
catalytic polymerization) and empowers to control parameters like size, surface functionalization or 
cargo loading (11).  
Radical miniemulsion polymerization 
During the process of radical MEP, a system of at least two immiscible phases is combined (Figure 
1A). In oil-and-water (o/w) miniemulsion, the continuous phase consists of demineralized water with a 
stabilizing ionic or steric surfactant. The dispersed phase contains the monomer or the dissolved 
polymer, the polymerization initiator and an ultrahydrophobic substance (13). In the first step, 
mechanical stirring of the two immiscible phases generates a temporary macroemulsion. To create a 
stable miniemulsion with smaller and homogeneously size-distributed droplets, the dispersion is 
exposed to high shear forces using ultrasonication. The terminal step of the radical MEP is the 
polymerization of the monomer. A chain reaction is initiated polymerizing the monomeric core of the 
nanodroplet. This results in the formation of solid and surfactant-stabilized nanoparticles (11). 
 
Figure 1: Radical miniemulsion polymerization. (A) Formulation of two immiscible phases. (B) Generation of a stable 
miniemulsion by mechanical stirring and ultrasound. (C) Radical polymerization of monomers or solvent evaporation for 
preformed polymers results in the formation of solid nanoparticles. The synthesis of particles inside an emulsion is critical, 





Other routes of synthesis are performed for nanoparticles consisting of preformed polymers (e. g. PLA 
nanoparticles) (14). The synthesis of those nanoparticles utilizes the solvent evaporation technique to 
form particles. In this particular case, the polymer is first dissolved in the dispersed phase. Evaporation 
of the solvent leads to the precipitation of the polymer inside the droplet. Finally, solid and tenside-
stabilized nanoparticles are obtained (11).  
1.1.1 Forces inside the nanodroplet 
In a nonpolymerized miniemulsion, mechanisms such as Ostwald ripening and coalescence 
extensively influence the stability of the dispersion (15). Both phenomenon are ascribed to the 
imbalance between the two major droplet forces – the external LaPlace pressure (pLaPlace) and the 
internal osmotic pressure (posm) (16). pLaPlace is calculated from the Young-LaPlace equation and 
describes the pressure difference between the inner and outer interface of the droplet. Here it is to 
mention that a decrease of the droplet size results in an increased pLaPlace (17). During droplet 
formation, pLaPlace drives the monomer transdiffusion through the aqueous phase (“Ostwald ripening”) 
(15). Ostwald ripening occurs in polydisperse emulsions and describes a process, where the total 
surface free energy of an emulsion is decreased owing to the reorganization of monomers from smaller 
to larger droplets. Notably, the process of Ostwald ripening can be suppressed by the increase of posm. 




) or by the 
addition of an ultrahydrophobe (e. g. hexadecane) into the droplets. Nonetheless, not only Ostwald 
ripening alters the size distribution of nanoparticle dispersions. Also collisions between two 
encountering droplets (“coalescence”) affect the average size distribution of nanoparticle dispersions. 
Coalescence can be suppressed by surfactants on the surface of the nanodroplet.  
1.1.2 Stabilization of nanoparticles in biological fluids 
Efficient stabilization of particles is necessary to avoid their aggregation in biological experiments. 
The colloidal stability of nanoparticles is thereby either obtained by ionic factors or steric stabilizers 
(18, 19). Steric stabilization can be achieved by the assembly of small particles on larger particles 
called pickering emulsion (18). Other approaches use long polymer chains that are adsorbed or 
covalently linked to the particle surface (18). In this particular case, the stability of the particle is 
mediated by the strong interaction of the chains with the continuous phase. With the proper solvent, 
the entropy of the polymer chains is reduced due to away-stretching of the chains from the particle by 
solvent influx into the chain matrix. Thereby, chain movements are restricted to a minimum resulting 
in a repulsion of the particle from others (20). The higher the density of stabilizing polymer chains is, 
the higher is the conformational order and the longer is the range of repulsion (21). Though, steric 
stabilization is not always convertible to all nanoparticle systems. Therefore, it has to be noticed that 




Stability of nanoparticles in biological media 
In general, colloidal stability is calculated by the total interaction potential of the sum of the repulsive 
electrostatic interaction energy (VE) and the attractive van der Waals energy (VA) (22). Electrostatic 
interactions decrease with an increased distance between the encountering nanoparticles while van der 
Waals forces act proportional to VE (Figure 2). Consequently, the total interaction energy depicts two 
minima and a single maximum. The maximum is the energy barrier vmax that is needed to prevent 
coagulation (22). Irreversible aggregation occurs, when the repulsive forces are too weak to preserve 
vmax. Especially in vitro and in vivo, the ionic strength of the media has a major effect on the 
aggregation of nanoparticles. Biological media often have an ionic strength of above 150 mM, which 
results in the screening of the nanoparticulate repulsive forces. Moreover, the impact of van der Waals 
forces are diminished (1). It is also worth to mention that the interplay of particles with proteins are 
crucial for their steric stability inside biological media (23).  
 
Figure 2: Interaction forces between two encountering nanoparticles over a short distance. The secondary minimum 
describes the temporarily more powerful van der Waals forces in a long distance range between nanoparticles. In this distance 
range, the attractive forces between the particles are too weak for a permanent aggregation. The secondary minimum defines 
the state, where vmax was overcome. Irreversible particle aggregation occurs (basic figure obtained from C. Weiß, MPI-P, 
Mainz). 
After the addition of nanoparticles into serum, the nanoparticle surface is covered by over one hundred 
adsorbed serum proteins (24, 25). Nanoparticulate surface molecules are screened by proteins that 
massively influence several features in respect of nanoparticulate surface charge, size and colloidal 
stability (26). However, different studies suggest that adsorbed proteins can also positively act as steric 
stabilization for nanoparticles preventing their aggregation (23). Technically, the amount of protein 
adsorption on nanoparticles is well controllable by the application of steric stabilizers on the 




as a promising candidate to suppress the formation of a protein corona (20, 27). In summary, this 
shows that the stabilization of nanoparticles is an important topic for biomedical applications. 
Colloidal stability needs to be guaranteed to perform reliable studies in vitro and in vivo with 
nonaggregated nanoparticles.  
1.1.3 Biodegradable poly-L-lactide nanoparticles 
Several investigations demonstrate the synthesis of nanoparticles from preformed polymers like 
polycyanoacrylate or poly-L-lactide (PLLA) by solvent evaporation (6, 28, 29). Polylactide (PLA) is 
indispensable in tissue engineering and drug delivery applications owing to their high biocompatibility 
(30). The ester bonds inside PLLA are hydrolytically cleavable by deesterification (31). Enzymes 
inside the acidic environment of the endolysosomal system degrade PLLA and generate the non-toxic 
product lactic acid (31). Subsequently, lactic acid can be easily removed by the organism (e. g. by 
citric acid cycle). However, it is worth to mention that the efficient degradation of the particles 
depends on several parameters including the molecular structure of the polymer, environmental 
conditions, crystallinity, chain orientation or the presence of co-polymers (32). A study of Gonzalez et 
al. showed that degradation of low molecular weight PLA microspheres takes more than eight month 
under in vitro conditions displaying the robust features of PLA (33). In spite of this, the 
biocompatibility and the high efficiency for cargo loading predestinates PLA nanoparticles as a 
serious candidate for drug delivery (6). In this work, we use the L enantiomer of the saturated poly-α-
hydroxy ester to form iron oxide loaded PLLA-Fe-PMI nanoparticles. 
1.1.4 Superparamagnetic iron oxide nanoparticles 
For biological applications, superparamagnetic iron oxide nanoparticles (SPIONs) are frequently 
composed of biocompatible magnetite or its oxidized form maghemite (34). These SPIONs can be 
embedded in a polystyrene or a poly-L-lactide matrix using a multistep protocol (6, 35, 36). In the first 
step of synthesis, magnetic nanoparticles are formed in a dispersion of oleic acid (35). In a second 
miniemulsion process, the stabilized magnetic nanoparticles are used as seeds for the polymeric matrix 
to form hybrid particles (37). Notably, these nanoparticles behave superparamagnetic (37). When a 
magnetic field is applied to the nanoparticles, the magnetic moment of all unpaired electrons is 
oriented in a single direction while the accuracy of orientation increases with the strength of the 
external magnetic field (38, 39). Owing to their superparamagnetic features, neighboring nanoparticles 
interact with each other and self-assemble in a single orientation (37). When the magnetic field is 
removed, the unpaired electrons disorient again, which results in the loss of their magnetic properties. 
The applications for these SPIONs are diverse. SPIONs can be used for cell separation, sample 
enrichment (e. g. organelle isolation) or as contrast agents in magnetic resonance imaging (40, 41). 




siRNA, Doxorubicin) are coupled to a particle (42). Nanoparticles are then intravenously applied to 
the organism. Accumulation of nanoparticles is achieved by placing a magnetic field besides the area 
of interest (43). However, the fate of such SPIONs is not clarified in detail. Especially, the interaction 
with membranes after their application remains less investigated. 
1.1.5 Nanoparticle-membrane interactions 
Cell membranes and artificial membranes either consist of lipids or polymers that self-assemble to 
ordered structures owing to their amphiphilic nature (44). The structure of a typical lipid can be 
described as two fatty acid chains that are linked by ester or acyl bonds to distinct backbones. In the 
case of phospholipids, the hydrophilic head is attracted to the water phase while the hydrophobic tail is 
repelled by the water (45). After self-assembly, the noncovalent interactions of the hydrophilic parts 
stabilize the membranes still guaranteeing a fluidic and floating system (46). These dynamics are even 
more complicated in cell membranes of mammalian cells. The interplay with embedded biomolecules 
and the large diversity of distinct types of lipids hamper the predictions e. g. of membrane dynamics. 
Exactly due to this reason, investigations of nano-membrane-interaction are frequently performed with 
artificial membrane models. Polymersomes or giant unilamellar vesicles represent a minimal system 
for investigations to study the different potential effects of nanoparticles on membranes (6, 47-50).  
Direct interactions of nanoparticles and membranes trigger membrane deformations 
In general, nanoparticle-membrane interactions lead to chain stretching of lipids, curvature of 
membranes and changes in the membranous lipid packing (51-53). This results in a different 
membrane organization. Especially in vitro, deformation of the bilayer may trigger cytotoxic effects 
(54). Nanoparticles were shown to increase the porosity of membranes after their intense interaction 
(55). Membrane thinning or membrane hole formation is induced by several nanoparticles resulting in 
the disruption of the membrane (55). Here, it is worth to mention that factors like particle size and 
hydrophobicity of the nanomaterials have an impact on membrane morphology. Hydrophilic 
nanoparticles smaller than 8 nm are embedded into membranes to reach a thermodynamically more 
favorable configuration (56). Other silica nanoparticles larger than 22 nm were found to induce an 
almost complete membrane wrapping around the particle (55). It was also shown that interacting 
nanoparticles induce the in-curving of the membrane, while noninteracting nanoparticles may be 
repelled from the surface leading to an out-curving of the membrane (57). Up to now, the imaging of 
such nanoparticle-membrane interaction is very limited due to technical reasons. However, Welsher 
and colleagues recently recorded a high resolution movie of a temporary nanoparticles-membrane 
interaction that can be described as a “kiss-and-run” mechanism (58). This shows that nanoparticles 
are not necessarily needed to permanently interact with membranes to be taken up. In summary, all of 
these observations shape a picture of nano-membrane-interactions and pave the way to understand 




1.1.6 Polymeric nanoparticle based drug delivery 
Since the regular application of drugs is commonly systemic, the transport of effectors to the site of 
action is often less than ideal. The cargo might degrade by hydrolysis, undergo unspecific interactions 
with healthy tissues or can be excreted via the biliar system (59). As a promising alternative, 
nanoparticle-based drug delivery could circumvent these issues. The proper design of nanoparticles 
can protect the cargo from degradation and assists in an efficient drug delivery due to their targeting 
properties. In these particular applications, micelles, dendrimers, liposomal formulations and a large 
number of different nanoparticles serve as carriers to deliver e. g. siRNA or anti-cancer drugs to the 
area of interest (60). Active targeting mechanisms (e. g. “enhanced permeation and retention effect”) 
additionally provide the more effective accumulation of nanospheres inside e. g. solid tumors (61).  
1.1.6.1 Passive and active targeting of nanoparticles 
A fundamental advantage in the treatment of solid tumors is the defective vascular architecture created 
by the rapid and uncontrolled growth of blood vessels inside the abnormal tissue (62). Combined with 
a poor lymphatic drainage, nanomaterials passively accumulate inside the cancer tissue in consequence 
of the EPR effect (63). In addition, an antigen-dependent targeting can be achieved by the specific 
binding of nanoparticles to pathological surface proteins. It is worth to mention that cancer cells 
overexpress particular antigens on their cell membrane. With the selection of the proper binding 
partner, nanoparticle accumulation can be increased by their specific targeting to the cell of interest 
(64). This predestines nanoparticles as ideal candidates for the targeting of cancer cells, if the target 
molecule is not significantly expressed in other parts of the body (65).  
In the past, several investigations confirmed the functionality of active targeting concepts. Dinauer et 
al. investigated an antigen-dependent targeting of T cells by anti-CD3-conjugated nanoparticles (66). 
They could show that these antibody-functionalized nanoparticles specifically bind to the CD3 
receptor, which induces an internalization of the nanospheres (66). Other approaches functionalize 
nanoparticles with DC-SIGN antibodies that bind this receptor on dendritic cells (67). Besides 
biomolecules, also synthetic molecules can serve for cell specific targeting applications (68). PLGA 
nanoparticles can be functionalized with prostate-specific-membrane-antigen-targeting aptamers (69). 
The authors demonstrate an efficient and cell specific delivery of the antitumor agent cisplatin to 
human prostate cancer cells (69).  
However, the design of nanoparticles for active targeting is challenging. The major prerequisites for 
these applications are that the targeted antigen needs to be well accessible to the nanoparticles and 
displays a high endocytic internalization rate. Unspecific uptake via bulk endocytosis has to be 
minimized to prevent unspecific delivery to other types of cells (70). Finally, the interaction of serum 
proteins with nanoparticles may change their specific binding properties to the target molecule (25). 




by the protein corona, thereby losing their target-specificity (26, 71). A solution for this could be 
provided by novel innovative synthesis methods. Here, the targeting molecule is attached via a spacer 
to the nanoparticle to circumvent the shielding effects of the protein corona (72). This approach could 
set the basis for a successful targeted delivery. 
1.1.6.2 Non-targeted nanoparticle uptake and controlled cargo release 
A large number of studies investigate the nonspecific uptake mechanisms of nanoparticles (73, 74). 
These studies mainly examine nontargeting nanoparticles with an encapsulated cargo to examine the 
intracellular drug release in cell culture models (75, 76). Notably, these release mechanisms are highly 
diverse (2). Cargo release either occurs by simple drug leakage from the particle matrix or by a 
disassembly of the nanomaterial (76). However, after cargo release, the effector molecules are often 
trapped inside endosomes while the target location is frequently found in the cytoplasm. To deliver the 
cargo more efficiently to the proper subcellular compartment, an efficient endosomal release 
mechanism is required. 
Endosomal-to-cytoplasmic release either occurs via the membranous diffusion of the payload into the 
cytosol or by the destruction/deformation of the endosomal membrane. It was demonstrated that the 
decoration of nanoparticles with cell-penetrating peptides (CPP) results in an endosomal-to-
cytoplasmic transfer of the nanocarriers (77). GALA peptides and even other peptides induce a 
membrane destabilization exclusively inside the acidic environment of the endolysosome (2, 78). In 
accordance to the approach to exploit endolysosomal pH changes for cargo release, also other 
applications have been demonstrated (79). Endosomolytic polymers with primary and/or tertiary 
amines destabilize the endolysosomal milieu by proton-binding (“proton sponge effect”) (80). These 
amines become protonated at an acidic pH (e. g. in the lysosome), which induce a vesicular influx of 
protons. Thereby, osmotic swelling and disruption of the endosome occurs (81).  
Notably, not only intracellular triggers but also extracellular stimuli are utilized for the controlled 
nanoparticulate cargo release into the cytosol. Bräuchle and colleagues demonstrate a photochemical 
rupture of the endosomes. Afterwards, a disulfide-bound dye molecule is activated inside the reducing 
conditions of the cytoplasm displaying an exposure of the nanoparticulate cargo to the cytosolic milieu 
(75). Further investigations reveal a near-infrared light-mediated release of photocaged siRNA from 
silica-coated upconversion nanoparticles into the cytosol (82). Taking all of this into account, a 
successful passive targeting and cargo release mainly depends on the design of the nanomaterial and 
the strategy of release. Further on, uptake routes and the intracellular trafficking of cargo can 




1.2  Uptake mechanisms of nanoparticulate systems 
Cells use endocytosis for a vast number of central processes. Uptake of extracellular nutrients and 
macromolecules as well as the surface expression of receptors/lipids is orchestrated by the endocytic 
system. Endocytosis is even indispensable for processes of cell adhesion and signal transduction (85). 
Moreover, these mechanisms serve as entry portals for pathogens or particles to gain access to the 
interior of a cell. Thereby, they exploit a large number of different pathways (86) (Figure 3). Here, 
clathrin-mediated endocytosis (CME) is undoubtedly the best studied mechanism of endocytosis (87). 
Other clathrin-independent pathways are caveolae-dependent endocytosis, RhoA-mediated 
endocytosis, Arf6-mediated entry, flotillin-orchestrated uptake as well as the CLIC/GEEC pathway 
(clathrin-independent carriers and GPI-enriched endocytic compartments) (85, 88-93). The bulk 
uptake of large volumes of extracellular fluids and particles is mainly mediated by (macro)pinocytic 
and phagocytic mechanisms (94, 95).  
 
Figure 3: Overview of the major endocytic pathways in mammalian cells. Modified from (85, 93, 96).  
1.2.1 Clathrin- and caveolae-mediated endocytosis 
Clathrin-mediated endocytosis (CME) is required for the internalization of surface molecules such as 
transferrin receptors, receptor tyrosine kinases or G-protein coupled receptors (97). Further on, cargoes 
such as cholera toxin B subunit or nanoparticles have been shown to utilize clathrin-mediated 
pathways (98, 99). The initial process of CME is accompanied by the assembly of cytoplasmic clathrin 
at regions of the plasma membrane (PM) called clathrin-coated pits (CCPs) (100). After the 
invagination of CCPs, the vesicles are pinched off from the PM to form clathrin-coated vesicles 
(CCVs) (101). The molecular signaling on CCVs is mainly mediated by proteins of the adaptor 
complex (102). These adaptor proteins interact with a variety of other regulatory proteins (e. g. AP180 
and epsin) that influence pit assembly, vesicle budding and cytoskeleton interactions (87, 103). 
One regulatory protein that is involved in clathrin lattice rearrangement is epsin 15, which interacts 




generate a curved and three dimensional amphiphatic helix for the assembly of clathrin baskets (87). 
Therefore, it is not surprising that the overexpression of the dominant negative mutant epsin 15 (DIII) 
suppresses the formation of clathrin-coated pits (104, 106). This shows that the associated regulatory 
proteins seem to have an important effect on CME. This also affects the regulatory protein AP180 
(103). Zhao and colleagues found that the overexpression of AP180 reduces clathrin accumulations on 
the plasma membrane. This provides information that AP180 is an important organizer in CME (103). 
Altogether, it is worth to mention that CME is a well understood endocytic pathway. CME as well as 
caveolae-mediated endocytosis are potential entry pathways of nanoparticles that necessarily have to 
be studied in detail.  
Caveolae-mediated endocytosis 
Caveolae are 50 - 80 nm large plasma membrane invaginations that orchestrate a clathrin-independent 
endocytic pathway (107). On a structural level, caveolae are composed of cholesterol, several 
sphingolipids, GPI-anchored proteins and the integral membrane proteins caveolin-1 and caveolin-2 
(108, 109). Caveolin-1 acts as the major organizing unit into which caveolin-2 is migrating (110, 111). 
This was shown with two experiments. The first experiment reveals that the stable expression of 
caveolin-1 in caveolae-deficient K562 cells induces the upregulation and recruitment of caveolin-2. 
Then, Parolini and colleagues showed a direct binding of both proteins to each other providing 
information about two necessary markers for the detection of caveolae at the PM (111). Originally, 
caveolae-mediated endocytosis was described as an entry mechanism of SV40 viruses (112). 
However, also other small particles with a size of ≤ 100 nm have been shown to utilize caveolae-
mediated pathways (113, 114). The terminal uptake of such nanoparticles is then conducted by the 
pinch off of the vesicles from the PM. The scission of vesicles in caveolae- as well as in clathrin-
mediated uptake is regulated by dynamin. 
1.2.2 Dynamin in clathrin- and caveolae-mediated endocytosis 
Dynamin is a GTPase that is recruited to CCPs and caveolae during the endocytic process (115, 116). 
The protein assists in the scission of vesicles from the plasma membrane after its slow accumulation 
around the growing pit (117). Originally, the relevance of dynamin for endocytosis was shown in 
experiments, where the overexpression of dominant negative Dyn2-K44A results in the inhibition of 
clathrin- and caveolae-mediated endocytosis (118). Morphologically, dynamin inhibition arrests 
endocytosis at a stage, where vesicles are trapped as tubular structures at the PM (116, 119). This 
results in an accumulation of non-budded vesicles (116). Altogether, this reveals a clear role for 
dynamin inside the two best characterized endocytic pathways. However, it is worth to mention that 
dynamin is also located inside membrane ruffles or podosomes (120, 121). These observations revive 
the discussions, whether dynamin exclusively acts in CME and caveolae-mediated endocytosis or also 




1.2.3 Clathrin and caveolae-independent mechanisms 
Nowadays, lively discussions raise issues about the presence of other less characterized endocytic 
pathways. In this research field, the literature provides a wide range of clathrin- and caveolae-
independent mechanisms (85). Though, the strict discrimination between these pathways is sometimes 
challenging since functional overlaps have partially been observed (88, 90). This rigorous 
classification is also hampered by the large number of investigated cargoes including viruses, toxins, 
GPI-linked proteins, interleukin receptors or other cargoes. However, the commonly accepted clathrin-
, caveolae- and macropinocytosis-independent pathways are RhoA-mediated uptake, CLIC/GEEC 
pathways and flotillin-mediated endocytosis.  
1.2.3.1 RhoA-mediated uptake 
One clathrin-independent but dynamin-dependent pathway is specifically regulated by the small 
GTPase RhoA (91, 107, 123). This pathway was first discovered in a study that investigated the 
internalization of the β-chain of the interleukin-2 receptor (IL-2Rβ) (107, 124). It was shown that 
neither dominant negative epsin 15 nor AP180 overexpression affected the uptake of IL-2Rβ (124). 
Clathrin-independency was further supported by the criterion that IL-2Rβ uptake is orchestrated by 
Rac1, PAK1 and PAK2 (123). These factors are not functional in CME. However, observations have 
shown that the overexpression of constitutively active RhoA can inhibit CME (124). Despite of this, a 
direct interaction of CME and RhoA is unlikely (85). Altogether, RhoA acts in a clathrin-independent 
pathway by the modulation of the actin cytoskeleton, thereby probably regulating a large number of 
other processes (125).  
1.2.3.2 CLIC/GEEC pathway 
A further clathrin- and caveolae-independent mechanism is represented by the CLIC/GEEC pathway 
(90). This entry mechanism orchestrates the internalization of glycosylphosphatidylinositol-anchored 
proteins, extracellular fluids and certain bacterial exotoxins (90). Morphologically, the CLIC/GEEC 
pathway is characterized by its ~ 40 nm wide tubular invaginations that are decorated with GTPase 
regulator associated with focal adhesion kinase-1 (GRAF1) and phosphatidylinositol-4,5-bisphosphate 
3-kinase (126). These membrane carriers are relatively devoid of caveolin-1 and flotillin-1 but are 
regulated by cdc42 and ARF1 (90, 95, 126-128). Interestingly, the internalized GPI-linked proteins 
can bypass conventional Rab5
+
 endocytic compartments raising questions of novel early endocytic 
compartments (85). Indeed, GPI-anchored proteins are directly transported to early endocytic vesicles 
termed as GPI-AP-enriched early endosomal compartment (GEEC). Altogether, these observations 
provide information about a pathway of fluid phase endocytosis that has to be taken into account, 




1.2.3.3 Flotillin-mediated endocytosis 
Flotillins are membrane proteins with a high homology to caveolin-1 that cluster as organized domains 
inside the PM (129). In 2006, flotillin-1 was originally described as a protein that mediates the entry of 
ctxB and the GPI-anchored protein CD59 (88). The authors show that flotillin domains pinch off from 
the PM in a clathrin-independent manner. After internalization, flotillins are present inside 
multivesicular bodies and even show a close association to other endosomal processes (130, 131). 
Flotillins have been suggested to be necessary for the Niemann-Pick-C1-like 1-mediated cholesterol 
uptake inside endosomes (130). It was shown that the knockdown of flotillins significantly attenuates 
the internalization of cholesterol and the endocytosis of NPC1L1 (130). These observations could 
bridge the gap for flotillin in nanoparticle uptake. Indeed, previous studies with polyplexes and silica 
nanoparticles showed a participation of flotillin in nanoparticle internalization (132, 133). All of these 
points propose a versatile but important role for flotillin in endocytic processes that have to be 
considered in the analysis of nanoparticle entry and trafficking.  
1.2.4 Macropinocytosis  
Classical macropinocytosis is a clathrin-, caveolae- and dynamin-independent process that occurs 
spontaneously or can be initiated by e. g. a transient activation of receptor tyrosine kinases (Figure 4 
and Figure 5) (134). During macropinocytosis, large volumes of fluids and extracellular objects are 
internalized via macropinosomes (135, 136). Morphologically, macropinocytosis can be characterized 
by ruffle formation and the internalization of classical fluid phase markers (e. g. HRP, dextran) (137). 
This process of internalization is orchestrated by several small GTPases such as Ras, Cdc42 and Rac1 
(138, 139). The early steps in macropinocytic signaling depend on the Ras/Cdc42/Rac1- or PI3K-
mediated activation of different kinases such as p21-activated kinase 1 (PAK1) (136). Active PAK1 
induces actin polymerization and lamellipodia formation (137). In the terminal step of 
macropinocytosis, PAK1 facilitates the closure of the macropinosomes by activating the carboxy-
terminal-binding protein-1/brefeldin A-ADP ribosylated substrate (CtBP-1/BARS) (135, 140).  
 







Other factors that influence classical macropinocytosis 
Considering the interactions of small GTPases on actin remodeling, it is not surprising that Rah/Rab34 
has been associated with macropinosome formation (141). Other studies describe the impact of Rab5 
and Rabankyrin-5 on the macropinocytic activity of fibroblasts and epithelial cells (142). While 
overexpression of Rabankyrin-5 increases the macropinocytic activity of the cells, an RNAi-mediated 
downregulation of Rabankyrin-5 diminishes the internalization rate of fluid phase markers and lipid 
nanoparticles (4, 142). The diversity of action mechanisms is also highlighted by the studies that 
implicate the kinases PLCγ, PKC and Src as factors for membrane ruffling (140, 143, 144). Besides, 
the ADP-ribosylation factor Arf6 was shown to alter membrane protrusions (145). Altogether, these 
studies connect a large number of factors to macropinocytic signaling events. With regards to actin 
rearrangements, small GTPases and several kinases seem to have major impacts on the macropinocytic 
activity of a cell and are the major targets during the investigations of nanoparticle uptake (Figure 5).  
 
Figure 5: Overview of the general macropinocytic signaling pathways. Macropinocytosis occurs spontaneously or is 
triggered by a growth factor-mediated activation of receptor tyrosine kinases (RTKs). Several small GTPases and kinases 
facilitate the signalling cascade resulting in actin modulation. Actin reorganization induces the formation of the 
macropinocytic cup. Modified from (140, 146).  
Macropinocytosis-like mechanisms 
Classical macropinocytosis is primarily reliant on the previously described criteria. However, it is 
worth to mention that also atypical macropinocytic-like mechanisms have been observed in many 




considered in fluid phase endocytosis or lack in comparison to classical macropinocytosis (140). In the 
field of virology, a large number of different atypical macropinocytic types have been well studied 
(140). Mulherkar et al. investigated a dynamin2-dependent macropinocytic entry of Ebola virus 
glycoprotein. Since dynamin has never been implicated in classical macropinocytosis so far, this 
mechanism can be considered as a macropinocytic-like pathway (148). Other groups reported an F-
actin and cholesterol-dependent, but an atypical pH-independent uptake of human cytomegalovirus 
into dendritic cells (149). Another case of macropinocytic-like entry was published for human 
papilloma virus type 16 (150). Entry and infection relies on the major hallmarks of classical 
macropinocytosis but does not depend on Rho GTPases which are major key players in 
macropinocytosis. In the field of nanotechnology, macropinocytic-like uptake mechanisms have 
hardly been investigated. However, a study of Iversen et al. focused on several criteria of classical 
macropinocytosis during quantum dot uptake. They found that ricin-conjugated quantum dots are 
internalized via a dynamin-dependent macropinocytic-like pathway that was not described before 
(147). Taken together, atypical macropinocytic-like uptake mechanisms are not only relevant in 
virology but can also be an issue in the investigation of nanoparticulate entry and intracellular 
nanoparticle trafficking.  
1.3  From early endocytic compartments to lysosomes – intracellular 
trafficking of nanomaterials 
As described in the former chapters, nanoparticles utilize different endocytic mechanisms for their 
cellular entry (93, 96). After their internalization, nanoparticles are transported along a specific 
endocytic route (83, 151, 152). The process of intracellular nanoparticle trafficking (INT) is very 
dynamic in record to the proteomic environment on the endocytic vesicles. During INT, important 
adaptor and effector proteins are recruited or exchanged on the vesicles´ surface (153). It is important 
to mention that homotypic/heterotypic fusion of vesicles and vesicular maturation processes can alter 
the protein composition on a nanoparticle-containing vesicle (153, 154). This already happens in the 
initial stages of intracellular trafficking. Early endosomes and early macropinosomes merge with each 
other to form a novel vesicle (140). Moreover, endocytic interactions with recycling endosomes as 
well as with vesicles of the trans-Golgi network induce the additional exchange of nonendocytic 
proteins with the endolysosomal system (154). Also the fusion of lysosomes with autophagosomes 
introduces components of e. g. defective organelles into the endocytic system (155, 156). Figure 6 
shows the fusion events and participating vesicles that may be associated with intracellular 





Figure 6: Potential routes of intracellular nanoparticles trafficking. The intravesicular pH values of the endolysosomal 
vesicles are depicted as distinctly colored vesicles. Abbreviations: EE: Early endosomes; RE: Recycling endosome; LE: Late 
endosome/multivesicular body; LY: Lysosome; TGN: Trans-Golgi-Network. Arrows indicate endocytic fusion events 
between the different compartments. Dotted lines indicate the possible macropinocytic interplay with the endocytic system. 
Adapted from (140, 157, 158).  
1.3.1 Early endocytic compartments  
Early endocytic vesicles are a heterogeneous class of vesicular carriers during the initial stage of 
intracellular trafficking (142, 159). Classical early endosomes can be identified by distinct markers 
such as EEA1 or Rab5 and coexist in different subpopulations (159, 160). A previous report identified 
at least two distinct classes of EE that display different maturation and mobility kinetics (161). The 
authors detected a first population of Rab5
+
 endosomes that rapidly accumulated Rab7 within a short 
time frame. The second population matures on a much slower time scale without accumulating Rab7 
(161). According to these data, the mobility of vesicles on microtubules can be correlated with their 
maturation state (161). While slowly maturating endosomes move to a less extent, rapidly maturing 
vesicles show a higher motility rate. If this is connected to the distinct Rab domains on early 




However, it is worth to mention that early endosomes contain separated surface patches of Rab4, Rab5 
and Rab11 (162). Especially, Rab4 and Rab11 have been shown to control recycling and endosomal 
fusion (162, 163). According to the study of Sönnichsen et al. it was proposed that the different 
domains on early endosomes promote the pinch off of early endosomal subvesicles that are introduced 
into the recycling pathway (Figure 6) (162). This shows that early endosomal compartments are 
closely related precursors of the cellular recycling pathways. However, these classical endosomes 
seem to be functionally different from early macropinosomes.  
Early macropinosomes 
Early macropinosomes are budded vesicles that are formed after macropinocytosis and partially bear 
markers of early endosomes (142). Classical macropinosomes are characterized by the surface markers 
Rab34, Rab5 and its effector Rabankyrin-5 (141, 142). Other studies highlight the transient association 
of switch-associated protein 70 (SWAP-70) with macropinosomes in dendritic cells (164). Further 
well accepted markers of growth factor induced macropinosomes are proteins of the sorting nexin 
family as well as Rac1 (137, 165). The biogenesis of macropinosomes can be triggered by EGF 
stimulation or via the overexpression of several sorting nexins such as SNX1 or SNX18 (166). After 
macropinosomes formation, vesicles can fuse with other endocytic compartments or mature to Rab7
+
 
late macropinosomes (140, 165, 167).  
1.3.2 Late endosomes – Multivesicular bodies 
Late endosomes are also termed as multivesicular bodies (MVBs) (168). These vesicles frequently 
originate from Rab5
+
 early endosomes and are considered to be control centers for different processes 
such as cell signaling or exocytosis (153, 168). Morphologically, MVBs are 400 – 1000 nm large 
organelles that contain small intraluminal vesicles (ILVs) in a size range of typically ~ 50 nm (169). 
When MVBs fuse with the plasma membrane, ILVs are externalized as exosomes in a Rab27b-
dependent manner (170, 171). All of these processes are well studied. However, the definite 
identification of MVBs remains challenging. Unique marker proteins are relatively few since MVB 
biogenesis mainly occurs transiently (168). Nowadays, characterization of MVBs is therefore 
performed by the detection of mannose 6-phosphate receptor (M6PR), Lamp1/Lamp2, distinct Rab 
proteins (Rab5, Rab7, Rab27, Rab35) as well as several tetraspanins (172). Here, it is to mention that 
the tetraspanins CD82, CD9, CD81 and CD63 are abundant on MVBs (171, 173). Also the 
intraluminal vesicles can be directly detected by the tetraspanin CD63 (174). In previous reports it was 
shown that CD63 transports the melanocytic protein Pmel17 on ILVs in an ESCRT (endosomal 
sorting complexes required for transport)-independent process (174, 175).  
Contrary to the sorting of Pmel17 onto ILVs, the biogenesis of MVBs as well as the degradation of 




biogenesis, Wollert and Hurley showed that the four components of ESCRT (0/I/II/III) induce the 
formation of intraluminal vesicles inside giant unilamellar vesicles (176). Thereby, they recorded the 
internalization of fluorescently-labeled ubiquitin. Inside cells, ubiquitinylation is an important 
modification for the degradation of membrane proteins via ESCRT. Monoubiquitinylated or 
polyubiquitinylated membrane proteins bind the ubiquitin-binding domain of ESCRT components, 
which results in the degradation of the proteins (177). Altogether, the functional relevance of 
functional ESCRTs has been well characterized. This was also shown in biomedical publications. 
Deregulation of the ESCRT machinery contributes significantly to many human diseases such as 
cancer or neurological diseases (178).  
However, it is worth to mention that not only the late endosomal deregulation of ESCRT can mediate 
severe diseases. In a particular case, a mutation of Niemann-Pick-disease C1 protein (NPC1) leads to a 
pathological cholesterol accumulation inside late endosomes (83, 179). Consequently, cholesterol 
homeostasis and intracellular trafficking pathways are disturbed. In this context, Sahay and colleagues 
showed that NPC1 deficient cells longer retain nanotransporters inside the endosomal system than 
healthy cells (83). This implies an important function of NPC1-dependent cholesterol homeostasis in 
intracellular trafficking pathways of nanoparticles (180).  
1.3.3 Lysosomes 
Lysosomes are seen as terminal organelles in endocytic and autophagocytic pathways (158). These 
vesicles are the final destination for a large number of cargos and mediate numerous functions such as 
the downregulation of surface receptors, inactivation of pathogens or MHC-peptide loading (151, 
156). Though, not only the functions of lysosomes are diverse. Electron microscopy reveals that the 
morphology and size of lysosomes is strikingly heterogeneous (181). They frequently contain 
electron-dense material and multilamellar membrane whorls (181). This material partially originates 
from the lysosomal fusion with autophagocytic vesicles resulting in the formation of a multilamellar-
body-like structure (182).  
Moreover, their acidic interior (pH 4.6-5) is maintained by several vacuolar H
+
 ATPases (183). This is 
especially important for hydrolytic enzymes with an acidic pH optimum (184). Lysosomes supply a 
protective membrane-shielded lumen for more than 50 different acid hydrolases (e. g. peptidases, 
proteinases, phosphatases, nucleases, glycosidases, sulphatases, lipases) (156). The transport of these 
proteins towards prelysosomal vesicles is frequently orchestrated by two independent M6P-receptors 
that recognize the M6P tag on the potential lysosomal proteins (185). After protein binding, the 
M6PR-protein-complex is shuttled from the trans-Golgi-network to endosomal vesicles, where the 
cargo dissociates from M6PRs due to the acidic environment (186). As a consequence, lysosomes can 
be distinguished from prelysosomal organelles by the lack of M6PR and the presence of Lamp1 and 




1.3.4 Fusion events and protein transport inside the endocytic system 
In a protein-free system, the fusion of vesicles is mainly based on the interaction of different forces 
between the two vesicular surfaces (187). Attractive forces like hydrophobicity and van der Waals 
forces have to overcome several repulsive forces (e. g. electrostatic) for a successful adhesion of the 
vesicles to each other (188). However, it is believed that the fusion of membranes cannot be induced 
by simple adhesion, but by factors (e. g. surface charges) that alter the steric configuration of 
individual lipids (189). The destabilization of single lipid domains facilitates the hydrophobic 
interplay between lipids on opposing membranes resulting in their fusion (190, 191). In cellular 
systems, fusion of organelles is additionally supported by two preliminary steps that are mediated by 
protein complexes. In the first step, a tethering step loosely connects the two merging vesicles to each 
other. In the subsequent step of docking, an irreversible binding of the vesicles is achieved that results 
in the terminal fusion of the organelles (181).  
The tethering of two early endosomes is mediated by the class C core vacuole/endosome tethering 
complex (CORVET) while late endosomes and lysosomes are connected via the vacuole protein 
sorting complex (HOPS) (192). In late endosomes/lysosome fusion processes, Rab7 is utilized as an 
adaptor protein for the effectors of the HOPS complex (181). Subsequently after formation of the 
tethering complex, the vesicular fusion is induced by the assembly of a trans-SNARE complex (181). 
SNARE (soluble N-ethylmaleimide-sensitive factor attachment protein receptor) proteins are 
characterized by a stretch of 60-70 amino acids that are arranged in heptad repeats (193). When a 
SNARE protein encounters other SNARE motifs, an alpha-helical structure is formed. In heterotypic 
late endosome/lysosome fusion, the SNARE complex consists of the R-SNARE VAMP7, Syntaxin-7, 
Syntaxin-8 and VTI1B (181). In homotypic endosome/endosome fusion, VAMP8 is utilized instead of 
VAMP7. It is believed that the formation of the SNARE complex finally results in the induction of 
vesicular fusion (194). Even in macropinosomes/lysosome fusion and in autophagosome/lysosome 
fusion a participation of SNARE proteins was observed (181). This gives rise to investigate SNARE 
proteins in intracellular nanoparticle trafficking. 
1.3.5 Intracellular trafficking of nanomaterials 
The first approaches that studied the intracellular trafficking of nanoparticles have already been made. 
Via the use of confocal spinning disc microscopy, Sandin et al. showed that polystyrene nanoparticles 
are transported via Rab7
+
 endosomes to their terminal lysosomal destination (151). Another study 
revealed similar results with polyplexes that actively moved through the cell inside endolysosomal 
structures (132). Both of these studies describe less colocalization of nanomaterials with recycling 
pathways and autophagocytic routes. However, nanoparticles can also exploit several secretory and 
endocytic pathways. Sahay and colleagues observed a transport of lipid nanoparticles into Rab11
+
 




reports detected α-Al2O3 nanoparticles inside LC3
+
 autophagosomes (152). All of these studies used 
well accepted markers for their investigations. However, these examinations are biased by the present 
knowledge about the recently known proteins in intracellular trafficking pathways of other objects 
such as viruses or membrane proteins. Therefore, one primary aim of this thesis is to provide novel 
information about the intracellular trafficking pathways in an unbiased approach. 
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1.4  Aims of the study 
This study was carried out to analyze the drug delivery abilities, the entry mechanisms and the 
intracellular trafficking of several polymeric nanoparticles. Thereby, the analysis of nano-bio 
interactions could reveal novel insights in terms of prospective applications for nanoparticles. In the 
first part of this study, we wanted to investigate whether biodegradable poly-L-lactide nanoparticles 
are a suitable candidate for a non-invasive drug delivery system in vitro. To analyze this, nanoparticle-
membrane interaction were preliminary studied with distinct cellular and cell-free systems. The 
primary goal was to investigate the release mechanism and the subcellular transport of the 
nanoparticulate cargo during nanoparticle-membrane interaction.  
Secondly, we were interested in the mechanisms by which polymeric nanoparticles enter the cell. In 
this project, we focused on the interaction of nanoparticles with the macropinocytic system. The 
internalization of nanoparticles could rely on the classical factors of macropinocytic signaling. 
Consequently, we intensively studied the influences of small GTPases and kinases on the 
internalization mechanism of nanoparticles. To validate the functionality of these GTPases in 
nanoparticle entry, we studied whether constitutively active or dominant negative forms of these 
effector proteins have an impact on nanoparticle entry. Additionally, a set of small inhibitory 
molecules and siRNAs was tested to inhibit several pathways of the endocytic system. We 
investigated, whether this had an effect on nanoparticle entry.  
In the third part of this thesis, we examined the intracellular trafficking of nanoparticles (INT). To 
identify novel proteins of INT, we wanted to establish an innovative and unbiased method that enables 
us to identify novel proteins in intracellular nanoparticle trafficking. The goal of this approach was to 
dissect the INT by label free quantitative mass spectrometry. To test the specificity of this method, we 
investigated promising proteins by confocal live cell imaging and other methods that could influence 
the nanoparticle trafficking. We finally examined whether the lysosomal milieu had an impact on the 




2. Materials and Methods 
Chapter 2 depicts all the materials and chemicals that were used in this study. Experiments were 
performed as described in the chapter “Methods”. The nanoparticles of this study were synthesized by 
Dr. Markus B. Bannwarth. The synthesis and characterization procedures are exactly described in his 
thesis (195).  
2.1  Materials 
In the following chapter, all relevant materials of this study are depicted.  
2.1.1 Nanoparticles 
Table 1 contains the abbreviations, properties and characterization parameters of all relevant 
nanoparticles that were used in this study.  









PS-COOH PS COOH SDS 73 PMI  (488nm/ 
525nm) 
n. d.  
PS-NH2-
BODIPY 
PS NH2 CTMA-CL 60 BODIPY II 
(488nm/ 
525nm) 
n. d.  
PLLA-Fe- 
PMI 
PLLA OH + magnetite SDS 126 PMI 
(488nm/ 
525nm) 
n. d.  





PS Sulfonate + 
magnetite 








Chemicals used in this study are listed in Table 2. 
Table 2: Chemicals.  
Chemical Supplier 
1,2-Dioleoyl-sn-glycero-3-phosphocholine Avanti Polar Lipids; U. S. A.  
2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Sigma Aldrich; U. S. A. 




4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid Sigma Aldrich; U. S. A. 
Agar Sigma Aldrich; U. S. A. 
Agarose Standard Roth; Germany 
Ampicillin Sigma Aldrich; U. S. A. 
BODIPY I/ BODIPY II Synthesized as described (196) 
Bovine serum albumin Sigma Aldrich; U. S. A. 
Calcium chloride Sigma Aldrich; U. S. A.  
cOmplete protease inhibitor cocktail Roche; Switzerland 
D(+)-Saccharose Roth; Germany 
Dimethylsulfoxid Sigma Aldrich; U. S. A. 
Dipotassium phosphate Sigma Aldrich; U. S. A. 
DL-Dithiothreitol Sigma Aldrich; U. S. A. 
Ethanol Sigma Aldrich; U. S. A. 
Ethylene glycol-bis(2-aminoethylether)- tetraacetic acid  Sigma Aldrich; U. S. A. 
Ethylenediaminetetraacetic acid Roth; Germany 
Fetal bovine serum Invitrogen; U. S. A. 
Gentamicin Invitrogen; U. S. A. 
Gluthatione Sigma Aldrich; U. S. A. 
Glycine Sigma Aldrich; U. S. A. 
Immersion oil for microscopy Leica; Germany 
Magnesium chloride Sigma Aldrich; U. S. A. 
Methanol  Fisher Scientific; U. S. A.  
N-(2,6-diisopropylphenyl)-perylene-3,4-dicarbonacid-imide (PMI) BASF; Germany 
Nile Red Sigma Aldrich; U. S. A. 
Nuclease-free water Qiagen; U. S. A.  
Oil Red O  Sigma Aldrich; U. S. A. 
Paraformaldehyde Sigma Aldrich; U. S. A. 
Penicillin/Streptomycin Invitrogen; U. S. A. 
Peptone Sigma Aldrich; U. S. A. 




Potassium chloride Sigma Aldrich; U. S. A. 
Pyruvate Life technologies; U. S. A.  
Saponin Sigma Aldrich; U. S. A. 
Sodium chloride Sigma Aldrich; U. S. A. 
Sodium hydroxide Sigma Aldrich; U. S. A. 
Thio-Urea Serva, Germany 
Triton X-100 Sigma Aldrich; U. S. A. 
Trizma Base Sigma Aldrich; U. S. A. 
Trypan blue solution (0.4%) Sigma Aldrich; U. S. A. 
Tryptone Sigma Aldrich; U. S. A. 
Urea Serva, Germany 
Yeast extract Sigma Aldrich; U. S. A. 
2.1.3 Instruments and Consumables 
Table 3 shows the instruments that were used in this work.  
Table 3: Instruments. 
Instrument Supplier 
4D Nucleofector Lonza; Switzerland 
Automated cell counter TC10 Bio-Rad; U. S. A. 
Bacteria incubator UM200 Memmert; Germany 
Cell culture flow c-(Max Pro)
3
-130  Berner; Germany 
Cell culture incubator C200 Labotec; Germany 
Centrifuge 5810R and 5430 Eppendorf; Germany 
Confocal laser scanning microscope Leica SP5 II with CW-
STED 
Leica; Germany 
Dry blotting system iBlot®  Invitrogen; U. S. A. 
Flow cytometer CyFlow ML Partec; Germany 
Fluorescence imager LAS-3000  Fujifilm, Japan 
Fluorescence microscope IX81-ZDC Olympus; Germany 
Freezer -20°  Liebherr; Germany 
Freezer -80°C Hera Freeze Top Thermo Scientific; Germany 
Hamilton pipette Hamilton Company; U. S. A. 
Incubator Innova 44 New Brunswick Scientific; U. S. A. 
Inverted microscope CKX41 Olympus; Germany 
Microcentrifuge Minispin plus Eppendorf; Germany 
Microscale AE100 Mettler Toledo; Switzerland 
Nitrogen tank LS6000 Taylor-Wharton; Germany 
PCR Mastercycler EP Gradient S Eppendorf; Germany 




Pipetting aid Accujet Pro Brand; Germany 
Platereader Infinite M1000 Tecan; Germany 
Power supply 250-EX Life technologies; U. S. A. 
Real time system CFX96 Bio-Rad; Germany 
SDS-PAGE/Western Blot chamber Mini/Maxi Biometra; Germany 
Thermo mixer HL by Ditabis; Germany 
Ultracentrifuge Optima
TM
 MAX  Beckman Coulter; U. S. A. 
UV-Vis photospectrometer ND-8000  Thermo Scientific; Germany 
Vacuum pump Vacusafe comfort  IBS Integra Bioscience; Germany 
Vortexer Reax Control Heidolph; Germany 
Water bath Memmert; Germany 
 
Table 4 displays the used consumables of this work.  
Table 4: Consumables. 
Consumables Supplier 
27G needle BD Biosciences; U. S. A.  
Adhesive PCR film Bio-Rad; Germany 
Cell culture flasks Greiner; Germany 
Celltrics sterile filters Partec, Germany 
FACS tubes Partec; Germany 
Falcon tubes (10 ml; 50 ml) Greiner; Germany 
Ibidi itreat µ-dishes IBIDI; Germany 
iBlot® anode stack Life technologies, U. S. A.  
iBlot® cathode stack Life technologies, U. S. A. 
Multiwell plates Corning Inc.; U. S. A. 
Nucleofector cuvettes (100 µl) Lonza, Switzerland 
NuPAGE 10% bis-tris gel Life technologies; U. S. A. 
Parafilm Pechiney Plastic Packaging, U. S. A.  
PCR tubes/PCR plates Bio-Rad; Germany 
Pipette tips Greiner, Germany 
Pipettes (5 ml; 10 ml; 25 ml; 50 ml) Greiner, Germany 
Protran
® 
nitrocellulose membrane Sigma Aldrich; Germany 
PVDF membrane Millipore, U. S. A.  
QIA shredder columns Qiagen; U. S. A. 
Single-use syringes Henke-Sass-Wolf; Germany 




2.1.4 Small molecule inhibitors 
Table 5 depicts the inhibitors with their known targets/mechanisms that were used for the suppression 
of different endocytic mechanisms. Inhibitors were dissolved and stored according to manufacturer´s 
recommendations.  
Table 5: Small molecule inhibitors of uptake. 
Inhibitor Supplier 
5-(N-Ethyl-N-isopropyl) amiloride (lowering of submembraneous 
pH) 
Sigma Aldrich; U. S. A. 
Bafilomycin A1 (Inhibition of v-type ATPases) Sigma Aldrich; U. S. A. 
Blebbistatin (Inhibition of Myosin) Sigma Aldrich; U. S. A. 
Brefeldin A (Inhibition of ARF1) Sigma Aldrich; U. S. A. 
CA-074 methyl ester (Inhibition of cathepsins) Sigma Aldrich; U. S. A. 
Chlorpromazine (Inhibition of CME) Sigma Aldrich; U. S. A. 
Cytochalasin D (Inhibition of F-Actin polymerization) Sigma Aldrich; U. S. A. 
Dynasore
®
 (Inhibition of Dynamin I/II) Sigma Aldrich; U. S. A. 
IPA-3 (Inhibition of PAK1) Tocris; U. S. A.  
Ly294002 (Inhibition of PI3K) Tocris; U. S. A. 
Methyl-β-cyclodextrin (Cholesterol depletion) Sigma Aldrich; U. S. A. 
Nocodazole (Inhibition of microtubule polymerization) Sigma Aldrich; U. S. A. 
Ro 31-8220 (Inhibition of PKC) Sigma Aldrich; U. S. A. 
U18666A (Cholesterol synthesis inhibitor) Merck; Germany 
U73122 (Inhibition of PLC) Sigma Aldrich; U. S. A. 
Wortmannin (Inhibition of PI3K) Sigma Aldrich; U. S. A. 
2.1.5 Cell lines and primary cells 
Cell lines used in this study are listed in Table 6.  
Table 6: Cell lines. 
Name Cell type Supplier 
Jurkat Immortalized CD3
+
 T lymphocytes DSMZ; Germany  
HeLa Cervical carcinoma DSMZ; Germany 
Multipotent human  
stroma cells  
(hMSCs) 
Human bone-marrow derived stem cells
+
 for 
CD29, CD73, CD44, CD90, CD105, CD146, 
CD166 and MHC class I; negative for CD1a, 
CD3, CD14, CD16, CD19, CD34, CD45, 
CD133, MHC class II and SSEA2 







Dyes used in this work are listed in Table 7. Dyes were used according to manufacturer´s protocol.  
Table 7: Dyes. 
Dye Supplier 
7-Aminoactinomycin D Sigma Aldrich; U. S. A. 
CellMask
TM
 DeepRed Invitrogen; U. S. A.  
CellMask
TM
 Orange Invitrogen; U. S. A. 
Hoechst 33342 Life technologies; U. S. A. 
LysoTracker DND-26 Invitrogen; U. S. A. 
Phalloidin Invitrogen; U. S. A. 
2.1.7 Antibodies and proteins 
Used primary antibodies, secondary antibodies and fluorescent marker proteins are listed in Table 8. 
Primary antibodies were titrated for immunofluorescence, flow cytometry and western blotting. 
Secondary antibodies were used in a dilution of 1:200. Fluorescent tracers were used as stated.  
Table 8: Primary, secondary antibodies and fluorescent tracers. 
Target Supplier 
Alexa Fluor 488 F(ab´)2 fragment of donkey anti-rabbit IgG Life technologies; U. S. A. 
Alexa Fluor 488 F(ab´)2 fragment of goat anti-mouse IgG Life technologies; U. S. A. 
Alexa Fluor 555 F(ab´)2 fragment of goat anti-mouse IgG Life technologies; U. S. A. 
Alexa Fluor 633 F(ab´)2 fragment of goat anti-guinea pig IgG Life technologies; U. S. A. 
Alexa Fluor 633 F(ab´)2 fragment of goat anti-mouse IgG Life technologies; U. S. A. 
Alexa Fluor 633 F(ab´)2 fragment of goat anti-rabbit IgG Life technologies; U. S. A. 
Guinea pig anti- human TIP47 Progen; Germany 
Mouse anti- human ADRP Fitzgerald; U. S. A.  
Mouse anti- human Cathepsin D BD Biosciences; U. S. A. 
Mouse anti- human Caveolin-1 Abcam, England 
Mouse anti- human CD63 Biolegend; U. S. A.  
Mouse anti- human CD82 ACRIS; Germany 
Mouse anti- human CD9 BD Biosciences; U. S. A.  
Mouse anti- human Dynamin I BD Biosciences; U. S. A.  
Mouse anti- human GAPDH Ambion; U. S. A.  
Mouse anti- human Lamp1 BD Biosciences; U. S. A.  
Mouse anti- human Lamp2 Abcam, England 
Mouse anti- human M6PR BD Biosciences; U. S. A.  
Mouse anti- human PMEL17 (NKI/beteb) Abcam; U. S. A.  




Mouse anti- human Ubiquitin Biolegend; U. S. A. 
Mouse anti-CD81 (5A6) Santa Cruz Biotechnology; U. S. A. 
Mouse anti-human Clathrin heavy chain BD Biosciences; U. S. A. 
Mouse anti-human Flotillin-1 BD Biosciences; U. S. A. 
Rabbit anti- human LC3B Life technologies; U. S. A. 
Rabbit anti- human NPC1 Abcam, England 
Rabbit anti- human Rab11 Life technologies; U. S. A.  
Bovine serum albumin Alexa Fluor 488 Life technologies; U. S. A. 
Cholera Toxin Subunit B Life technologies; U. S. A. 
Transferrin-Alexa Fluor 488 Life technologies; U. S. A. 
2.1.8 Plasmids  
Plasmids obtained from other laboratories/companies are listed in Table 9. 
Table 9: Published or purchasable plasmids.  
Plasmid Addgene ID number Source 
Alpha 5 integrin-GFP 15238 Addgene; U. S. A. 
Arf4-GFP 39556 Addgene; U. S. A. 
EGFP-Dyn2 K44A n. a.  Dr. Sandra Ritz, MPI-P 
GFP-Rab11-wt 12674 Addgene; U. S. A. 
GFP-Rab5DN (S34N) 35141 Addgene; U. S. A. 
GFP-RhoB 23225 Addgene; U. S. A. 
pcDNA3 HA ARF1 DN-T31N 10833 Addgene, U. S. A.  
pcDNA3 HA Arf6  10834 Addgene; U. S. A. 
pcDNA3 HA Arf6 DN-T27N 10831 Addgene; U. S. A. 
pcDNA3-EGFP-Cdc42-Q61L 12600 Addgene; U. S. A. 
pcDNA3-EGFP-Cdc42-T17N 12976 Addgene; U. S. A. 
pcDNA3-EGFP-RhoA-T19N 12967 Addgene; U. S. A. 
pCMV6-AC-GFP-PMEL (NM_006928) n. a. Origene; U. S. A.  
pCMV6-AC-GFP-SWAP70 (NM_015055) n. a. Origene; U. S. A.  
pEGFP VAMP7 (1-220) 42316 Addgene; U. S. A. 
pEGFP-Rab5A-wt n. a.  Dr. Sandra Ritz, MPI-P 
pEGFP-Tubulin  30487 Addgene; U. S. A. 
pEGFP-β-Actin n. a.  Dr. Sandra Ritz, MPI-P 
pmaxGFP
TM
 n. a.  Lonza; Switzerland 




2.1.9 Self-designed plasmids 
shRNA constructs were generated by cloning of DNA oligonucleotides into pRNAi-H1-green and 
pRNAi-H1-neo vectors. Cloning was conducted according to the manufacturer´s protocol (Biosettia; 
U. S. A.). shRNA constructs were used to obtain a knockdown of human CD9, CD81, CD82, CD63, 
flotillin-1, clathrin heavy chain, caveolin-1, NPC1 and dynamin-1. The used oligonucleotides were 
ordered from Biosettia and are listed in Table 10. Simone-Franziska Glaser performed the cloning of 
the constructs into pRNAi-H1-green. 
Table 10: DNA oligonucleotides cloned in pRNAi-H1-green and pRNAi-H1-neo.  




































NM_005803 Flotillin-1 GGCAGAACAAGGAGATGTT AAAAGGCAGAACAAGGAGATGTTTTG
GATCCAAAACATCTCCTTGTTCTGCC 
NM_000271 NPC1 GCCTCTCTGAATGATACAA AAAAGCCTCTCTGAATGATACAATTG
GATCCAATTGTATCATTCAGAGAGGC 
2.1.10 siRNA/esiRNA 
Table 11 shows the siRNAs/esiRNAs that were used to downregulate the listed target proteins.  
Table 11: siRNAs and esiRNAs.  
Target Sequence/Ref. number Supplier 
ATG7-AF555  GGTCAAAGGACGAAGATAATT  Qiagen; U. S. A. 
Caveolin-1 GCCGUGUCUAUUCCAUCUATT  Ambion; U. S. A. 




CD81 UGAUGUUCGUUGGCUUCGUTT  MWG, Germany 
CD82 GCCCUCAAGGGUGUGUAUATT  Ambion; U. S. A. 
CD9 GGAGUCUAUAUUCUGAUCGTT  Ambion; U. S. A. 
Cdc42-esiRNA EHU117241 Sigma Aldrich; U. S. A. 
Clathrin heavy chain UAAUCCAAUUCGAAGACCAAUTT  MWG, Germany 
Dynamin I/II sc-43736  Santa Cruz Biotechnology; U. S. A. 
Flotillin-1 sc-35391 Santa Cruz Biotechnology; U. S. A.  
NPC1 s9669 Life technologies; U. S. A. 
Rab5A S11678 Life technologies; U. S. A. 
Rabankyrin-5-
esiRNA 
EHU089471 Sigma Aldrich; U. S. A.  
Rac1 S11711 Life technologies; U. S. A. 
2.1.11 Primer 
All primers for quantitative real time PCR were purchased from Eurofins MWG Operon (Germany) 
and are listed in Table 12.  
Table 12: Primer. 
Target Oligonucleotide sequence 
Caveolin-1 5´ GCGACCCTAAACACCTGAAC 3´ 
3´ TGTGTGTCAAAAGTGCCGTA 5´ 
CD63 5´ CGAAAAACAACCACACTGCT 3´ 
3´ TTTAGGGAAGGTACAGCTTC 5´ 
CD81 5´ CTCCAGCACACTGACTGCTT 3´ 
3´ TCGTTGGAGAAGTTCCTCCT 5´ 
CD82 5´ ACTGGACAGACAACGCTGAG 3´  
3´ GTTGTCGGAAAGACACTCCT 5´ 
CD9 5´ GCATGCTGGGACTGTTCTTT 3´ 
3´ TAAGGGTGTTCCTACTCCAC 5´ 
cdc42 5´ TTGATACTGCAGGGCAAGAG 3´ 
3´ ATCTCAGGCACCCACTTTTC 5´ 
Clathrin heavy chain 5´ GAGCCTCTTGCTGACATCAC 3´ 
3´ TTATTAGCGGGTAGACTTCC 5´ 
DMT1 5´ TGAATGCCACAATACGAAGG 3´ 
3´ ATAAAGCCACAGCCGATGA 5´ 
Dynamin-1 5´ CGATATCGAGCTGGCTTACA 3´ 
3´ AGTCCCTTGGTCCTACTCTA 5´ 
Flotillin-1 5´ GCATTGCCCAGGTAAAAATC 3´ 
3´ CTTCTGCCTCCGACTCTAAC 5´ 




3´ GGTAGTTACTGGGGAAGTAA 5´  
NPC1 5´ AAGGGGACGACTTCTTTGTG 3´ 
3´ ACACTGGTCCACCAAACGTA 5´ 
Rac1 5´ CCCGTGAAGAAGAGGAAGAG 3´ 
3´ TTGAGCAAAGCGTACAAAGG 5´ 
β-Actin 5´ TCGTGCGTGACATTAAGGGG 3´ 
3´ GTACTTGCGCTCAGGAGGAG 5´ 
2.1.12 Enzymes 
Enzymes for cloning, qPCR and tryptic digest are listed in Table 13. 
Table 13: Enzymes. 
Enzyme Supplier 
BamHI NEB; Germany 
PacI NEB; Germany 
Reverse transcriptase Bio-Rad; Germany 
T4 ligase NEB; Germany 
Trypsin Invitrogen; Germany 




 TOP10 chemically competent E. coli (Invitrogen; U. S. A.) were used for the 
transformation of plasmids and the growth of cultures for plasmid preparations. Bacteria were stored 
at – 80°C.  
2.1.14 Buffers, solutions and markers 
Table 14 depicts commercially available buffers, solutions and markers utilized in this study.  
Table 14: Buffers, solutions and markers.  
Buffer  Supplier 
10x Hybridization buffer  Biosettia; U. S. A. 
10x Ligation buffer  NEB; Germany 
10x Restriction enzyme buffer 3  NEB; Germany 
10x T4 Ligase buffer  NEB; Germany 
1x Dulbecco´s phosphate buffered saline  Invitrogen; U. S. A. 
1x Tris-acetate-EDTA buffer  Sigma Aldrich; U. S. A. 
2x LiSD-buffer NuPAGE  Invitrogen; U. S. A.  






 50 bp/100bp Ladder Fermentas; U. S. A. 
Hypochloride solution for flow systems Partec; Germany 
Novex
® 
AP Chemiluminescent substrate Invitrogen; U. S. A.  
NuPAGE
® 
Reducing agent Invitrogen; U. S. A.  
NuPAGE
®
 SDS Sample buffer Invitrogen; U. S. A. 
SeeBlue
®
 Plus2 prestained standard Life technologies; U. S. A.  
Sheath Fluid for flow systems Partec; Germany 
SYBR
® 
Safe DNA gel stain Invitrogen; U. S. A. 
2.1.15 Media and sera 
Table 15 lists the media, supplements and sera for bacterial culture and mammalian cell culture.  
Table 15: Media, supplements and sera. 
Medium Supplier 
Ciprofloxacin Sigma Aldrich; U. S. A. 
Dulbecco´s Modified Eagle Medium (DMEM) Invitrogen; U. S. A. 
Fetal calf serum (FCS) Lonza; Switzerland 
GlutaMAX
TM
 supplement 100x Life technologies; U. S. A. 
ImMedia
TM
 Amp Agar Invitrogen; U. S. A. 
ImMedia
TM
 Amp Liquid Invitrogen; U. S. A. 
ImMedia
TM
 Kan Liquid Invitrogen; U. S. A. 
ImMedia
TM
 Kan Liquid Invitrogen; U. S. A. 
Non-essential amino acids 100x PAA; Austria 
Penicillin/Streptomycin (Pen/Strep) 100x Invitrogen; U. S. A.  
RPMI-1640 Invitrogen; U. S. A. 
S. O. C. medium Invitrogen; U. S. A. 
Self-made nucleofection buffer According to (197) 
α-MEM Lonza; Switzerland 
0.25% Trypsin-EDTA Life technologies; U. S. A. 
2.5% Trypsin Life technologies; U. S. A. 
2.1.16 Commercial kits 
Table 16 depicts the used commercial kits. 
Table 16: Commercial kits.  
Kit Supplier 
Amaxa-SE cell line 4D-nucleofector X Kit L Lonza; Switzerland 
CellTiter-Glo
®
 Luminescent cell viability assay Promega; U. S. A. 






Green supermix Bio-Rad; U. S. A. 
iScript
TM
 DNA synthesis kit Bio-Rad; U. S. A. 
Lipofectamin 2000 Invitrogen; U. S. A. 
Novex
® 
Western breeze Invitrogen; U. S. A.  
Qiagen plasmid midi kit Qiagen; U. S. A. 
Qiagen plasmid mini kit Qiagen; U. S. A. 
RNeasy mini kit Qiagen; U. S. A. 
2.1.17 Software and bioinformatics 
The used software and online tools are depicted in Table 17.  
Table 17: Software and bioinformatic tools.  
Software Supplier/Source 
Bio-Rad CFX manager Bio-Rad; Germany 
DAVID ontology analysis http://david.abcc.ncifcrf.gov/ 
FCS Express V4.0 DeNovo Software; U. S. A. 
FlowMax 3 Partec; Germany 
Graph Pad Prism 5 Graphpad software inc; U. S. A. 
i-control 1.6.19.0 Tecan; Germany 
ImageJ (Fiji) http://rsbweb.nih.gov/ij/ 
LASAF confocal software Leica; Germany 
ND-8000 V2.0 Thermo Scientific; Germany 
Primer3 http://bioinfo.ut.ee/primer3-0.4.0/ 
shRNA Designer http://biosettia.com/support/shrna-designer 





2.2  Methods 
In this segment, a description of all used methods is provided.  
2.2.1 Preparation of giant unilamellar vesicles 
For release studies of nanoparticulate cargo, 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC) giant 
vesicles were prepared by electroformation. 10 mM DOPC (Avanti lipids, U. S. A.) were dissolved in 
chloroform. 25 µl dissolved DOPC was introduced dropwise on indium tin oxide (ITO) coated glass 
electrodes (5 x 5 cm
2
, 20 nm ITO) and dried under vacuum for 2 h. The two electrodes were clamped 
together and separated by a PDMS spacer. The gap was filled with 400 µl MilliQ water and the 
electrodes were connected to an AC volt generator (20 MHz programmable function generator, Series 
8200, Kontron Messtechnik, Germany) under the following conditions: 1 V at 10 Hz for 2 h. Vesicles 
were diluted 1:10 in water and release experiments were started with the exposure of GUVs to 150 µg 
ml
-1
 nanoparticles for 0 to 180 min (198).  
2.2.2 Molecular biology and protein biochemistry 
In the following section, methods of plasmid cloning and techniques of protein biochemistry are 
described. 
2.2.2.1 Transformation of E. coli 
For the amplification of plasmid DNA in bacteria, chemically competent OneShot
®
 TOP10 E. coli 
(Life technologies; U. S. A.) were used. For the transformation, bacteria were thawed on ice for 5 min. 
30-300 ng of plasmid was added to the bacteria and incubated on ice for another 15 - 20 min. Heat-
shock was performed at 42 °C for 30 sec. After chilling on ice for 2 min, the transformed bacteria 
were incubated in 1.5 ml S. O. C. medium for 1 h at 37 °C under agitation. The culture was plated on 
antibiotic LB agar and incubated for 12 - 16 h at 37 °C. 
2.2.2.2 Plasmid DNA isolation from E. coli 
To amplify plasmid DNA at small or medium scales, a picked E. coli colony was cultured in 50 - 100 
ml antibiotic LB medium overnight at 37°C. Cells were harvested at 6000 x g for 15 min at 4 °C. 
Plasmid DNA was isolated with the Qiagen Mini/Midi preparation kits according to manufacturer´s 
instructions. The DNA pellet was dissolved in an appropriate volume of nuclease-free water and 




2.2.2.3 DNA concentration measurements 
Concentrations of plasmid DNA and RNA were measured by determining the absorbance (A260) using 
a NanoDrop 8000 (Thermo Scientific). Protein impurities were routinely checked by determining the 
A260/A280 ratio. Samples with an absorbance ratio A260/A280 of 1.8-2.0 were used for further 
experiments.  
2.2.2.4 SDS-PAGE 
To separate complex protein mixtures and cell lysates according to their size, a SDS-PAGE was 
performed. The protein sample was mixed with LDS sample buffer, heated up for 5 min at 95 °C and 
was then loaded on a 10% NuPAGE bis-tris gel. As a protein marker, the SeeBlue Plus2 prestained 
marker (Life technologies) was used. Proteins were separated at 100 V for 1.5 h and then forwarded to 
western blotting or coomassie staining. Coomassie staining was performed after the protocol of 
Candiano et al.(199). 
2.2.2.5 Western blotting 
Transfer of proteins to PVDF membranes was performed with the iBlot dry-blotting system according 
to the manufacturer´s protocol (Life technologies). Development of blots was conducted using the 
western breeze immunodetection kits (Life technologies). The blots were recorded inside a LAS3000 
imager (Fujifilm, Japan). 
2.2.2.6 RNA isolation and cDNA synthesis 
cDNA synthesis was performed after RNA isolation (Qiagen RNeasy kit) from treated or untreated 
cells utilizing the iScript cDNA synthesis kit (Bio-Rad). cDNA synthesis was performed as stated in 
the manufacturer´s protocol (Bio-Rad). Concentrations of RNA solutions were determined by 
Nanodrop measurements. Quality of RNA was investigated on a 3 wt% agarose gel, which was loaded 
with SYBR green.  
2.2.2.7 Quantitative real time polymerase chain reaction 
Quantitative real time PCR was used to analyze the expression levels of mRNA after siRNA-mediated 
mRNA knockdown. Briefly, SYBR green insertion into specifically amplified PCR products was 
measured. Gene expression was evaluated by the comparative ∆∆Ct-method (200). Normalization of 
data was based on the expression levels of the two reference genes GAPDH and β-actin. Calculations 




2.2.3 Cell culture 
All experiments were aseptically carried out with HeLa, Jurkat and multipotent mesenchymal stroma 
cells (hMSCs) according to security level S1 safety issues. HeLa cells (DSMZ, Germany) were 
cultivated in DMEM (Life Technologies) that was supplemented with 10% fetal calf serum 
(Invitrogen, U.S.A.), 100 units penicillin, 100 µg ml
-1
 streptomycin and 1 mM pyruvate (all Life 
technologies). Jurkat cells were cultivated in RPMI-1640 supplemented with 10% fetal calf serum 
(Invitrogen), 100 units penicillin, 100 µg ml
-1
 streptomycin and 1 mM pyruvate. Multipotent 
mesenchymal stroma cells were cultured in α-MEM with 20% FCS, 100 units penicillin, 100 µg ml-1, 
1 mM pyruvate and 2 µg ml
-1
 ciprofloxacin. Cells were passaged until a confluency of ~80% was 
reached. All cells were incubated in a humidified incubator with 5% CO2 at 37 °C (Labotec, 
Germany). 
2.2.3.1 Nanoparticle treatment of cells 
Nanoparticle studies were performed with the standard concentrations of 75 µg ml
-1
 or 150 µg ml
-1
 
(solid content). For this, cells were seeded at a concentration of 15.000 – 20.000 cells per cm-2. 
Nanoparticles were dispersed in full growth medium, added to cells and incubated for the indicated 
time. Afterwards, nanoparticles were removed by washing and cells were forwarded to the indicated 
analysis. 
2.2.3.2 Feeding of lipid droplets and nanoparticle cargo release 
For nanoparticle cargo release studies, HeLa cells were fed with oleic acid. For this, the complexation 
of fatty acid free BSA was performed with oleic acid. 100 mM oleic acid was dissolved in 10 ml of 
100 mM NaOH at 50 °C. In parallel, 150 mg fatty acid free BSA was dissolved in 1.15 ml PBS under 
shaking at 50 °C. The molar ratio of OA/BSA was set to 6:1 (pH 7.6). For the feeding of lipid droplets, 
HeLa cells were incubated with 25 µM OA-BSA overnight. The BSA-carrier served as a control. For 
cargo release experiments, 150 µl ml
-1
 nanoparticles were added for 30 min and fluorescence images 
were acquired using an Olympus XI81 fluorescence microscope.  
2.2.3.3 Modification of endocytosis and cell signaling by small inhibitor 
molecules 
Inhibition of different endocytosis and signaling pathways was conducted utilizing freely permeable 
small inhibitor molecules (Table 5). Inhibitors were dissolved according to manufacturer´s 
recommendations – most frequently in DMSO. Depending on the accepted concentrations in literature 
and the observed cytotoxic effects, the preincubation of the inhibitors was performed for 30 - 60 min 
in PBS at the indicated concentrations. For cytochalasin D and the reversible PI3K inhibitor 




and controls were added to the cells as long as indicated. Quantification of endocytosis was performed 
by flow cytometry.  
2.2.3.4 Nucleofection of siRNA and transfection of plasmid DNA 
The transfection of HeLa cells with siRNA was performed by nucleofection. 5 x 10
5
 cells were 
resuspended in 90 µl of SE cell line solution. 30 - 300 pmol of siRNA was added. Nucleofection was 
carried out in a 100 µl nucleofector cuvette that fitted into the 4D nucleofector (Lonza, Switzerland). 
A cell line-specific nucleofection program was applied. Nucleofected cells were transferred into 1 ml 
of full growth medium. After 2 - 3 days of knockdown, mRNA and protein levels were evaluated by 
qPCR and western blotting, respectively. Transfection of plasmid DNA was performed using Fugene 
HD (Promega) according to manufacturer´s protocol. Evaluation of protein expression was checked 24 
- 48 h after transfection.  
2.2.4 Magnetic separation of intracellular vesicles 
For the purification of intracellular vesicles from cells, HeLa cells were loaded with SPIOPSN and the 
magnetic isolation of vesicles was performed. For this, 150 µg ml
-1
 nanoparticles were added to 1.8 x 
10
7
 HeLa cells growing in the exponential phase (DSMZ, Germany). Cells were exposed to 
nanoparticles for 20 h at 37 °C and 5% CO2. Then, cells were thoroughly washed ten times with a total 
of 1000 ml of PBS (Life technologies) to remove extracellular particles and debris. After the 
neutralization of trypsin with cell culture medium, further washes were conducted. The last washing 
fraction was centrifuged (20.000 x g, 30 min) and macroscopically checked for free nanoparticles. 
Afterwards, cell disruption was performed using a 27 G needle (BD biosciences). Disruption was 
microscopically monitored after exactly 35 strokes. This step was performed on ice and in 0.5 ml PBS 
with cOmplete protease inhibitor (Roche). Cell debris was removed by cooled centrifugation (5 min at 
453 x g). The supernatant was recentrifuged until no debris was detectable. The brownish cytosolic 
supernatant was then injected into a custom-made magnetic sorting device with a strong neodymium 
magnet (Article no. Q-60-30-15-N; Supermagnete; Germany). Magnetic adhesion was conducted over 
12 h under cooling and in the presence of protease inhibitors in a strong magnetic field. The small 
magnetic pellet was carefully washed five times with 3 ml PBS (with protease inhibitor). For quality 
control, parts of the magnetic pellet were transferred to transmission electron microscopy and checked 
for non-vesicular impurities. An SDS-PAGE was performed to observe first differences in protein 
composition of the fractions. For label free quantitative LC-MS, nanoparticle associated proteins were 
solubilized in 25 µl buffer (7 M urea, 2 M thiourea, 4% CHAPS). After solubilization, nanoparticles 
were removed for 30 min at 20.000 x g and the supernatant was forwarded to LC-MS analysis. The 




2.2.5 Mouse experiments and in vitro cell sorting 
Investigations of the in vivo distribution of nanoparticles were performed in the lab of PD Dr. Ralph 
Meyer at the University medical center in Mainz. For this, 2 mg of SPIOPSN were tail-vein-injected 
into NSG mice. After 20 h of SPIOPSN exposure, peripheral blood, spleen, liver and kidney were 
prepared. Single cell suspensions were obtained using a cell strainer. Single cells were magnetically 
separated by MACS columns and forwarded to confocal microscopy for qualitative analysis. 
2.2.6 Immunocytochemistry 
The following section describes the methods used for the detection of intracellular proteins and the 
staining of cell compartments. 
2.2.6.1 Immunofluorescence staining 
For immunostainings, 15.000 cells cm
-2 
were seeded in Ibidi iTreat µ-dishes. After nanoparticle 
incubation, cells were fixed with 4% paraformaldehyde and 0.025% glutaraldehyde for 20 min (both 
Sigma Aldrich). Cell permeabilization was conducted with 0.1% saponin (Sigma Aldrich) for 10 min 
at RT. Blocking was performed by the incubation of the cells with 3% BSA for 10 min at 37 °C. The 
primary antibodies were incubated for 60 min in 1% BSA at 37 °C. After washing, the respective 
secondary antibody was applied for 30 min in 1% BSA at 37 °C. The sample was washed again and 
then forwarded to confocal microscopy.  
2.2.6.2 Filipin staining, CellMask Orange staining and LysoTracker staining 
Cholesterol was stained with filipin (83). After washing of the cells with PBS, 50 µg ml
-1
 filipin in 
PBS was applied to the cells for 15 min. Cells were washed two times with PBS and then analyzed by 
fluorescence microscopy. Cell Mask Orange and LysoTracker stainings were performed according to 
manufacturer´s instructions.  
2.2.7 Microscopy 
In the upcoming section, the used microscopic methods are described. 
2.2.7.1 Fluorescence microscopy 
An Olympus XI81 fluorescence microscope equipped with a Olympus U-RFL-T-Mercury lamp unit 
was used for fluorescent microscopy to visualize GUVs and cells. An UPlanFI 100x/1.30 immersion 
oil objective was used for the experiments. CellSense Dimension software (Olympus) was utilized for 




2.2.7.2 Confocal microscopy 
Cells were imaged by confocal laser scanning microscopy using a commercial setup (LSM SP5 STED 
Leica laser scanning confocal microscope, Leica Microsystems, Germany) consisting of an inverse 
fluorescence microscope DMI 6000 CS. The microscope was equipped with a laser combination and 
with five detectors operating in a range of 400 - 800 nm. A HCX PL APO CS 63x/1.4-0.6 oil objective 
was used. Nanoparticles (pseudocolored red) were excited with an argon laser (20 mW; λ=514 nm) 
and detected at 530 - 545 nm. Secondary antibodies were excited with a 488 nm HeNe laser (pseudo-
colored green) and detected at 510 - 525 nm in a sequential scanning mode. PMI was pseudocolored in 
green. Image analysis was performed with LAS AF software (Leica, Germany). Recording of z-Stacks 
was conducted in a stepsize of 300 nm. For live cell imaging, cells were incubated with nanoparticles, 
washed with DMEM and PBS and analyzed by confocal microscopy using the XYT-mode recording a 
single image each 3s. Images were evaluated with LAS AF 3000 software (Leica) or Velocity 
(PerkinElmer).  
2.2.7.3 Cryo high pressure freezing electron microscopy 
Cryo high pressure freezing electron microscopy experiments were performed by Claudia 
Messerschmidt as described in the published work (201).  
2.2.8 Flow cytometry 
Nanoparticle uptake was quantitatively measured by flow cytometry. Cells were seeded at 15 000 cells 
cm
-2
 and incubated with 75 - 150 µg ml
-1
 nanoparticles for the indicated time. Then, cells were washed 
with DPBS (Life Technologies), trypsinized and forwarded to flow cytometry. Flow cytometric 
analysis was performed using a CyFlow ML cytometer (Partec) with a 488 nm laser for the excitation 
of BODIPY and a 527 nm band pass filter for emission detection. Cytotoxicity was measured staining 
the cells with 28.6 mg ml
-1
 7-aminoactinomycin D (7-AAD). Excitation of 7-AAD was conducted at 
562 nm and emission was measured at 682 nm. Data analysis was performed using FCS Express V4 
software (DeNovo Software, U.S.A.) by selecting the counted cells on a forward/sideward scatter plot, 
thereby excluding cell debris. These events were further analyzed for uptake. Median intensity was 
determined in triplicates. 
2.2.9 Fluorescence spectroscopy 
Fluorescence spectroscopy was performed by using a Tecan Infinite
®
 M1000 PRO (Tecan, Germany). 
Samples were prepared in a 96-well plate (Greiner). Absorbance or fluorescence measurements were 
performed with the standardized settings of the software icontrol
®




2.2.10 TOP3-based label free quantitative mass spectrometry 
Samples were prepared for mass spectrometry as described in section 2.2.4. TOP3-based label free 
quantitative mass spectrometry measurements were performed by Dr. Stefan Tenzer (Institute of 
Immunology, University clinics Mainz) (24). Database alignment of the peptide fragments was 
conducted by Dr. Stefan Tenzer.  
2.2.11 DAVID ontology analysis 
After the data evaluation of the MS spectra, protein enrichment factors were determined. All proteins 
that were > 2-fold enriched inside the magnetic fraction in comparison to the nonmagnetic supernatant 
were forwarded to DAVID protein ontology analysis (http://david.abcc.ncifcrf.gov/). Functional 
annotation clustering was performed using DAVID ontology analysis with the GOTERM_CC_FAT. 
High stringency analysis classified proteins in different annotation clusters. P-values and benjamini-
values were calculated. Reconstruction of intracellular nanoparticle trafficking is based on the 
GOTERMs “vesicles” and “lysosome”. 
2.2.12 Statistical analysis 
Statistical analysis of the data was performed using MS Office Excel 2010 (Microsoft) and GraphPad 
Prism 5.0 (GraphPad software, U. S. A.). For statistics, mean and standard deviation of the data sets 
were calculated. For analytical statistics, treated groups were compared and analyzed with GraphPad 
Prism 5.0. To compare two data sets, a Student´s t-test was performed. Data groups with a p-value less 













The following chapter provides the major results of this work. The gained observations are subdivided 
into three parts. The first section is based on the publication “Drug delivery without nanoparticle 
uptake: delivery by a kiss-and-run mechanism on the cell membrane” describing the interaction of 
nanoparticles with cell membranes and the non-invasive delivery of hydrophobic molecules to cells 
(6). The second part reveals the results of the entry mechanisms of superparamagnetic iron oxide 
polystyrene nanoparticles (2). Finally, the third section presents the findings of the intracellular 
nanoparticle trafficking (Hofmann et al., major revision). 
3.1 Nanoparticles deliver cargo to cells via a “kiss-and-run” mechanism 
In the first part of this study, we have investigated the drug delivery potential of biodegradable poly-L-
lactide nanoparticles in terms of drug release kinetics, drug release mechanisms and subcellular 
distribution of the nanoparticulate cargo. The initial idea was to demonstrate a novel and non-invasive 
strategy for drug delivery, since nearly all concepts of nanoparticulate drug delivery devices rely on 
intracellular nanoparticle uptake. One major drawback of invasive drug delivery systems is that the 
nanoparticulate drug stays inside the endosomal lumen, while the target site is frequently located 
inside the cytoplasm. Release can only be triggered by the disruption of the endosome or by the 
disassembly of the nanomaterial through fairly unknown endolysosomal components of nanoparticle-
containing vesicles. From the site of material science, this strategy also requires a sophisticated 
synthesis protocol to obtain such nanomaterials (6, 83, 202-204). To bypass complex endocytosis 
mechanisms and ambitious synthesis routes, a direct way of cargo delivery right on the cell membrane 
could avoid these hurdles.  
One of the most important prerequisites for the demonstration of such a non-invasive drug delivery 
mechanism is the rapid delivery of the cargo within several minutes. The likelihood of a regular 
nanoparticulate endocytosis has to be minimized, since cargo release can then occur via the endosomal 
membrane. After intensive research on this, we have identified a suitable and biodegradable 
nanoparticulate system that was synthesized of poly-L-lactide (detailed description of nanomaterial 
properties in Table 1). Additionally, the nanoparticles were loaded with the hydrophobic and 
fluorescent model cargo N-(2,6-diisopropylphenyl)-perylene-3,4-dicarbonacid-imide (PMI, BASF) to 
monitor cargo release. The magnetite load assisted in the detection of the nanoparticles by 
transmission electron microscopy (TEM). To examine the nanoparticulate cargo release in more detail, 






3.1.1 Hydrophobic nanoparticulate cargo is rapidly delivered into highly 
diffractive organelles of Jurkat and HeLa cells 
To test whether PLLA-Fe-PMI nanoparticles have the potential to rapidly and non-invasively release 
their cargo molecules, we studied the interactions with the human T lymphocyte cell line Jurkat. 
Previous studies from our group and others showed that primary T lymphocytes and Jurkat cells lack 
the uptake of polymeric nanoparticles (66, 205, 206). Therefore, Jurkat cells are a suitable system to 
demonstrate the non-invasive delivery of the cargo molecules. Experimentally, Jurkat cells were 
incubated with PLLA-Fe-PMI nanoparticles for 20 min as seen in the representative confocal images 
in Figure 7. Confocal images were recorded every 2-3 min to track the intracellular cargo delivery. 
After 5 min of incubation, a perfect colocalization of PMI with highly diffractive organelles was 
observed (n = 200 cells; colocalization of PMI with highly diffractive organelles = 100%). Similar 
observations were recorded for the PMI transport into the cervical cancer cell line HeLa (n = 120 cells; 
100% colocalization of PMI with highly diffractive organelles).  
Over time, the PMI signal accumulated inside the highly diffractive organelles. PMI accumulation was 
dependent on the PLLA-Fe-PMI concentration as shown by flow cytometry (Figure 7C). Further 
experiments with hMSCs (n = 10 cells; 100% colocalization with highly diffractive organelles) 
additionally confirmed the results of a rapid cargo delivery in primary cells (data not shown). Several 
other tested nanoparticles such as PLLA-PMI and PS-COOH-PMI revealed similar results in concerns 
to the velocity of PMI delivery into highly diffractive organelles of HeLa cells as also shown in the 





Figure 7: The nanoparticulate cargo PMI is rapidly delivered into a subcellular compartment with a high diffractive 
index. (A) Jurkat cells were exposed to 150 µg ml-1 PLLA-Fe-PMI nanoparticles. PMI accumulation was analyzed by 
confocal live cell imaging. A low intracellular accumulation of PMI was visible after 5 min of incubation. PMI further 
accumulated inside organelles that had a high diffractive index in DIC microscopy (white arrows). (B) HeLa cells were 
exposed to 150 µg ml-1 PLLA-Fe-PMI nanoparticles. The accumulation of PMI inside highly diffractive organelles was 
subsequently recorded by confocal microscopy after 15 min of nanoparticle incubation (white arrows). (C) HeLa cells were 
exposed to 150 µg ml-1 and 300 µg ml-1 PLLA-Fe-PMI for 1 h, respectively. PMI delivery was quantified by flow cytometric. 
Scale bars: 10 µm. Representative images are shown. 
To assure that the staining of intracellular compartments originated from the nanoparticle and not from 
the free dye, we analyzed if non-encapsulated dye molecules are present in our nanoparticulate 
dispersion. For these experiments, the supernatants of PLLA-Fe-PMI were obtained by the 
centrifugation of the nanoparticle stock solution. Subsequently, experiments with nanoparticle 
supernatants were performed. To study the presence of free dye molecules, the same volume of PLLA-
Fe-PMI supernatant was added to HeLa cells that was equal to the used volumes in the nanoparticle-
containing experiments (Figure 8A). Also a three times higher amount of supernatant did not stain the 
intracellular compartments. Moreover, we measured the fluorescence of the supernatants by 
fluorescence spectroscopy (Figure 8B). In summary, the results showed that the nanoparticle 
supernatants significantly lacked free dye molecules in in vitro experiments after two hours of 
exposure to HeLa cells. Therefore, it was not surprising that only the treatment with PLLA-Fe-PMI 
nanoparticles induced an accumulation of PMI inside the cells (Figure 8A). The analysis of the 
supernatants by fluorescence spectroscopy confirmed that the investigated nanoparticle suspension 





Figure 8: Significant absence of free dye molecules in nanoparticulate supernatants demonstrates that PLLA-Fe-PMI 
nanoparticles directly deliver PMI to the cells. Supernatants of PLLA-Fe-PMI nanoparticles were tested for the presence 
of free dye molecules in the continuous phase. (A) PLLA-Fe-PMI supernatants were obtained by the centrifugation of PLLA-
Fe-PMI nanoparticles (30 min; 20 000 x g). The appropriate volume of supernatant was added to HeLa cells for 2 h at 37°C 
that equated to the volumes of the solid contents of 150 µg ml-1 and 450 µg ml-1, respectively. Water and pure PLLA-Fe-PMI 
nanoparticles (150 µg ml-1) served as controls. (B) The fluorescence of PLLA-Fe-PMI supernatants was measured by 
fluorescence spectroscopy. Water and PLLA-Fe-PMI nanoparticles (150 µg ml-1) served as a control. Values are given as 
mean + SD. *** indicates p < 0.001. Scale bar: 10 µm. TL: Transmission light. FL: Fluorescence light. Representative 
images are shown. 
Taken together, it was shown that PLLA-Fe-PMI nanoparticles directly deliver PMI to Jurkat, HeLa 
and multipotent human stroma cells in a rapid and efficient manner. In all cells, PMI accumulated 
inside organelles with a highly diffractive index (Figure 9).  
3.1.2 Hydrophobic PMI accumulates inside lipid droplets 
By keeping the previous images of DIC microscopy in mind, we suspected that the highly diffractive 
intracellular compartments could be lipid droplets (LDs) (207). Lipid droplets are intracellular 
organelles that are present in most of the cells, thereby playing a fundamental role in storing neutral 
lipids (e. g. triacylglycerols and sterol esters) (208). Lipid droplets are stabilized by a monolayer of 
amphiphilic phospholipids, whereas integral proteins such as tail-interacting protein 47 (TIP47) or 
adipose differentiation-related protein (ADRP) are present as important constituents of the LD 




To study the subcellular disposition of PMI more precisely, we started to artificially increase the 
number of lipid droplets by the feeding of HeLa cells with BSA-coupled oleic acid (209). After 18 h 
of oleic acid treatment, PLLA-Fe-PMI nanoparticles were exposed to the cells (Figure 9). After 5 - 15 
min, PMI accumulated again inside these highly diffractive organelles that had increased in number 
and size due to the oleic acid treatment. These results indicated that the total intracellular accumulation 
of PMI is dependent on the mass of incorporated fatty acids inside LDs.  
 
Figure 9: The nanoparticulate cargo PMI accumulates inside hydrophobic lipid droplets. HeLa cells were exposed to 
PLLA-Fe-PMI nanoparticles. Cells were analyzed for the subcellular disposition of PMI. (A) HeLa cells were fed with pure 
BSA carrier or with 25 µM BSA-oleic acid complexes for 18 h. Afterwards, cells were exposed to 150 µg ml-1 PLLA-Fe-
PMI nanoparticles for 15 min. The PMI signal was analyzed by fluorescence microscopy (white arrows). (B) 150 µg ml-1 
PLLA-Fe-PMI nanoparticles were incubated for 15 min on HeLa cells. After fixation and permeabilization, cells were 
immunostained for the lipid droplet markers TIP47 and ADRP. Boxes at the bottom right corner show a magnification of the 
original images. (C) A correlative microscopy approach of a single cell combining transmission electron microscopy (1) and 
confocal microscopy (2) assisted in the generation of an ultrastructure/fluorescence overlay image to study the disposition of 
the fluorescent signal and the PLLA-Fe-PMI nanoparticle. Magnification displays PLLA-Fe-PMI nanoparticles (black 
arrows) in close proximity to the cell membrane. Scale bar: 10 µm. N1/N2: Nucleus 1/ Nucleus 2 (TEM micrographs were 
recorded by Claudia Messerschmidt). Representative images are shown. 
In order to confirm these results further, PMI signals were analyzed for their colocalization with TIP47 
and ADRP by immunofluorescence stainings. The PMI signals perfectly colocalized with TIP47 (n = 




colocalization: 100%) after nanoparticle exposure. Transmission light analysis identified a high 
PMI/TIP47/ADRP colocalization with organelles of a high diffractive index. Moreover, a correlative 
TEM/cLSM approach demonstrated a lack of nanoparticles after 30 min inside cells indicating that 
PMI delivery is not mediated by an endosomal escape of the dye. Despite of extensive TEM studies, 
PLLA-Fe-PMI nanoparticles were only detected in the extracellular regions close to the plasma 
membrane. From these observations one could assume that the interactions between membrane and 
nanoparticles are not permanent. Indeed, in all live cell imaging experiments, we detected only 
temporary membrane interactions of PLLA-Fe-PMI nanoparticles that might mediate the delivery of 
PMI into the cells. Taken together, we could conclude that the encapsulated molecule PMI is released 
from the nanoparticles into the phospholipid membrane of the cell. This phenomenon was also noticed 
in release experiments with giant unilamellar vesicles (Figure 10). 
3.1.3 Nanoparticulate PMI release is triggered by the contact with 
hydrophobic media and via the temporary surface interactions with 
giant unilamellar vesicles 
With the previous results, we demonstrated a rapid release and a specific transport of PMI into lipid 
droplets. In the next experiments, we wanted to gain knowledge about the non-invasive release 
mechanism of PMI from the PLLA-Fe-PMI nanoparticles. Therefore, we first examined the release of 
PMI inside different hydrophobic and hydrophilic media (Figure 10A). The release was investigated 
under permanent contact between the media and nanoparticles for 45 min at 37 °C. Afterwards, we 
quantified the released dye in the supernatants by fluorescence spectroscopy. We showed that regular 
growth medium and 1% DMSO failed to trigger the release of hydrophobic cargo into the continuous 
phase, whereas glyceryl trioleate induced a significant release of PMI into the hydrophobic phase 
(Figure 10). These results demonstrated that hydrophobic environments can induce the effective 
release of hydrophobic molecules out of nanoparticles.  
Then, we analyzed whether hydrophobic surfaces like artificial cell membranes can potentially trigger 
the release of PMI. To solve this question, we performed cargo release experiments with giant 
unilamellar vesicles to simulate a hydrophobic cell membrane a nanoparticle can interact with (Figure 
10C). These experiments were performed in pure water and with PLLA-Fe-PMI nanoparticles. The 
exposure of PLLA-Fe-PMI to DOPC vesicles led to an accumulation of PMI inside the membrane of 
the GUVs. During this live vesicle experiment, PLLA-Fe-PMI nanoparticles were observed to briefly 
interact with GUVs for 50 - 100 ms leaving the membrane after a short touching event (Figure 10C; 
white arrows). We referred to this event as a brief “kiss”, leaving behind some stains on the touched 
object. After its “kiss”, the particle detached and “runs” away (“kiss-and-run” mechanism). After 15 – 





Figure 10: PMI is released from the nanoparticle by hydrophobic interactions with media and surfaces. (A)150 µg ml-1 
PLLA-Fe-PMI nanoparticles were incubated in 1% DMSO, full growth medium and in glyceryl trioleate solution. The 
samples were shortly mixed and stored for 45 min at 37°C. After centrifugation, the fluorescence intensity of the supernatant 
was quantified by fluorescence spectroscopy (measurements were performed by Dr. Markus B. Bannwarth). (B) Giant 
vesicles made of 1,2-dioleoyl-sn-glycero-3-phosphocholine were prepared by electroformation. PLLA-Fe-PMI nanoparticle 
supernatant, BODIPY and PMI were tested for their features to stain membranes. (C) DOPC vesicles were exposed to 150 µg 
ml-1 PLLA-Fe-PMI nanoparticles for 15 min. PMI accumulation was then recorded by live vesicle imaging to show the “kiss-
and-run” mechanism.  
Hence, we concluded that the investigated PMI-containing nanoparticles briefly interacted with the 
phospholipid bilayer of cells and GUVs, thereby releasing the hydrophobic cargo. In cell experiments, 
PMI diffused through the membrane and accumulated inside the even more hydrophobic surrounding 
of lipid droplets, while in the case of GUVs only the membrane was stained. In all cases, we observed 
a “kiss-and-run” mechanism for nanoparticles with noncovalently bound cargo molecules. In contrary, 
cargo release was suppressed by the covalent bonding of the cargo to the polymeric matrix (Figure 
11). 
3.1.4 Covalent-bonding of cargo to the polymeric matrix leads to the 
retention of the cargo molecules inside nanoparticles 
In summary, all nanoparticles (with non-covalently bound PMI) that have been tested in this study 
revealed excellent drug delivery properties. To block the delivery of cargo by “kiss-and-run”, 
polystyrene nanospheres with covalently-bound dyes were synthesized and analyzed by live vesicle 




linked BODIPY dye) that strongly interacted with the giant vesicle. The nanoparticles dashed around 
on the surface of the vesicle without releasing the dye molecules (Figure 11; white arrows). In 
contrast, superparamagnetic nanoparticles (SPIOPSN-BODIPY) failed to permanently interact with 
the surface of the giant vesicle. However, they also revealed a “kiss-and-run”-like mechanism lacking 
dye release.  
 
Figure 11: Covalent bonding of cargo molecules to the polymeric matrix inhibits dye release by the “kiss-and-run” 
mechanism. (A) GUVs (DOPC) were exposed to 150 µg ml-1 PS-NH2-BODIPY nanoparticles for 15 min. Live vesicle 
imaging was utilized to show “kiss-and-run”. (B) 150 µg ml-1 SPIOPSN-BODIPY were incubated on GUVs (DOPC) for 15 
min. Live vesicle imaging was utilized to show “kiss-and-run”. (C) HeLa cells were exposed to 150 µg ml-1 SPIOPSN-
BODIPY for 20 h. The lipid droplet marker TIP47 was visualized by immunostainings. Representative images are shown. 
(D) HeLa cells were exposed to SPIOPSN-BODIPY supernatants (volume equaled to the solid content volume of   150 µg 
ml-1). 20 h later, cells were stained for TIP47 (green). (E) Quantification of free dye molecules was performed by 




In cell experiments with SPIOPSN, the nanoparticles also displayed a “kiss-and-run” mechanism in 
form of a temporary membrane interaction. However, the nanoparticles lacked the colocalization with 
the lipid droplet marker TIP47 showing that no hydrophobic dye molecules was released from the 
particles (Figure 11C). Further on, we investigated whether the nanoparticle solution contained free 
dye molecules. The significant absence of free dye in the supernatant of the nanoparticle dispersion 
was shown by in vitro measurements and fluorescence spectroscopy (Figure 11D/E).  
These observations implied that a covalent bonding between dyes and the polymeric matrix of 
nanoparticles blocked the dye release by “kiss-and-run”. In this case, SPIOPSN-BODIPY 
nanoparticles are potentially attractive to study cellular entry mechanisms (see section 3.2).  
3.2  SPIOPSN are endocytosed by a macropinocytic-like mechanism  
Having investigated the drug delivery properties of several nanoparticles, a well-characterized 
nanoparticle (SPIOPSN-BODIPY) was identified to analyze the entry mechanisms and intracellular 
trafficking pathways of polymeric nanoparticles. SPIOPSN-BODIPY are negatively charged 
superparamagnetic iron oxide polystyrene nanoparticles with an average size of 126 nm that showed 
less aggregation, only temporarily-interacted with cell membranes and were efficiently taken up into 
cells. This led us to the analysis of the uptake mechanism, which is utilized by these nanoparticles to 
enter a cell.  
3.2.1 SPIOPSN are cointernalized with dextran-488 and entry is dependent 
on F-actin 
To investigate the entry mechanisms of SPIOPSN, we first analyzed the fluid phase uptake in co-
internalization experiments with fluorescently labeled dextran-488. Therefore, HeLa cells were 
coincubated with SPIOPSN and dextran-488. Colocalization was analyzed after 6 h of incubation by 
confocal microscopy (Figure 12). Examinations showed that SPIOPSN were transported via dextran-
488-filled vesicles. These organelles were also visible by transmission light. Since dextran-488 
internalization is generally accepted as a tracer of an F-actin-dependent process called 
macropinocytosis, we pretreated HeLa cells with cytochalasin D to prevent actin polymerization. After 
5 h of SPIOPSN exposure, we detected a significant drop of the internalization rate of nanoparticles in 
cytochalasin D pretreated cells as compared to untreated cells (decrease to 36.84%, SD 5.17%, n = 6, 
*** indicates p < 0.001, Student´s t test). Uptake of dextran-488 was inhibited to a comparable amount 





Figure 12: SPIOPSN are cointernalized with the fluid phase marker dextran-488 and entry is dependent on F-actin 
polymerization. (A) HeLa cells were coincubated with 5 µg ml-1 10 kDa dextran-488 and SPIOPSN for 6 h. Colocalization 
was then analyzed by confocal microscopy. Scale bar: 1 µm. (B) HeLa cells were preincubated with 150 µM cytochalasin D 
for 45 min at 37°C. Afterwards, HeLa cells were exposed to 150 µg ml-1 SPIOPSN or dextran-488 for 5 h, respectively. 
Uptake was quantified by flow cytometry. (C) 150 µg ml-1 SPIOPSN were incubated on HeLa for 20 h and then analyzed for 
macropinocytic structures by cryo-transmission electron microscopy. (D) 1200 µg ml-1 PLLA-Fe-PMI nanoparticles were 
incubated for 24 h on HeLa cells and then analyzed for macropinocytic structures (white box) by cryo-transmission electron 
microscopy (TEM micrographs were taken by C. Messerschmidt). Scale bar: 100 nm. Representative images are shown. 
These data pointed towards a macropinocytic uptake mechanism. This hypothesis was supported by 
transmission electron microscopy, where potential macropinocytic-like structures were identified for 
SPIOPSN-BODIPY and for PLLA-Fe-PMI nanoparticles. Therefore, we further asked whether small 
GTPases, which are supposed to be involved in macropinocytosis, mediate the entry of SPIOPSN into 
HeLa cells (Figure 13).  
3.2.2 SPIOPSN entry is accompanied by the small GTPases Rac1 and cdc42 
in the initial stages of uptake 
The formation of macropinosomes is a complex process that is subdivided into cup initiation, cup 




tightly regulated by several small GTPases (146). To focus on the early effectors of classical 
macropinocytosis, we overexpressed constitutively active Rac1 Q61L, cdc42 Q61L and cdc42 T17N 
as GFP fusion proteins in HeLa cells. 24 h after transfection, SPIOPSN were added to the cells for 6 h. 
Colocalization of SPIOPSN with Rac1 was analyzed by confocal microscopy. To our knowledge, 
nanoparticles were found for the first time in roundly shaped Rac1 Q61L
+
 macropinosomes (Figure 
13). Nanoparticle tracking analysis revealed that nanoparticles moved inside a defined volume. No 
direct movements of Rac1 Q61L vesicles were observed. This implied that these vesicles were not 
budding off from the membrane displaying an early maturation stage of SPIOPSN-containing 
macropinosomes.  
 
Figure 13: The initial stage of SPIOPSN entry is mediated by the small GTPases Rac1. (A) HeLa cells were transfected 
with Rac1 Q61L-GFP. 24 h later, cells were exposed to 150 µg ml-1 SPIOPSN for 6 h. SPIOPSN entry was analyzed by 
confocal microscopy. Scale bar (left image): 10 µm. Scale bar (right image): 1 µm. (B) SPIOPSN movement inside Rac1 
Q61L-GFP+ vesicles was analyzed by live cell imaging generating a motility profile of the nanoparticle on the left site. Scale 
bar: 1 µm. Representative images are shown.  
Similar images were recorded after the overexpression of cdc42 Q61L (Figure 14). After 6 h of 
incubation, SPIOPSN were located inside roundly shaped premacropinosomes. The morphology of 
these organelles was similar to the Rac1 Q61L phenotype. In contrary to this, the overexpression of 
dominant negative cdc42 T17N resulted in a distinct phenotype, also displaying the colocalization 
with SPIOPSN. Surprisingly, we did not observe a significantly reduced uptake of SPIOPSN in cdc42 
T17N
+
 cells (211). Also the downregulation of cdc42 by esiRNA failed to suppress the number of 
internalized SPIOPSN (Figure 14C). Here, flow cytometric quantification showed no significant 
changes in SPIOPSN uptake after knockdown. Therefore, we concluded that cdc42 accompanied the 





Figure 14: The initial stage of SPIOPSN entry is accompanied by the small GTPases cdc42. (A) HeLa cells were 
transfected with cdc42 Q61L-GFP for 24 h. Afterwards, cells were exposed to 150 µg ml-1 SPIOPSN for 6 h. Colocalization 
was analyzed by confocal microscopy. (B) HeLa cells were transfected with cdc42 T17N-GFP for 24 h. Subsequently, cells 
were exposed to 150 µg ml-1 SPIOPSN for 6 h. Colocalization was analyzed by confocal microscopy. SPIOPSN movement 
inside cdc42 T17N+ vesicles was recorded by live cell imaging. Representative images are shown. (C) HeLa cells were 
nucleofected with cdc42 esiRNA. Knockdown efficiency was determined after 3 d by qRT-PCR. HeLa cells were exposed to 
150 µg ml-1 SPIOPSN. 6 h later, uptake was quantified by flow cytometry.  
Taken together, with cdc42 and Rac1, novel proteins have been identified that are associated with the 
early SPIOPSN-containing macropinosomes. However, we could not show that the overexpression of 
cdc42 T17N and cdc42 knockdown altered the number of internalized SPIOPSN. These observations 
pointed towards an atypical macropinocytic-like mechanism. Further on, these investigations raised 





3.2.3 SPIOPSN entry is dependent on Na+/H+ exchangers, phosphoinositide 
3-kinase and p21-activated kinase 1 but not on phosphokinase C or 
phospholipase C 
Next, we were interested in the signaling mechanisms, which mediated the endocytosis of SPIOPSN. 
The previous observations led to the hypothesis that SPIOPSN are internalized by a macropinocytic-
like mechanism. To prove this, we preliminary investigated the generally accepted factors that 




 exchangers controlled 
SPIOPSN entry (94). Other factors that were shown to regulate viral macropinocytosis are kinases. 
Two of the most important kinases are p21-activated kinase (PAK1) and phosphoinositide 3-kinase 
(PI3K) (136). Further regulatory kinases such as the protein kinase C (PKC) and phospholipase C have 
been implicated to be necessary for a classical macropinocytosis (144, 213). 




 exchangers) had an inhibitory 
effect on SPIOPSN entry, we pretreated HeLa cells with a high, but nontoxic concentration of EIPA. 
After 5 h of SPIOPSN incubation, uptake decreased to 75.50% (SD 0.23%; n = 4; *** indicates p < 
0.001; Student´s t test) (Figure 15). The uptake of fluid-phase marker dextran-488 was reduced to 
83.66% (n = 3; *** indicates p < 0.001, student´s t test) in comparison to nontreated cells.  
Furthermore, we observed a suppressed uptake of SPIOPSN after PI3K inhibition in wortmannin- 
pretreated HeLa cells (n = 6; *** indicates p < 0.001, student´t t test; 73.27% uptake in comparison to 
non-treated cells; SD 2.01). Similar results were obtained after the pretreatment of cells with the PI3K 
inhibitor Ly294002 (n = 6; *** indicates p < 0.001, student´t t test; reduction of uptake down to 
61.24%; SD 2%). Inhibition of PAK1 by IPA3 diminished SPIOPSN uptake to 75.51% in comparison 
to nontreated cells (n = 3; *** indicates p < 0.001, student´t t test; SD 1.23%). The control experiment 
showed that PAK1 inhibition significantly suppressed the internalization rate of the fluid-phase marker 





Figure 15: Na+/H+ exchangers, PI3K and PAK1 control the uptake of SPIOPSN. Flow cytometric quantification of 
SPIOPSN uptake in HeLa cells. Cells were pretreated (30 - 45 min) with several inhibitors for Na+/H+ exchangers (EIPA), 
PI3K (Wortmannin and Ly294002), PAK1 (IPA3), protein kinase C (Ro-31-8220) and phospholipase C (U73122). The 
applied concentrations showed no morphological toxicity. After pretreatment, HeLa cells were exposed to 150 µg ml-1 
SPIOPSN for 5 h. Subsequently, the uptake of SPIOPSN was quantified by flow cytometry. Reversible inhibitors were 
coincubated with nanoparticles. DMSO served as a negative control. Dextran served as a control for fluid-phase endocytosis. 
(A) Pretreatment of HeLa cells with 100 µM EIPA (n = 3 independent experiments; *** indicates p < 0.001, student´s t test). 
(B) Pretreatment with 25 nM Wortmannin and with 50 µM of Ly294002 (n = 3 independent experiments; *** indicates p < 
0.001, student´s t test), respectively. (C) Pretreatment with 25 µM IPA3 (n = 3 independent experiments; *** indicates p < 
0.001, student´s t test). (D) Pretreatment with 7 mM Ro-31-8220 (n = 2 independent experiments). (E) Pretreatment with 10 
µM U73122 (n = 2 independent experiments).  
Then, we investigated the effects of phospholipase C (Inhibitor U73122) and phosphokinase C 
(Inhibitor Ro-31-8220) on the internalization rate of SPIOPSN. Cells were exposed to high but non-
toxic concentrations of both inhibitors. Taken together, no significant changes in the uptake of 
SPIOPSN were observed. This showed that PLC and PKC did not play are role during the entry of 
SPIOPSN. Other factors that were tested included nocodazole. Inhibition of microtubule 
polymerization by nocodazole reduced SPIOPSN internalization to 75.50% (n = 2; SD 3.55%; data not 
shown). Though, this was not surprising since nocodazole inhibits a large number of distinct 
mechanisms. Exactly due to this reason, we focused on a more specific mechanism and investigated 
the effect of dynamin II on the entry rate of SPIOPSN. We found that the internalization of SPIOPSN 




3.2.4 The macropinocytic-like uptake of SPIOPSN is dependent on dynamin 
II 
After demonstrating that several kinases affected the endocytosis of SPIOPSN, we focused on the 
GTPase dynamin II. Dynamin II has been extensively studied in CME and caveolae-dependent 
endocytosis. However, the participation of dynamin II in macropinocytic processes has been 
controversially discussed (214). In spite of this, we investigated the role of dynamin II during the entry 
of SPIOPSN. Our experiments showed that the overexpression of dominant negative dynamin 2 
K44A-GFP resulted in a significant reduction of SPIOPSN uptake in comparison to non-transfected 
cells (white circles in Figure 16A). This was confirmed by the dynasore-mediated inhibition of 
dynamin II (uptake in comparison the non-treated control: 68.68%, n = 3; *** indicates p < 0.001; SD 
2.06%). Altogether, these data indicated that dynamin II played an important role during the entry of 
SPIOPSN. 
 
Figure 16: Dynamin II is required for the internalization of SPIOPSN. A qualitative and quantitative analysis of 
SPIOPSN uptake in dependence on dynamin II manipulations was performed. (A) 24 h after transfection of Dyn2K44A-GFP, 
HeLa cells were exposed to 150 µg ml-1 SPIOPSN for 6 h. The uptake of SPIOPSN was qualitatively analyzed by confocal 
microscopy. White borders indicate GFP-negative cells. Representative images are shown. (B) HeLa cells were pretreated 
with 100 µM Dynasore for 40 min. Dynasore-treated and nontreated cells were exposed to 150 µg ml-1 SPIOPSN for 5 h.    
40 µg ml-1 Alexa Fluor-488 coupled transferrin served as a control. Uptake was quantified by flow cytometry (p < 0.001; n 
=3 independent experiments). In all samples, uptake was quantified as the median of the cellular fluorescence intensity.  
This chapter and the previous sections showed that several inhibitors were tested to explore the factors 
that mediated SPIOPSN uptake. Contrary to the inhibitor experiments, we investigated whether 
several stimulatory effects have an impact on the uptake of SPIOPSN. Surprisingly, the data revealed 
that the stimulation of macropinocytosis via DAG and EGF resulted in a reduced uptake of SPIOPSN 




3.2.5 Stimulation of classical macropinocytic pathways inhibits the uptake of 
SPIOPSN 
Phorbol-12-myristate-13-acetate is a phorbol ester that is known to activate phosphokinase C. Thus, 
downstream pathways such as macropinocytosis and others can be triggered (215). Further on, growth 
factor mediated macropinocytosis can be induced by epidermal growth factor (EGF) stimulation (134, 
216).  
To approach the question, if classical stimulators of macropinocytosis can boost the uptake of 
SPIOPSN, we pretreated HeLa cells with PMA or EGF for 45 min. Subsequently, we removed the 
supernatant and incubated SPIOPSN for 5 h. The incubation with dextran-488 served as a control of 
fluid-phase endocytosis. After incubation, SPIOPSN uptake was quantified by flow cytometry. Upon 
PMA stimulation, SPIOPSN uptake decreased to 75.5%; (SD 1.6%; n = 6; *** indicates p < 0.001; 
student´s t test), whereas dextran uptake was stimulated to ~190%; (SD 0.8%; n = 4; *** indicates p < 
0.001, student´s t test) in comparison to the untreated control (Figure 17). Moreover, the stimulation of 
HeLa cells with EGF decreased the uptake of SPIOPSNs, too. This was also qualitatively confirmed 
by the imaging of EGF-stimulated and nonstimulated HeLa cells. Dextran uptake was not affected by 






Figure 17: Stimulation of classical macropinocytic pathways suppress SPIOPSN uptake. (A) To stimulate 
macropinocytosis, HeLa cells were treated with 50 nM phorbol-12-myristate-13-acetate (PMA) for 45 min. Stimulated and 
non-stimulated cells were exposed to 150 µg ml-1 SPIOPSN or 2.5 µg ml-1 dextran-488 (10 kDa) for 5 h, respectively. Uptake 
was quantified by flow cytometry. (n = 6; p < 0.001; student´s t test). (B) HeLa cells were stimulated with 150 ng ml-1 
epidermal growth factor (EGF) for 45 min. Cells were exposed to 150 µg ml-1 SPIOPSN or 2.5 µg ml-1 Dextran-488 (10 kDa) 
for 5 h, respectively. Uptake was quantified by flow cytometry. Qualitative analysis of SPIOPSN uptake (A+B) was 
performed by confocal microscopy. Scale bar: 10 µm. Values are given as median + SD. *** indicates p < 0.001. 
Representative images are shown.  
Altogether, these experiments confirmed that SPIOPSN uptake is mediated by an atypical pathway of 
macropinocytosis. To exclude the participation of other endocytic pathways, we investigated the role 
of caveolin-1 and clathrin during SPIOPSN entry (Figure 18 and Figure 19).  
3.2.6 SPIOPSN are not taken up by a clathrin- and caveolae-dependent 
mechanisms 
After the validation that SPIOPSN are taken up by an atypical macropinocytic mechanism, we wanted 
to exclude any participation of other pathways that could orchestrate SPIOPSN endocytosis. To 
approach this, we pretreated HeLa cells with chlorpromazine to block clathrin-mediated endocytosis 
(Figure 17). Furthermore, we silenced clathrin heavy chain by siRNAs and overexpressed epsin 15 
DIII to block clathrin lattice assembly (106). siRNA-mediated silencing of clathrin heavy chain led to 
a downregulation of clathrin HC down to ~40%. Qualitatively as well as quantitatively no significant 




mediated inhibition of CME, where also no significant changes in the uptake of SPIOPSN were 
observed.  
 
Figure 18: SPIOPSN are not internalized via a clathrin-mediated endocytic mechanism. HeLa cells were transfected 
with siRNA to silence the clathrin heavy chains. Additionally, CME was inhibited by chlorpromazine treatment and via the 
overexpression of epsin 15 DIII-GFP. Subsequently, SPIOPSN uptake was qualitatively and quantitatively analyzed. (A) 
Three days after the nucleofection of siRNA, downregulation of clathrin heavy chain was quantified by western blotting. (B) 
Mock treated and siRNA treated HeLa cells were exposed to 150 µg ml-1 SPIOPSN for 6 h. Immunofluorescence stainings 
for clathrin heavy chains were performed. Uptake was qualitatively examined by confocal imaging. (C) Uptake of SPIOPSN 
in siRNA- and mock-treated cells was quantified by flow cytometry (n = 4). (D) HeLa cells were pretreated with 25 µM 
chlorpromazine and then exposed to 150 µg ml-1 SPIOPSN for 5 h. Quantification of uptake was performed via flow 
cytometric analysis (n = 4). (E) HeLa cells were transfected with epsin 15-DIII-GFP. 24 h after transfection, cells were 
exposed to 150 µg ml-1 SPIOPSN for 6 h. Uptake was qualitatively studied by confocal microscopy. Scale bars: 10 µm.  
Representative images are shown.  
Moreover, also the overexpression of dominant-negative epsin 15 (DIII) did not display any impact on 
the internalization rate of SPIOPSN. Taking all of this into account, we concluded that CME is not 




Next, we investigated the impact of caveolae-mediated endocytosis on the uptake rate of SPIOPSN. 
Three days after nucleofection, siRNA-mediated silencing suppressed the levels of caveolin-1 to          
~ 32% (Figure 19A). Qualitatively and quantitatively, no differences in SPIOPSN uptake were 
observed. As expected, overexpression of caveolin-1 did not significantly alter the amount of 
SPIOPSN that were internalized (Figure 19D). Therefore, we concluded that SPIOPSN are not 
internalized by a caveolin-1 dependent mechanism.  
 
Figure 19: Caveolin-1 is not significantly required during the internalization process of SPIOPSN. HeLa cells were 
transfected with siRNA to silence caveolin-1. Caveolae-mediated endocytosis was disturbed by the overexpression of 
caveolin-1-GFP. The uptake of SPIOPSN was qualitatively and quantitatively analyzed. (A) Three days after nucleofection, 
downregulation of caveolin-1 was quantified by western blotting (B) Immunofluorescence stainings were performed for 
caveolin-1. Uptake was qualitatively determined by confocal imaging. (C) Mock- and siRNA treated cells were exposed to 
150 µg ml-1 SPIOPSN for 6 h. Uptake was quantified by flow cytometry. (D) HeLa cells were transfected with caveolin-1-
GFP. 24 h after transfection, cells were exposed to 150 µg ml-1 SPIOPSN for 6 h. Uptake was qualitatively studied by 





Other pathways that might have an impact on the internalization rate of SPIOPSN were also 
investigated. Among others, we focused on the CLIC/GEEC-mediated endocytosis. To investigate 
whether this pathway mediates the uptake of SPIOPSN, we performed cointernalization experiments 
with the CLIC/GEEC marker cholera toxin subunit B to analyze the colocalization with SPIOPSN 
(data not shown). In this particular case, no colocalization of SPIOPSN with ctxB was observed. 
Therefore, we concluded that SPIOPSN are not taken up via the CLIC/GEEC pathway. This was 
confirmed by TEM studies were no tubular CLIC/GEEC-like invaginations were observed.  
Further on, we checked whether the small GTPase RhoA had an impact on the uptake of SPIOPSN 
(data not shown). The overexpression of the dominant negative RhoA had no effect on the 
internalization rate of SPIOPSN. Therefore, we concluded that SPIOPSN did not exploit a RhoA-
mediated endocytosis.  
3.2.7 Other factors that orchestrate SPIOPSN entry: RNAi screening 
identifies flotillin-1 and the tetraspanin CD81 as important factors 
during the uptake process of SPIOPSN  
As shown in the previous sections, the uptake of SPIOPSN is partially dependent on factors of a 
macropinocytic-like mechanism. Still, it is equally important to mention that uptake seemed not to be 
affected by CME; caveolae-mediated endocytosis, RhoA-mediated endocytosis or the CLIC/GEEC 
pathway. Also the ADP-ribosylation factor Arf6 does not seem to play a role in the uptake of 
SPIOPSN (Figure 25). However, the literature also provides several proteins that have been described 
to act independently from the commonly accepted endocytic pathways (88, 217). Therefore, we 
investigated the influences of some proteins that were assumed to interact with SPIOPSN. 
Since tetraspanins and flotillin-1 were earlier described as part of the plasma membrane, of 
intracellular vesicles and as proteins that control the endocytotic machinery, we focused on these 
factors. We studied the internalization rates of SPIOPSNs after RNAi-mediated silencing of flotillin-1 
and the tetraspanins CD82, CD81, CD63 and CD9. The reason for the selection of these distinct 
proteins is based on an experiment, where we magnetically isolated SPIOPSN-containing vesicles 
(shown in Figure 35). The previously mentioned vesicular proteins were present inside this fraction as 
detected by peptide mass spectrometry. These data implicated that SPIOPSN-containing vesicles 
contained significant amounts of flotillin-1 and the previously mentioned tetraspanins.  
Knockdown was verified by the quantitative evaluation of the western blots except for the expression 
levels of CD82. The expression levels of CD82 knockdown was validated by qRT-PCR. We observed 
a silencing rate of ~15% (remaining CD82 mRNA; data not shown). Subsequently after gene 
silencing, the uptake rates of SPIOPSN were quantified. Flow cytometric analysis revealed a 




test) and CD81 (n = 4; p < 0.001, student´s t test). The knockdown of the tetraspanins CD82, CD63 
and CD9 did not impair SPIOPSN uptake (Figure 20).  
 
Figure 20: Flotillin-1 and CD81 partially control the internalization of SPIOPSN. To silence flotillin-1 and CD81, HeLa 
cells were nucleofected with 60 pmol of target-specific siRNA. (A) 3 d after nucleofection, protein expression levels were 
determined by western blotting (all samples: n = 3; p < 0.001; student´s t test). Knockdown of CD82 was quantified by q-RT-
PCR (mRNA silencing down to ~15%; data not shown). (B) 3 d after nucleofection, HeLa cells were exposed to 150 µg ml-1 
SPIOPSN for 6 h. The uptake of nanoparticles was quantified by flow cytometry. Significant changes in uptake were 
observed in flotillin-1 and CD81 silenced samples in comparison to the mock control. No significant changes in SPIOPSN 
uptake were detected in the samples that were silenced for CD82, CD63 and CD9.  
Altogether, it was shown that CD81 and flotillin-1 had an impact on the internalization mechanisms of 
the nanoparticles. Since the membrane organization of CD81 and flotillin-1 was previously shown to 
depend on cholesterol, we investigated the impact of cholesterol depletion on the uptake of SPIOPSN 
(Figure 21) (131, 218). Moreover, it is worth to mention that cholesterol was also suggested to have a 
major impact on macropinocytic events.  
3.2.8 Changes in cholesterol levels influence the endocytosis of SPIOPSN 
Since the depletion of cholesterol often deregulates macropinocytic processes, we tested whether 
changes in cholesterol homeostasis have an impact on the internalization rate of SPIOPSNs. 
Therefore, we depleted the membranous cholesterol by the treatment of methyl-β-cyclodextrin (Figure 
21). After cholesterol depletion and nanoparticle exposure, we observed a significant drop of the 
amount of internalized nanoparticles to 75.24% (n = 6; ** indicates p < 0.01; SD 2.57%). We further 
disturbed the intracellular cholesterol homeostasis by the cholesterol synthesis inhibitor U18666A. 




cells were exposed to nanoparticles. The uptake of SPIOPSN was quantified by flow cytometry. 
Dextran served as a control. We observed a concentration-dependent drop of SPIOPSN and dextran in 
U18666A-deregulated cells (n = 6; *** indicates p < 0.001).  
 
Figure 21: Deregulation of the cholesterol homeostasis decreases SPIOPSN uptake. (A) HeLa cells were pretreated with 
5 mM methyl-β-cyclodextrin for 45 min. Subsequently, cells were exposed to 150 µg ml-1 SPIOPSN for 5 h. The uptake was 
quantitatively measured by flow cytometry (n = 6; ** indicates p < 0.05; student´s t test). (B) To achieve an endolysosomal 
accumulation of cholesterol, HeLa cells were treated with 1.5 µg ml-1 and 3 µg ml-1 U18666A for 24 h, respectively. The 
accumulation of cholesterol was detected by filipin stainings. Scale bar: 10 µm. (C) After 24 h of U18666A treatment, cells 
were exposed to 150 µg ml-1 SPIOPSN and 2.5 µg ml-1 dextran-488, respectively. After 5 h of incubation, uptake was 
quantified by flow cytometry. Values are given as mean + SD (n = 6; *** indicates p < 0.001, student´t t test).  
These data implied that the deregulation of the cellular cholesterol homeostasis resulted in a decreased 
amount of internalized nanoparticles. Since we have shown that an NPC-like phenotype can reduce the 
internalization rate of nanoparticles we focused on the cholesterol transporter NPC1. NPC1 and NPC2 
were identified by mass spectrometry and seemed to directly interact with SPIOPSN (Figure 34). 
Therefore, we silenced NPC1 by RNAi. The assumption was that the downregulation of NPC1 
(remaining protein ~ 27%, data not shown) induces a deregulation of the intracellular cholesterol 
homeostasis and a decrease of the internalization rate of nanoparticles. However, no reduction of the 
uptake rate of SPIOPSN was observed (data not shown). Therefore, we tested other factors that were 





3.2.9 ARF1 is an important factor in SPIOPSN uptake 
ADP-ribosylation factor 1 (ARF1) is a small GTP-binding protein that has a crucial function during 
the process of COP vesicle formation (219). Furthermore, it was also shown that ARF1 regulates 
macropinocytic events (220). Experimentally, ARF1 can be inhibited by brefeldin A or by the 
overexpression of dominant negative mutants (221).  
To investigate the role of ARF1 during the uptake of SPIOPSN, we firstly blocked ARF1 by a 
pharmacological treatment of HeLa cells with brefeldin A. Subsequently, the pretreated cells were 
exposed to nanoparticles and nanoparticulate uptake was quantified (Figure 22). Brefeldin A treated 
cells showed a significantly decreased internalization rate of SPIOPSN (71.7%; n = 6; * indicates p < 
0.05; SD 10,6%). Dextran uptake was not affected by the brefeldin A treatment. Owing to this result, 
we now asked whether SPIOPSN are directly associated with ARF1. Since we have identified ARF1 
as a SPIOPSN-associated protein by mass spectrometry, we overexpressed a dominant negative 
mutant of ARF1 in HeLa cells and measured the colocalization with SPIOPSN. Here, rare events of 
colocalization were observed. This low rate of colocalization was also linked to the observation that 
less nanoparticles were taken up from ARF1 T31N
+
 cells. Refering to this we concluded that the 
nonfunctional ARF1 had a massive effect on the uptake of SPIOPSN. Therefore, we quantified the 
number of endocytic vesicles of ARF1 T31N transfected and nontransfected cells by analyzing the 




cells, it was shown that the number of endocytosed 
SPIOPSN was significantly decreased in the ARF1 T31N
+
 fraction (n = 31; *** indicates p < 0.001) 





Figure 22: ARF1 has a crucial function during the uptake of SPIOPSN. SPIOPSN uptake was investigated upon ARF1 
inhibition. (A) HeLa cells were pretreated with 10 µg ml-1 brefeldin A to inhibit ARF1. Pretreated and nontreated HeLa cells 
were exposed to 150 µg ml-1 SPIOPSN for 6 h. Uptake of SPIOPSN was quantified by flow cytometry (n = 6; * indicates p < 
0.05, student´s t test). (B) Colocalization studies with the dominant negative mutant ARF1 T31N-GFP revealed rare 
colocalization events with SPIOPSN after 6 h of nanoparticle exposure. Scale bar: 10 µm. ROI: Scale bar: 1 µm. (C) HeLa 
cells were transfected with ARF1 T31N-GFP. 24 h later, cells were exposed to 150 µg ml-1 SPIOPSN for 6 h. Qualitative 
confocal images revealed a massively reduced amount of internalized nanoparticles in ARF1 T31N-GFP+ cells. (D) z-stacks 
of ARF1 T31N-GFP+ and GFP- cells were recorded to manually quantify the number of SPIOPSN-containing vesicles after 6 
h of nanoparticle exposure. A significant reduction of SPIOPSN-containing vesicles in ARF1 T31N-GFP+ cells was observed 
(p < 0.001; student´s t test). Representative images are shown. 
Altogether, it was shown that ARF1 is a crucial factor during the uptake of SPIOPSN. Whether ARF1 
is also deregulated after the deacidification of the endocytic system is unknown. However, this is not 
the major question we wanted to solve. In the next section, we showed that the deacidification of the 
endocytic system resulted in a drop of the nanoparticulate uptake rate (Figure 23).  
3.2.10 Deacidification of the endolysosomal vesicles affects uptake of 
SPIOPSN 
The acidification of the endolysosomal system is facilitated by the endolysosomal v-type ATPase H
+
 
pumps. To approach the question, if deacidification of the endolysosomal system affects the uptake of 
SPIOPSN, v-type ATPase H
+
 pumps were inhibited by bafilomycin A1. The efficiency of inhibition 
was confirmed by LysoTracker staining (Figure 23). If our hypothesis holds true, HeLa cells should 
reduce their ability to internalize SPIOPSN. Therefore, we pretreated HeLa cells with bafilomycin A1 
for 45 min and then exposed them to SPIOPSN or dextran. Deacidification of the endolysosomal 




the pretreatment of HeLa cells with bafilomycin A1 reduced SPIOPSN uptake to 59% (SD 4.9%; n = 
6; *** indicates p < 0.001). Dextran uptake was reduced to 25% (SD 3.26%; n =6; *** indicates p < 
0.001).  
 
Figure 23: Deacidification of the endolysosomal system inhibits the uptake of SPIOPSN. The acidification of the 
endolysosomal system was blocked by bafilomycin A1, an inhibitor of vacuolar-type H+ ATPase. (A) HeLa cells were 
pretreated with 10 nM Bafilomycin A1 for 45 min. Acidification/deacidification was visualized by the staining with 
LysoTracker green DND-26. Scale bar: 10 µm. (B) Pretreated HeLa cells were incubated for 5 h with 150 µg ml-1 SPIOPSN 
or 2.5 µg ml-1 AF-Dextran-488. Uptake was quantitatively analyzed by flow cytometry. Values are given as median + SD (n 
= 6;*** indicates p < 0.001).  
To summarize the results of chapter 3.2, we found that SPIOPSN were internalized by a 
macropinocytic-like mechanism. This mechanism depends on several classical factors of 
macropinocytosis but also showed some unexpected features. With this information, the work was 
continued. It was assumed that the primary nanoparticulate portal of entry was a macropinosome-like 
organelle. The pinch off of this organelle results in an intracellular trafficking of nanoparticles that we 






3.3  Reconstruction of intracellular nanoparticle trafficking 
The previous chapters showed that SPIOPSN have been internalized via a macropinocytic-like 
mechanism. The identified mechanism is dependent on several factors that have never been associated 
with nanoparticulate entry. This newly gained knowledge raised interesting issues that primarily 
focused on the fate of the nanoparticles after their entry. Indeed, the intracellular nanoparticle 
trafficking after macropinocytic-like entry is less investigated. Therefore, we asked how SPIOPSN 
traffic through the cell when the primary compartment is a macropinosome-like organelle. 
3.3.1 SPIOPSN are primarily transported via macropinosome-like organelles 
Preliminary, we analyzed several classical markers of early endosomes in the initial stage of 
endocytosis. Therefore, we focused on the Ras-related protein 5A (Rab5A), which is known to be 
present on classical macropinosomes and early endosomes (142, 222). In colocalization experiments 
with overexpressed Rab5A wt, only low amounts of colocalization with nanoparticles was observed. 
However, we found some SPIOPSN inside Rab5A
+
 vesicles after 6 h of exposure (Figure 24A/B). 
These Rab5A
+
 vesicles were visible under transmission light and resembled fluid-filled vesicles 
(Figure 24B). Since Rab5 was described as an important protein in the biogenesis of endosomes and 
macropinosomes, we analyzed whether the downregulation of Rab5A had an impact on the 
internalization rate of SPIOPSN. Surprisingly, no reduction in the endocytosis rate of SPIOPSN was 
observed (Figure 24D). Other proteins that have been described as markers of early endosomes are 
early endosome antigen 1 (EEA1). In this case, no colocalization of EEA1 with SPIOPSN was found 
in immunofluorescence staining. This was confirmed by the MS data, where EEA1 was not enriched 






Figure 24: SPIOPSN colocalize with Rab5A in the early stage of nanoparticle trafficking. (A) HeLa cells were 
transfected with Rab5A wt-GFP. 24 h after transfection, cells were exposed to 150 µg ml-1 SPIOPSN for 6 h. Colocalization 
of SPIOPSN was analyzed with Rab5A by confocal live cell imaging. Less colocalization was found with the early 
endosomal marker Rab5A. Scale bar: 10 µm. (B) Live cell imaging displayed SPIOPSN that moved inside Rab5A+ vesicles, 
which were visible in transmission light (last panel). Scale bar: 1 µm (C) To investigate the effect of Rab5A depletion on the 
uptake of SPIOPSN, Rab5A was silenced by RNAi. Knockdown efficiency was determined by western blotting. (D) Rab5A-
siRNA sample and mock control were incubated with 150 µg ml-1 SPIOPSN for 6 h. Uptake of SPIOPSN was quantitatively 
determined by flow cytometry. Representative images are shown.  
We further focused on the interaction of SPIOPSN-containing vesicles with typical proteins that were 
previously associated with macropinosomes. In earlier studies, it was shown that SWAP-70 is a 
component of macropinosomes (164). To study the participation of SWAP-70 in SPIOPSN trafficking 
in more detail, we overexpressed SWAP-70-GFP and analyzed its colocalization with SPIOPSN. 
Despite of extensive studies, we failed to show a colocalization with SWAP-70 (Figure 25). Therefore, 
the studies were continued with the focus on the small GTPase RhoB. RhoB was previously described 
as a factor that was involved in macropinocytosis of viral particles (223). Since we have identified the 
small GTPase RhoB as an SPIOPSN-associated protein by mass spectrometry, colocalization 
experiments with RhoB wt-GFP were performed. SPIOPSN colocalized with RhoB in regions close to 
the membrane and in endosome-like structures. Further observations revealed that RhoB/SPIOPSN
+
 





Figure 25: RhoB is associated with SPIOPSN-containing macropinosomes. To investigate specific markers of 
macropinosomes, several proteins were overexpressed. SWAP-70 is a protein that was shown to be transiently present on 
macropinosomes. RhoB is a small GTPase that was associated with macropinocytosis. ARF6-GFP is a small GTPase that is 
known to transiently mediate classical macropinocytosis. After 24 h of transfection, HeLa cells were exposed to 150 µg ml-1 
SPIOPSN for 6 h. Subsequently, colocalization was analyzed by confocal live cell imaging. (A) SWAP-70 displayed no 
colocalization with SPIOPSN. (B) Colocalization of SPIOPSN with RhoB was found in close proximity to the cell membrane 
(B) and in the perinuclear regions of the cell. (C) Live cell imaging showed that SPIOPSN moved within fluid-phase filled 
RhoB+ vesicles through the cell. (D) Less colocalization was observed with α5-Integrin-GFP (E) No colocalization was found 
with ARF6 DN-HA. Detection of ARF6 DN-HA was performed by immunofluorescence. Qualitatively, the expression of 
dominant negative ARF6 did not alter the internalization rate of SPIOPSN in comparison to nontransfected cells. 
Representative images are shown.  
Next, overexpression of α5-Integrin-GFP resulted in rare colocalization events with SPIOPSN. α5-
Integrins were previously identified as important proteins during the early macropinocytic stages of 
adenoviruses (224). Moreover, we investigated the influences of ARF6 on SPIOPSN trafficking. 
ADP-ribosylation factor 6 is a GTP-binding protein that was identified as a modulator of Rac-
GTPases. Previous work showed that ARF6 can control the actin structure and colocalized with an 
early phagosomal mechanisms (92). To get a closer insight if ARF6 has an impact on SPIOPSN 




exposed to SPIOPSN and cells were immunostained for ARF6-HA. Neither colocalization nor a 
reduction of SPIOPSN internalization was observed. Therefore, we concluded that ARF6 did not 
affect the macropinocytic structures of SPIOPSN-containing vesicles. This was also confirmed by 
mass spectrometry, where no association of SPIOPSN with ARF6 was observed. Taken together, we 
found that SPIOPSN are internalized via a fluid-filled macropinocytic organelle. Up next, we wanted 
to know whether the SPIOPSN traffic a regular route via late endosomes (Figure 26).  
3.3.2 SPIOPSN traffic along Rab7+ and Rab9+ late endosomes  
The colocalization of SPIOPSN with markers of early endosomes/early macropinosomes gave rise to 
the assumption that SPIOPSN trafficked along the endolysosomal system. Therefore, colocalization 
studies with the late endosomal marker Rab7 and Rab9 were performed. Rab7 was previously 
identified as a protein that replaced Rab5 in later stages of intracellular trafficking (153). Rab9 is a 
GTPase that is present on late endosomes and plays a role in the endosome-to-trans-Golgi-network 
transport (225). Indeed, after the overexpression of Rab7 and Rab9, SPIOPSN colocalized with both 
markers (Figure 26). Live cell imaging revealed that SPIOPSN were actively transported through the 
cell. The presence of Rab7 and Rab9 was confirmed by mass spectrometry, where both markers were 
identified in the magnetically enriched fraction.  
 
Figure 26: SPIOPSN are transported along Rab7 and Rab9+ late endosomes. HeLa cells were transfected with Rab7 wt-
GFP (A; Scale bar: 10 µm; magnification: 1 µm) and Rab9 wt-GFP (B; Scale bar: 5 µm; magnification: 1 µm) to detect late 
endosomes. 24 h after transfection, cells were exposed to 150 µg ml-1 SPIOPSN for 6 h. Colocalization with Rab-proteins 
was investigated by confocal live cell imaging. Motion profiles of nanoparticles were generated to track the movements of 




3.3.3 The R-SNARE protein VAMP7 is present on SPIOPSN-containing 
vesicles 




 vesicles it was assumed that SPIOPSN were 
transported via late endosomes. To investigate whether these late endosomes fuse with lysosomes, we 
investigated the colocalization of SPIOPSN with the vesicle-associated membrane protein 7 
(VAMP7). VAMP7 is a membrane protein of the SNARE family that mediates the heterotypic fusion 
of late endosomes and lysosomes (191). To investigate the participation of VAMP7 in SPIOPSN 
trafficking, full-length VAMP7-GFP was overexpressed and SPIOPSN trafficking was investigated by 
confocal live cell imaging. A colocalization of SPIOPSN with VAMP7 was observed. The tracked 
nanoparticles were actively transported inside VAMP7
+ 
vesicles through the cell (Figure 27). An 
association of VAMP7 with SPIOPSN was also shown by mass spectrometry. Here, we identified 
VAMP7 as an enriched protein of the magnetic vesicular fraction. 
 
Figure 27: VAMP7 is associated with SPIOPSN-containing vesicles. To investigate the presence of VAMP7 on 
SPIOPSN-containing vesicles, we overexpressed VAMP7-GFP. (A) HeLa cells were transfected with VAMP7-GFP. 24 h 
later, cells were exposed to 150 µg ml-1 SPIOPSN for 6 h. Subsequently, colocalization of SPIOPSN with VAMP7 was 
analyzed by confocal live cell imaging (Scale bar: 10 µm). (B) Confocal live cell imaging displayed an active transport of 




3.3.4 SPIOPSN are transported inside vesicles that are positive for markers 
of intraluminal vesicles 
Early and late endosomes accumulate intraluminal vesicles (ILVs) during the processes of vesicular 
maturation (171). ILVs have been shown to carry several markers such as the melanocytic protein 
Pmel17. In previous reports it was demonstrated that Pmel17 is sorted via an ubiquitin-/ ESCRT-
independent mechanism into ILVs of MVBs (174, 226). Furthermore, it was shown that the 
tetraspanin CD63 decorates the ILVs (227). Therefore, Pmel17 and CD63 were used to investigate the 
association of SPIOPSN with multivesicular bodies. As expected, we have identified no native Pmel17 
in HeLa cells (Figure 28B). Therefore, we overexpressed Pmel17 in HeLa cells. 24 h after 
transfection, cells were exposed to SPIOPSN. The detection of Pmel17 was performed by 
immunofluorescence. Notably, a clear colocalization of Pmel17 with nanoparticles was observed. 
Next, we incubated HeLa cells with SPIOPSN and detected CD63 by immunofluorescence staining. 
Nanoparticles displayed a high rate of colocalization with CD63 (Figure 28).  
 
Figure 28: SPIOPSN are transported inside vesicles that are positive for the intraluminal vesicle marker Pmel17 and 
CD63. (A) HeLa cells were transfected with Pmel17. 24 h later, cells were exposed to 150 µg ml-1 SPIOPSN for 6 h. Pmel17 
was detected by immunostaining. Colocalization was analyzed by confocal microscopy. Scale bar: 10 µm. (B) Staining of 
nontransfected HeLa cells with NKI/Beteb antibodies showed that HeLa cells lack the expression of Pmel17. Scale bar 10 
µm. (C) HeLa cells were incubated with 150 µg ml-1 SPIOPSN for 20 h and then stained for CD63. Scale bar: 10 µm. Spots 
of colocalization were marked with white arrows (n = 5; representative images are shown).  
Since previous reports suggested that Pmel17 is sorted via an ESCRT-independent mechanism into 
MVBs, we hypothesized that SPIOPSN-containing vesicles contained a low amount of ubiquitin. 
Indeed, we were not able to detect ubiquitin by immunofluorescence in any SPIOPSN-containing 
vesicle (data not shown). In spite of this, the morphology of SPIOPSN-containing vesicles revealed 




3.3.5 SPIOPSN are transported via multivesicular bodies to multilamellar 
lysosomes 
The data of the previous sections showed that SPIOPSN were transported via early endocytic vesicles 
to multivesicular bodies. To confirm this on an ultrastructural level, cryo-freezed sections of 
nanoparticle-exposed HeLa cells were prepared. After recording the TEM micrographs, SPIOPSN-
containing-vesicles were subclassified owing to distinct morphological criteria. Vesicles that lacked 
intraluminal vesicles were classified as early endocytic vesicles. Vesicles, which contained ILVs were 
categorized as multivesicular bodies. Multilamellar lysosomes are vesicles that stored membrane 
whorls of an onion-like structure. Further on, we recorded hybrid structures of multivesicular bodies 
and multilamellar lysosomes/multilamellar bodies (MLL or MLB). These vesicles contained 
intraluminal vesicles and membrane whorls. 
The analysis of the TEM micrographs confirmed the previous experiments of confocal imaging. 
SPIOPSN were transported along early endocytic vesicles, multivesicular bodies, MVB-MLL-hybrid 
organelles and multilamellar lysosomes (Figure 29). To analyze the distribution of SPIOPSN inside 
the distinct types of vesicles more precisely, a semiquantitative classification was performed. The 
morphological subcategorization of the vesicles was based on the formerly described criteria. 
Quantification was performed with the data of four independent experiments, counting the identified 
SPIOPSN-containing vesicles on the prepared slices inside more than 25 cells. Taken together, most of 
the SPIOPSN were found inside MVB/MLL-hybrid organelles and in multilamellar lysosomes after 20 





Figure 29: SPIOPSN are transported inside morphologically distinct vesicles along the endolysosomal pathway 
(HeLa). Cryo-TEM micrographs revealed the different types of vesicles that contained electron dense SPIOPSN (dark areas). 
Scale bar: 200 nm. (A) HeLa cells were exposed to 150 µg ml-1 SPIOPSN for 20 h. Cells were cryo-freezed and prepared for 
TEM. SPIOPSN were found in vesicles with a size range of 0.5 – 1 µm in diameter. Vesicles without ILVs were identified 
(early endocytic vesicles). Multivesicular bodies contained SPIOPSN and intraluminal vesicles (size ~ 50 nm). Multilamellar 
lysosomes were identified. MVB/MLB-hybrid organelles were found. (B) Semiquantitative analysis of TEM micrographs 
revealed that SPIOPSN were mainly present inside multilamellar bodies after 20 h of incubation (n = 4 independent 
experiments). Vesicles were categorized due to their morphological appearance as shown in the scheme in (A). (Sample 
preparation and TEM micrographs were prepared by C. Messerschmidt).  
To assure that MLBs are the final organelle in SPIOPSN trafficking, HeLa cells were pulsed for 6 h 
with SPIOPSN. This procedure was followed by a postincubation of 14 h without nanoparticles in the 
growth medium. Notably, almost all of the SPIOPSN accumulated inside MLB-like-structures (data 





Similar experiments were performed with primary human mesenchymal stroma cells. Here, we were 
able to confirm the former data. Early endocytic vesicles, as well as multivesicular bodies and 
multilamellar lysosomes participated in the transport of SPIOPSN. After 20 h of SPIOPSN exposure, 
most of the nanoparticles were found in Cathepsin D
+
 lysosomal compartments (Figure 30).  
 
Figure 30: SPIOPSN are transported inside morphologically distinct vesicles along the endolysosomal pathway 
(hMSCs). (A) hMSCs were exposed to 150 µg ml-1 SPIOPSN for 20 h and prepared for TEM. Micrographs showed 
SPIOPSN densly packed inside early endosomes, multivesicular bodies and multilamellar lysosomes. Scale bar: 1 µm. (TEM 
micrographs were taken by C. Messerschmidt). (B) After 20 h, most of the SPIOPSN were found in Cathepsin D+ vesicles. 
Scale bar of upper image: 10 µm. Scale bar of magnification: 1 µm. (n = 3; representative images are shown).  
Notably, the observation that SPIOPSN were stored inside lysosomes was also recorded for HeLa 
cells. After 20 h of nanoparticle exposure, most of the SPIOPSN accumulated inside vesicles that bore 





Figure 31: SPIOPSN are finally stored inside Lamp1/2+ and Cathepsin D+ lysosomes. HeLa cells were exposed to       
150 µg ml-1 SPIOPSN for 20 h, fixed, permeabilized and double-stained for the lysosomal markers Lamp1/Lamp2. Another 
sample was stained for the lysosomal marker cathepsin D. SPIOPSN showed colocalization with both markers (n = 8). 
Representative images are shown  
3.3.6 SPIOPSN are neither exocytosed nor transported by autophagosomes 
Next, we analyzed whether intracellular nanoparticle trafficking interfered with recycling pathways or 
autophagosomal trafficking. Since we have identified Rab11A and Rab11B by mass spectrometry, we 
asked the question whether SPIOPSN are generally exocytosed by recycling endosomes. To quantify 
this process, HeLa cells were pulsed for 4 h with SPIOPSN and postincubated without nanoparticles 
for another 16 h. The mean fluorescence intensity of the cells was measured over time. Notably, no 
significant drop of the fluorescent nanoparticle signal was observed (Figure 32A). We concluded that 
SPIOPSN were not exocytosed by the cell. This observation was confirmed by the following set of 
experiments. Intensive research on this project confirmed that SPIOPSN did not colocalize with Rab11 
wt-GFP and Rab11 that was visualized by immunofluorescence stainings (Figure 32B). Consequently, 
we suggested that SPIOPSN were not significantly externalized by the recycling pathways.  
To investigate the interplay with autophagosomes, HeLa cells were incubated with SPIOPSN and 
immunostained for the autophagosomal marker LC3. Also here, SPIOPSN did not colocalize with the 





Figure 32: SPIOPSN are neither exocytosed by Rab11+ recycling endosomes nor transported via LC3B+ 
autophagosomes. (A) To test whether SPIOPSN are exocytosed, we pulsed HeLa cells for 4 h with 150 µg ml-1 SPIOPSN. 
After a washing step, we postincubated the cells without nanoparticles for another 16 h. The mean fluorescence intensity of 
the nanoparticles was recorded over time. Full-time exposed cells served as a control. No significant exocytosis of SPIOPSN 
was observed after 20 h of total exposure. (B) HeLa cells were transfected with Rab11 wt-GFP. 24 h later, cells were exposed 
to 150 µg ml-1 SPIOPSN for 20 h. Live cell imaging displayed no clear colocalization of Rab11 with SPIOPSN. 
(C/Magnification: D) HeLa cells were exposed to 150 µg ml-1 SPIOPSN and then immunostained for Rab11 after 20 h of 
nanoparticle exposure. SPIOPSN displayed very low amounts of colocalization with Rab11+ endosomes. (E) To study the 
crosstalk of SPIOPSN trafficking with the autophagosomal pathway, we incubated HeLa cells with 150 µg ml-1 SPIOPSN. 20 
h later, autophagosomes were immunostained for LC3. Cells were examined by confocal imaging. No clear colocalization of 




3.3.7 In vivo distribution of SPIOPSN in mice  
The former chapters described the intracellular trafficking routes of nanoparticles. In the upcoming 
sections, we exploited the formerly gained knowledge and the superparamagnetic features of the 
nanoparticles to further investigate the intracellular trafficking pathways and the biodistribution of 
nanoparticles.  
To study whether superparamagnetic nanoparticles were an appropriate tool to analyze the 
biodistribution in mice, we tail-vain injected SPIOPSN into NSG mice. 24 h later, peripheral blood, 
bladder fluid, spleen, liver and kidney were isolated. Single cell suspensions were obtained from 
spleen, liver and kidney. SPIOPSN-containing cells were magnetically isolated and examined via 
confocal microscopy. In summary, a magnetic enrichment of cells from the peripheral blood failed. 
Therefore, we concluded that nanoparticles were efficiently cleared from the blood stream without the 
uptake by the phagocytic system of the blood. In this context, it is worth to mention that NSG mice are 
immunodeficient mice with less or no phagocytic cells (228).  
Also kidney cells and the bladder fluids lacked SPIOPSN. In contrary, massive amounts of SPIOPSN 
accumulated inside liver and spleen. Most of the SPIOPSN displayed endocytic structures that 





Figure 33: In vivo distribution of SPIOPSN. 2 mg of SPIOPSN were tail-vain injected into NSG mice (n = 4). 24 h later, 
spleen, liver, kidney, peripheral blood and bladder were isolated. Single-cell suspensions were generated. Tissue fractions 
were magnetically sorted by MACS. Uptake was qualitatively analyzed by confocal microscopy. (A) Splenic cells 
internalized SPIOPSN via endocytic structures. The left image shows a randomly recorded overview about the isolated 
fraction. The right image displays a randomly chosen magnification of SPIOPSN-containing cells (B) Liver cells internalized 
SPIOPSN via endocytic-like vesicles. The left image presents an overview about the isolated fraction. The right image 
displays a randomly chosen magnification of SPIOPSN-containing cells. (C) No SPIOPSN were detected inside the 
magnetically enriched fraction of the kidney. Scale bar: 10 µm. Tail-vain injection and animal preparation was performed by 
Patricia Okwieka, University Medical Center, Mainz.  
Taking all of the results into account, we resumed that SPIOPSN are applicable to study their 
biodistribution (in vivo) after magnetic cell separation. We could show that SPIOPSN are taken up into 
endocytic-like vesicles in vivo. These vesicles resembled the identified structures in vitro. Therefore, 
we thought about an approach to exploit the magnetic features of the SPIOPSN on a subcellular level. 
The aim of the next project was the magnetic isolation of intracellular SPIOPSN-containing vesicles. 
With this application, we wanted to dissect the intracellular nanoparticle trafficking on a proteomic 






3.3.8 Shaping a picture of endocytosis: Reconstruction of intracellular 
nanoparticle trafficking 
As stated in the previous chapters, we found that SPIOPSN are trafficked from macropinosomes via 
multivesicular bodies to multilamellar lysosomes. Therefore, we asked whether we could characterize 
the SPIOPSN-containing vesicles in more detail.  
To obtain a proteomic snapshot of SPIOPSN-containing vesicles, HeLa cells were incubated with 
SPIOPSN for 20 h (Figure 34). Subsequently, noninternalized SPIOPSN were removed by extensive 
washing. Cells were mechanically disrupted and cell debris was removed by multistep centrifugation. 
SPIOPSN-containing vesicles were magnetically separated in a magnetic field for 12 h under cooling 
and with the addition of protease inhibitors. The magnetic fraction was carefully washed with PBS and 
then solubilized inside urea buffer. The nonmagnetic fraction was also solubilized with urea buffer. 
Quality controls were performed by the analysis of the magnetic/nonmagnetic fraction by TEM and 
SDS-PAGE. Subsequently, the fractions were forwarded to Dr. Stefan Tenzer, who performed the 
mass spectrometry measurements (Institute for Immunology, University Medical Center, Mainz).  
 
Figure 34: Scheme for the isolation of intracellular magnetic vesicles and their analysis by quantitative peptide mass 
spectrometry. 1.8 x 107 HeLa cells were exposed to 150 µg ml-1 SPIOPSN for 20 h. After incubation, non-                   
internalized SPIOPSN were extensively removed by washing. Cells were trypsinized, centrifuged and extensively washed 
with PBS. The terminal washing fraction was centrifuged at 20 000 x g for 30 min. No free SPIOPSN were detected. To 
obtain the cytosol with SPIOPSN-containing vesicles, cells were mechanically disrupted. Intact cells and debris were 
removed by centrifugation. This step was repeated until no pellet was visible anymore. The cytosolic supernatant with the 
magnetic endosomes were injected into a custom-made magnetic device. Magnetic separation of SPIOPSN-containing 
vesicles was performed for 12 h under cooling and the inhibition of proteases. The magnetic pellet was carefully washed with 
PBS. Proteins of the magnetic and the nonmagnetic fraction were solubilized in urea buffer. Peptides were generated by a 
tryptic digest. Samples were quantitatively measured by a TOP3-dependent MS approach and peptide fragments were 
identified by a database-related search. Enrichment factors are based on the determined ppm values and were calculated 
comparing the magnetic vs. the nonmagnetic fraction. Enriched proteins were forwarded to DAVID ontology analysis and 
classified by their subcellular localization. Intracellular nanoparticle trafficking was reconstructed based on the results of 





After mass spectrometry measurements and data evaluation, the amount of proteins between the 
magnetic and the nonmagnetic fraction was compared. Based on the averaged ppm values of the 
quantified proteins, protein enrichment factors were calculated (example in Table 18).  
Table 18: Calculation of the protein enrichment factors (example). Ppm values of the proteins in the magnetic fraction 
were compared with the ppm values of the proteins of the supernatant. Based on the averaged ppm values, enrichment factors 
were calculated for each protein. The calculation of the enrichment factor of the protein Rab5C is shown as an example. 
Quantification of proteins was performed in triplicates. Averaged ppm values were calculated. 






RAB5C_HUMAN 34285 6339 5,41 
3.3.9 DAVID protein ontology analysis of the vesicular fraction reveals an 
association of endolysosomal proteins with SPIOPSN-containing 
vesicles 
Overall, we were able to identify and quantify 1492 proteins in the magnetically enriched fraction, 
whereas 884 were significantly enriched by a factor of at least 2 in comparison to the nonmagnetic 
fraction. We then applied the online tool “DAVID protein ontology” to analyze the intracellular 
nanoparticle trafficking (INT) in silico (229). Proteins were grouped into annotation clusters owing to 
their known subcellular localization in literature (Table 19). 
Table 19: DAVID protein ontology analysis (GOTERM: GOTERM_CC_FAT). Proteins that were magnetically enriched 
> 2-fold in comparison to the nonmagnetic supernatant have been considered in DAVID ontology analysis. The ontology 
analysis clustered the different proteins owing to their known subcellular localization. The enrichment scores for the distinct 
subgroups are based on the EASE score. In the presented table, the starting five annotation clusters are shown with 
enrichment scores larger than 9. The full analysis is provided in the supplementary information of this thesis. Counts show 
the proteins that are classified into the individual terms. We mainly identified proteins of the endolysosomal system and from 
mitochondria. P-value: modified fisher exact p-value. The smaller the p-value, the higher enriched the proteins inside the 
respective class. The proteins of the red-marked GOTERMs are listed in the supplementary information of this work.   
Annotation Cluster  Enrichment Score/ Term Protein count p-value  
Annotation Cluster 1 Enrichment Score: 42.07   
  envelope 145 3.6E-45 
  organelle envelope 144 1.2E-44 
  mitochondrial envelope  115 7.1E-43 
  mitochondrial membrane 111 1.6E-42 
  mitochondrial inner 
membrane 
96 5.3E-41 
  organelle inner membrane 99 1.5E-40 
Annotation Cluster 2 Enrichment Score: 29.76   
  lysosome  69 1.3E-30 
  lytic vacuole 69 1.3E-30 
  vacuole 75 2.9E-30 




Annotation Cluster 3 Enrichment Score: 16.73 
  vesicle 105 3.8E-18 
  membrane-bounded 
vesicle 
93 2.5E-17 
  cytoplasmic membrane-
bounded vesicle 
91 2.9E-17 
  cytoplasmic vesicle 100 4.2E-17 
Annotation Cluster 4 Enrichment Score: 9.24   
  membrane fraction 99 2.9E-10 
  insoluble fraction 101 4.7E-10 
  cell fraction 120 1.4E-9 
3.3.10 Reconstruction of intracellular nanoparticle trafficking 
The dissection of intracellular nanoparticle trafficking is based on the identified proteins that were 
categorized into the GOTERMs lysosome and vesicle (Table 19, for a detailed protein list, see 
supplementary information). We used the simplest endocytic model for the reconstruction of INT 
(Figure 35). In our approach, we identified several enriched endolysosomal proteins in the magnetic 
fraction. Early endosomes can be recognized by the markers RAB5A and RAB5C (230). Further 
adaptor proteins such as proteins from the AP-1/AP-2 family (e. g. AP1A1, AP1B1, AP2B2) have 
been described as key players in endocytic trafficking (231, 232). Proteins such as RhoB and ARF1 
have been associated with the (macro)pinocytic machinery (90, 233).  
RAB7A and RAB9 are important markers of multivesicular bodies (234). MVBs have been associated 
with several tetraspanins (e. g. CD9, CD63, CD81, CD82) and HLA molecules (e. g. HLA MHC class 
I antigen A*68) (173, 174, 235-237). Further proteins that are present on MVBs are Niemann Pick 
disease C1 (NPC1) and Niemann Pick disease C2 (NPC2) (238). Flotillin 1 (FLOT1) and flotillin 2 
(FLOT2) was also identified by MS. Proteins such as LAMP1 and LAMP2, Mannose-6-P-receptor-
CD (MPRD) and Mannose-6-P-receptor-CI (MPRI) have been shown to associate with the 
endolysosomal pathway (239, 240). LTOR1, LTOR2, LTOR3 are present on lysosomes and mediate 
several events of intracellular trafficking (241). We were also able to identify several v-type proton 
ATPase pumps that obtain the lysosomal pH (e. g. VATG1, VATC1). In case of recycling endosomes, 
RAB11A and RAB11B were identified. RAB11 is mainly associated with recycling endosomes, but 
also fulfills different tasks inside the cell, for instance on MVBs (162, 242). Additionally, we 








































































































































































































Altogether, we have identified a large number of novel marker proteins that were associated with 
SPIOPSN-containing vesicles. These proteins enable us to create a snapshot of the participating 
vesicles during nanoparticle trafficking after 20 h of exposure. Since we have detected the majority of 
nanoparticles inside lysosome-like organelles after 20 h, it was not surprising that we have identified a 
large number of enriched lysosomal matrix proteins. Therefore, we reconstructed the intravesicular 
milieu of a nanoparticle in more detail (Figure 36).  
3.3.11 Reconstruction of the intravesicular lysosomal matrix 
The hydrolases and cofactors of the lysosomal matrix have been extensively studied in the proteomic 
field (156). Many of the previous investigations performed density gradient fractionation or affinity 
chromatography to obtain the vesicles of interest. Our approach utilized the magnetic isolation of 
SPIOPSN-containing vesicles.  
In our study, we have identified acetylgalactosamine-6-sulphatase N (GALNS) and N-
acetylglucosamine-6-sulphatase (GNS) as hydrolases for the degradation of chondroitin sulphate and 
keratin sulphate. Acid ceramidase (ASAH1) is known to hydrolyze ceramide into sphingosine and free 
fatty acids. Arylsulphatase A (ARSA) and arylsulphatase B (ARSB) hydrolyzes cerebroside sulphates. 
Cathepsin B/D/Z/L1/C are enzymes for unspecific proteolysis. The CLN5 protein was also identified 
as a lysosomal matrix protein. Other identified proteins are hexosaminidase A (HEXA) and 
hexosaminidase B (HEXB). These proteins have the potential to degrade GM2 gangliosides. β-
mannosidase (MANBA) cleaves mannosyl residues. Palmitoyl-protein thioesterase 1 and palmitoyl-
protein thioesterase 2 removes thioester-linked fatty acyl groups from proteins and peptides. Proteins 





Figure 36: The proteomic dissection of a nanoparticle-containing lysosome. The data of mass spectrometry revealed that 
several lysosomal proteins were enriched inside the magnetic fraction. Protein abbreviations are given as Uniprot_ID. Full 
names are provided by the supplementary information. 
The reconstruction of the lysosomal milieu of nanoparticles becomes especially important for the 
design of biodegradable nanocarriers. Frequently, the nanoparticle synthesis is often not tailormade for 
the endolysosomal system. Consequently, the intravesicular degradation of the nanocarriers fails. 
Since we used a non-biodegradable nanoparticle, we were not able to show the degradation of the 
particle itself. However, we tested whether the components of the lysosome can degrade the 
nanoparticulate protein corona (Figure 37 and Figure 38).  
3.3.12 The nanoparticle protein corona is degraded inside Lamp1+/Lamp2+ 
lysosomes 
Based on the gained knowledge about the reconstructed lysosomal matrix, we next asked the question 
whether the enzymes of the lysosomal matrix have the potential to degrade the protein corona of 
SPIOPSN. The nanoparticulate protein corona is formed, when nanoparticles enter a biological fluid 
with proteins (244). To investigate whether the protein corona is degraded inside the lysosome, 
SPIOPSN were incubated with Alexa Fluor 647 labelled bovine serum albumin to adsorb a 





Figure 37: Schematic illustration of the system that was used to study the degradation of the protein corona inside the 
lysosomes. Nanoparticles were preincubated in pure BSA647 for 60 min. Afterwards, nanoparticles were diluted with media 
and then added to the cells. After incubation, cells were immunostained for Lamp1/2. SPIOPSN and BSA647 were analyzed 
for colocalization with the lysosomal markers by confocal microscopy.  
The coincubation of SPIOPSN with BSA647 (without preincubation) led to the internalization of both 
cargos into different vesicles only showing a minor rate of colocalization (Figure 38). This shows that 
BSA-AF647 was not significantly adsorbed on the surface of nanoparticles, which were already 
covered with proteins. Furthermore, we concluded that SPIOPSN and BSA647 exploited distinct 
internalization pathways. Taking this into account for the following experiments, we resumed that we 
only could detect preadsorbed proteins on the nanoparticles. Indeed, the incubation of BSA647- 
preincubated SPIOPSN revealed strong signals of colocalization between SPIOPSN and BSA647. 
Therefore, it was concluded that the protein corona is cointernalized with the nanoparticle into 
endocytic vesicles. Next, we investigated, whether BSA647 is still present inside lysosomes. 
Interestingly, no BSA647 was observed inside Lamp1/Lamp2
+
 vesicles. In contrary, vesicles negative 
for Lamp1/2 still contained BSA647. Our interpretation for this was that BSA647 is degraded inside 
Lamp1/Lamp2
+
 organelles. The investigation of BSA647-coated SPIOPSN revealed that the 
nanoparticles inside Lamp1/Lamp2
+
 vesicles lack BSA647 after 20 h of incubation (Figure 38). Owing 






Figure 38: The protein corona is cointernalized with nanoparticles and then degraded inside the lysosome. (A) HeLa 
cells were coexposed to 150 µg ml-1 SPIOPSN and 0.5 mg ml-1 BSA647 for 8 h. Almost no colocalization was observed. (B) 
150 µg ml-1 SPIOPSN were preincubated in 0.5 mg ml-1 BSA647 for 60 min and then added for 6 h to HeLa cells. A large 
number of colocalization spots were observed (white arrows). (C) HeLa cells were incubated with BSA647 for 20 h. BSA647 
was not detectable in Lamp1/2+ lysosomes. (D) Cells were exposed to BSA647-preincubated SPIOPSN (150 µg ml-1) for 20 
h. No BSA647 was present on SPIOPSN. Minor amounts of excess BSA647 accumulated inside Lamp1/Lamp2- cells after 
20 h of incubation. (E) Magnification of Lamp1/2+ lysosomes containing SPIOPSN. Less to no BSA647 was detected inside 






This study aimed to elucidate the interaction of polymeric nanoparticles with biological systems in 
terms of drug delivery, entry and intracellular trafficking pathways of nanomaterials. In summary, we 
could show that biodegradable PLLA nanoparticles are potentially suitable for a rapid and effective 
delivery of drugs by a novel mechanism we referred to as “kiss-and-run”. For the first time, we 
provide evidence for a non-invasive mechanism transporting nanoparticulate cargo over the cell 
membrane into lipid droplets. The nanoparticulate cargo release occurs during several milliseconds 
owing to a physicochemical interaction between the nanoparticle and the plasma membrane.  
We further show that these polymeric nanoparticles are taken up by cells after their long-term 
exposure. Therefore, issues about the uptake mechanisms and intracellular trafficking pathways of 
polymeric nanoparticles were raised. For this project, we changed the polymer of the nanoparticle to 
polystyrene. We show that ~ 126 nm large SPIOPSN are internalized by a macropinocytic-like entry 
mechanism. In a series of experiments we demonstrate that their entry mainly depends on distinct 
small GTPases, kinases and on cholesterol.  
Further on, we established a novel method for the unbiased dissection of intracellular nanoparticle 
trafficking. This method is based on the identification of proteins, which are located on nanoparticle-
containing vesicles. Under native conditions, nanoparticles are transported from early endocytic 
vesicles via multivesicular bodies into the terminal multilamellar lysosomes. This dissection of INT 
may serve as a novel fundament to describe nanoparticle trafficking in more detail. Taking all of these 
data together, we propose a novel drug delivery mechanism for polymeric nanoparticles and 
investigated a so far unknown mechanism of the entry and trafficking of polymeric nanoparticles.  
4.1 Interaction of polymeric nanoparticles with biological systems can trigger 
a release of different nanoparticulate components 
Polymeric nanoparticles are a versatile tool to shield drugs from environmental influences (2, 6). The 
primary goal of these drug delivery vehicles is the transport of the loaded cargo to the location of 
interest (43, 245). However, less is known about the release of nanoparticulate components that 
coexist inside the nanoparticle and should primarily not be delivered. These factors include polymers, 
stabilizing surfactants or dye molecules (246). Notably, the circumstance that these factors sometimes 
are released is no disadvantage. Moreover, this observation was utilized to study the mechanism of 
nanoparticulate drug delivery in more detail. To track the interaction of nanoparticles with cells, we 
chose a nanoparticulate model system with a noncovalently-bound dye. This enabled us to 




The release kinetics of PMI during the exposure of HeLa cells or other cell types to PLLA-Fe-PMI 
nanoparticles reproducibly revealed a fast accumulation of the model dye into lipid droplets (Figure 7, 
Figure 8 and Figure 9). To our knowledge, no comparable study exists that could show an uptake of 
nanoparticles within the first five minutes of exposure. Such fast rates of internalization are only 
known for biomacromolecules (e. g. EGF) or for freely diffusing small molecules (247, 248). 
Therefore, we assumed and also demonstrated that the encapsulated dye molecules were independently 
transported from the polymeric matrix into the cells (Figure 9). Interestingly, this phenomenon was 
afterwards also recognized for other nanoparticles (e. g. PLLA-PMI or PS-COOH) (6). Tomcin and 
colleagues used these observations and demonstrated that also other components of nanoparticles (e. g. 
surfactants) are released during nano-bio-interactions (249). They microscopically showed a release of 
block-co-polymers from nanoparticles before the nanoparticle itself enters the cell.  
Another interesting observation was made during the investigation of the interaction of cells with 
SPIOPSN. Here an undesired delivery of a nanoparticulate component was observed. After 
nanoparticle exposure, it was obvious that the number of intracellular TIP47
+
 lipid droplets had more 
than doubled (data not shown). It seemed that this effect is triggered by a surfactant-like component of 
the nanoparticle. During miniemulsion polymerization, SPIOs are generated inside oleic acid droplets 
that are probably not completely removed from the nanoparticle after their magnetic purification (35, 
37). In biological experiments it is likely that oleic acid molecules are released from the particle and 
are subsequently stored inside lipid droplets. In vitro, this is artifically achieved by the feeding of cells 
with a BSA carrier, which is complexed with oleic acid (209). In the context of lipid droplets and 
nanoparticles, it is worth to mention that other studies also observed a increase of LDs after 
nanoparticle exposure (250, 251). Here the authors assumed that the increase of LDs is triggered by 
the quantum dot-mediated induction of reactive oxygen species. After the exposure of PC12 cell to 
CdTe nanoparticles, the amount of ROS was significantly increased in the culture (250). We also 
considered this and measured ROS levels and the mRNA levels of hypoxia-inducible transcription 
factor-1α (data not shown). However, no significant elevation of these factors was observed (data not 
shown). Therefore, it was concluded that the increased number of LDs is based on the import and the 
incorporation of nanoparticulate oleic acid into LDs.  
Taken together, the observation of a membrane-nanoparticle-interaction-triggered release of 
nanoparticulate components is exciting. Though, this newly gained knowledge also raises issues about 
the relevance of these data for other studies. Here it should be noted that a large number of distinct 
nanoparticles are synthesized and tested for their interaction with biological systems (252). Thereby, a 
variety of studies already used noncovalently bound fluorescent tracers in nanoparticles that might be 
released during biological experiments (253). Most notably in uptake studies of nanoparticles, the 
release of such fluorescent dyes or the presence of nonencapsulated dye molecules can result in the 




recognize that the deep characterization of the nanomaterial is a major prerequisite for their 
application in biological studies (256). Furthermore, the scientific community has to raise issues about 
the fate of such distinct hydrophobic molecules (e. g. dyes or drugs) that are released from 
nanoparticles and partially accumulate inside lipid droplets (208). Since the biology of LDs is so far 
less understood, one can only hardly predict the biological consequences after the disposition of 
distinct hydrophobic drugs. Especially, the question whether the hydrophobic molecule can be 
released after LD disassembly is a point that needs to be clarified in the future.  
Prospective applications that could utilize the non-invasive “kiss-and-run” mechanism 
In general, non-invasive nanoparticle-based drug delivery mechanisms can be utilized to gain access to 
cells with a low rate of endocytosis. In the human body, several cells are predestined for a rapid and 
high uptake of extracellular material due to their high phagocytic potential (257). Conversely, other 
cell types such as lymphocytes naturally lack high endocytic rates (206). These cells are hardly 
accessible via invasive drug delivery mechanisms (205). However, in several cases an intracellular 
delivery of drugs is mandatory. For such applications, one can exploit the “kiss-and-run” mechanism.  
Moreover, the accumulation of hydrophobic substances inside lipid droplets bears the potential to 
develop novel applications. One example could be the treatment of dyslipidemic patients (258). So far, 
the metabolism of LDs is less understood, but it is known that the fatty acid synthesis depends on the 
enzymes DGAT1 and DGAT2 (259). In dyslipidemic patients, an excess of lipid storage is observed 
(260). To counteract this, the nanoparticulate delivery of a niacin-conjugate to LDs seems to be 
promising for a therapeutic approach (258). Others reported the importance of LDs in the life cycle of 
hepatitis C viruses (HCV) (261). It was shown that the replication of HCV depends on LDs. Someday 
this could give the motivation to establish a nanoparticle-based drug delivery approach for the 
targeting of LDs to inhibit the life cycle of HCV.  
4.2 PLLA and polystyrene nanoparticles release hydrophobic cargo on 
hydrophobic surfaces by “kiss-and-run” 
Before PMI accumulates inside lipid droplets, PMI is released by a “kiss-and-run” mechanism (Figure 
10). This mechanism can be described as a physico-chemical and temporary interaction of the 
nanoparticle with a hydrophobic membrane (Figure 39). But what are the parameters that drive the 
release of PMI out of the polymeric matrix? Probably one of the most crucial factors is the partition 
coefficient of the hydrophobic substance (262). This coefficient describes the ratio of distribution of a 
compound in two imminiscible phases (263, 264). In pharmacokinetics of nanoparticulate systems it is 
desirable that the compound is hydrophobic enough to stay in the nanoparticle. However, the cargo 




cell membrane, the cargo should further have the ability to cross the hydrophilic cytoplasm to reach 
the target location (265).  
 
Figure 39: Schematic illustration of the kiss-and-run mechanism. Nanoparticles briefly interact with the lipid bilayer of a 
cell (A) or a giant unilamellar vesicle (B), thereby releasing its dye that accumulates in lipid droplets (LD) or in the 
membrane, respectively. 
It seems as though PMI fulfills all of these requirements (Figure 9 and Figure 10). Whether this is the 
case for other molecules was also investigated during this work. We analyzed several other 
hydrophobic drugs such as etoposide and podophyllotoxin for their release properties out of PLLA 
nanoparticles (data not shown). We assumed that the drug release of these compounds also occurs via 
“kiss-and-run”. In one of the experiments we compared the effects of free podophyllotoxin (low 
dosage) with podophyllotoxin that was loaded into PLLA nanoparticles (high dosage). Microtubule 
(MT) depolymerization was morphologically tracked using U2OS-TagRFP-Tubulin cells 
(Marinpharm, Germany). In these experiments we could demonstrate that free podophyllotoxin can 
induce a MT depolymerization within 5 min. In contrary, the treatment of cells with nanoparticle-
encapsulated podophyllotoxin (high dosage load) failed to induce a rapid microtubule 
depolymerization (266). This reveals that an efficient drug release by “kiss-and-run” probably also 
depends on the chosen drug. But this is certainly only one drawback of nanoparticulate drug delivery 
systems (267). An additional factor that could influence the release kinetics in vitro and in vivo is the 
protein corona of nanoparticles. Interestingly, Paula et al. reported that the formation of a protein 
corona significantly decreases the efficiency of drug release out of mesoporous silica nanoparticles 




On the interface of membranes and nanoparticles, distinct mechanisms could drive the release of 
hydrophobic substances out of nanoparticles (55). In general it is known that surfactants have the 
potential to disrupt the membrane organization by changing the lipid conformation (269). Since 
nanoparticles are stabilized with surfactants such as sodiumdodecyl sulfate (SDS) it would not be 
surprising that lipids are reorganized after nanoparticle-membrane interaction (35). Exactly, this 
interaction could favor the release of the cargo out of the nanoparticle. Other factors that could have an 
impact on the release mechanism of drugs on the membrane are the hydrophobicity of the 
nanomaterial and the strength of interaction between nanoparticles and cellular membranes (55). In 
this study, we analyzed different nanoparticles on their interactions with giant unilamellar vesicles 
(Figure 10 and Figure 11). As an example, PS-NH2-BODIPY (NH2 functionalized) as well as PLLA-
Fe-PMI (COOH functionalized) and SPIOPSN-BODIPY (Sulfonate functionalized) displayed two 
completely different motifs of interaction on the giant unilamellar vesicles. The positively charged PS-
NH2-BODIPY nanoparticles have been observed to permanently interact with the GUVs by dashing 
around onto the vesicles surface (Figure 11A). Interestingly, after some time of interaction, the 
nanoparticles disrupted the vesicles implying a strong interaction between both partners. In contrary, 
the negatively charged nanoparticles PLLA-Fe-PMI and SPIOPSN-BODIPY only temporarily 
interacted with the GUV without destroying it (Figure 11B).  
If the strength of interaction leads to an increased efficiency of cargo release is not clear from our 
observations since we have used covalently-bound dyes for these experiments. However, we 
demonstrated that the disruption of the membrane was only induced by strongly interacting and 
aminofunctionalized nanoparticles (own observation). Lui et al. supported this hypothesis (270). They 
showed that the surface functionalization of silica nanoparticles has an important impact on the 
membrane integrity of tethered bilayers (270). The authors compared four types of surface 
functionalizations (COOH, NH2, bare, PEG). According to their data they observed a distinct order for 
the surface functionalization regarding their potential to disrupt membranes (amine > carboxyl ~ bare 
> PEG). In other studies, the mechanism of disruption leads to a hole formation after membrane-
nanoparticle interaction (271). Further on, computer simulations calculated that nanoparticle-
membrane interactions are also able to induce a thinning of the contacted membrane (272). Over time, 
this could also result in the collapse of the membrane (55).  
To come back to the release mechanism of PMI, one needs also to discuss the effect of hydrophobicity 
on the interactions of nanoparticles. As previously mentioned, it was demonstrated that PLLA-Fe-PMI 
nanoparticles release their hydrophobic cargo PMI in hydrophobic media and on hydrophobic surfaces 
of GUVs (Figure 10). This shows that hydrophobicity might be a crucial factor that can drive the 
interactions between nanoparticles and lipid membranes. In the past, several simulations calculated the 
impact of hydrophobic nanoparticles on membranes. Yang and colleagues modeled the simulation of a 




hydrophobic nanoparticles with membranes can result in their inclusion into the bilayer, the 
semihydrophobic nanoparticle is only found to adsorb into the membrane. Also a morphological 
reorganization of the membrane lipids strongly depends on the hydrophobicity of nanoparticles (51). 
All of these calculations referring to the impact of hydrophobicity on the nanoparticle-membrane 
interactions are in compliance with the provided data of this thesis. Based on the release experiments 
that have been performed, we propose that the release for PMI is mainly triggered by hydrophobic 
interactions between the membrane and the nanoparticles. This hydrophobic interaction could 
temporarily provide a more favorable hydrophobic environment for the PMI inside the membrane than 
inside the nanoparticle.  
4.3 Polymeric superparamagnetic nanoparticles are internalized by a 
macropinocytic-like mechanism 
After the long-term exposure of PLLA-FE-PMI nanoparticles, we observed their uptake into cells. 
Morphologically, the endocytic structures that mediated the nanoparticle uptake resembled 
macropinocytic ruffles (Figure 12). However, we previously showed that PLLA-Fe-PMI nanoparticles 
are not suitable to investigate nanoparticle uptake mechanisms (6). To reliably study the entry 
mechanisms of polymeric nanoparticles, we therefore used well-characterized superparamagnetic iron 
oxide polystyrene nanoparticles (SPIOPSN) with a fluorescently bound fluorochrome (BODIPY). The 
SPIOPSN fulfilled all requirements that were necessary to conduct these kinds of studies (6, 37). Since 
we have shown that SPIOPSN only temporarily interact with cell membranes, we demonstrated an 
uptake of SPIOPSN via the fluid phase endocytosis (Figure 12).  
4.3.1 The entry of SPIOPSN is dependent on several factors of 
macropinocytosis 
To examine the entry routes of SPIOPSN, several endocytic pathways have been investigated by the 
application of different freely permeable inhibitor molecules (Table 5). The set of inhibitors covered a 
large number of different endocytic pathways. After intensive research on this project, we mainly 
focused on inhibitors of macropinocytosis (Figure 12 and Figure 15). Since no standards for the 
investigation of nanoparticulate macropinocytosis are defined yet, we checked several criteria that 
have been considered as crucial in viral macropinocytic mechanisms (140). These include the 
cointernalization of SPIOPSN with fluid-phase tracers. Furthermore, it is necessary to examine the 





exchangers play a major role (94). Last but not least, the influences of several kinases, dynamin, 
myosin II and microtubule dynamics have to be checked (212). We have summarized some of the 




Table 20: Factors worth to test in classical macropinocytosis (212). 
Factors Effect 
F-actin cytoskeleton Inhibition influences ruffling and blebbing. 
Fluid-phase uptake Macropinocytic cargoes often colocalize with fluid 
phase markers (e. g. HRP, Dextran). 





exchangers Inhibition by amiloride blocks macropinocytosis by 
the lowering of submembraneous pH. 
Kinases Inhibition of signaling kinases should suppress 
macropinocytosis. 
 
Our images show the co-uptake of SPIOPSN with fluorescently-labeled dextran, an important marker 
of fluid phase endocytosis (Figure 12). As previously demonstrated, dextran is utilized for the tracking 
of macropinosomes (274). Morphologically, we could show the internalization of nanoparticles via 
heterogeneously sized vesicles that are also visible by DIC microscopy (Figure 12). Therefore, we 
concluded from our experiments that SPIOPSN are internalized via a mechanism of fluid-phase 
endocytosis (212). Further experiments with an inhibitor of F-actin polymerization allowed to assume 
that actin reorganization plays an important role during the entry of SPIOPSN and dextran (Figure 12). 
Previous reports for several cargo molecules like peptides, viruses and fluid phase markers already 
showed a major participation of actin during their cellular entry (275, 276). Also on an ultrastructural 
level, we partially observe the classical macropinocytic ruffles and protrusions that embraced 
SPIOPSN and PLLA-Fe-PMI nanoparticles (Figure 12) (277).  
4.3.2 SPIOPSN internalization is accompanied by the small GTPases Rac1 
and cdc42 
As a consequence of this pathway, the entry of SPIOPSN might depend on some small GTPases that 
are known to induce the reorganization of the actin cytoskeleton (127, 278). To our knowledge, no one 
has shown the participation of small GTPases during the uptake of nanoparticles. Therefore, we 
characterized the possible effects of Rac1 as a small GTPase that is known to be located on the inside 
of macropinocytic ruffles (136, 137). It was demonstrated that the overexpression of the permanently 
active mutant of Rac1 Q61L induced the formation of roundly-shaped vesicles (Figure 13). These 
organelles were previously described as nonbudded premacropinosomes (137). The overexpression of 
this mutant drastically increased the probability to track SPIOPSN during the early stages of uptake 
since the terminal vesicular budding was not completed yet (137). And indeed, SPIOPSN were found 
in roundly-shaped premacropinosomes that seemed to be trapped in the early stages of fluid phase 
uptake (Figure 13). The same phenotype has been observed after the overexpression of constitutively 




a comparable confocal close-up image of this cdc42 Q61L-induced phenotype. However, it is 
generally accepted that the small GTPase cdc42 is tightly associated with Rac1 implying similar 
effects after overexpression (279, 280). Further on, it is known that both proteins act in the preliminary 
stages of macropinocytic ruffle formation (280). Based on this argumentation, it was not so surprising 
that SPIOPSN were found in roundly-shaped cdc42 Q61L
+
 and Rac1 Q61L
+
 premacropinosomes.  
Moreover, it is also worth to mention that dominant negative cdc42 T17N-GFP colocalized with 
SPIOPSN. In this particular case, the vesicles were not static as seen after the overexpression of the 




vesicles directly moved through the cell 
resembling budded cdc42
+
-macropinocytic vesicle (Figure 14). The colocalization of cdc42 with 
nanoparticle-containing vesicles is in accordance with the data of the mass spectrometric analysis, 
where we identified cdc42 as a protein of the SPIOPSN-associated fraction (Supplementary Table S4). 
However, no quantitative and qualitative reduction of the internalization rate of SPIOPSN was 
observed after esiRNA-mediated knockdown of cdc42 and the overexpression of cdc42 T17N (Figure 
14). The impact of cdc42 knockdown was previously shown for the macropinocytic uptake of the 
ebola virus (211). In this study the authors reported a reduction of viral uptake after the siRNA-
mediated downregulation of cdc42. Taking all of these data into account, we concluded that in spite of 
the colocalization, cdc42 is not prominent enough to significantly control the uptake rate of SPIOPSN. 
Consequently, we proposed that the nanoparticles are taken up by an atypical macropinocytic 
mechanism (150).  
4.3.3 SPIOPSN entry is triggered by an atypical type of macropinocytosis 
As demonstrated by confocal imaging, SPIOPSN are internalized via macropinocytic structures 
(Figure 12, Figure 13 and Figure 14). These specific membrane domains are ordered structures (212). 
Their formation is tightly regulated by several kinases (140, 146). Most of the kinases were shown to 
modulate the actin cytoskeleton via several routes (281, 282). Thereby, the PI3K signaling is one of 
the major pathways, which mediate macropinocytosis (283). Combinations of different experiments 
allow concluding that PI3K signaling acts in a first order followed by the signaling of PLC (144, 284). 
Stable transfections as well as pharmacological inhibition of PI3K and PLC demonstrated that both 
enzymes are essential factors in macropinocytic signaling (285). Taking these observations into 
account, we pharmacologically inhibited PI3K by wortmannin and Ly294002 (Figure 15). Notably, we 
observed a significant drop of internalized SPIOPSN by analyzing PI3K-inhibited cells. 
Subsequently, the PI3K downstream signaling proteins PKC and PLC were inhibited. Both factors are 
important actin modulators (144, 286). Therefore, it was even more than surprising that even high 
concentrations of specific inhibitors for PKC and PLC did not alter the internalization rate of 
SPIOPSN. It is important to mention that this observation is consistent with a case in the field of 




uniform picture of macropinocytosis can hardly be shaped. Since the exact mechanisms are still 
elusive and seem to mainly depend on the investigated cell type and cargo it is challenging to set a 
standard (140). Also the multiple options of actin reorganization make it hard to draw a clear picture 
of macropinocytic mechanisms. This also includes the kinase PAK1. PAK1 binds the GTP-bound 
form of cdc42/Rac1 and modulates the actin cytoskeleton (287). Indeed, we showed that the 
pharmacological inhibition of PAK1 suppressed the entry of SPIOPSN in the same manner compared 
to PI3K inhibition (Figure 15).  
Cup closure or the scission of macropinosomes 
Besides the modulation of the actin cytoskeleton, the closure of the macropinosome depends on PAK1 
and requires the phosphorylation of CtBP1/BARS in growth factor triggered macropinocytosis and 
during echovirus-1 entry (135, 288). This process seems to be independent from dynamin (135). 
Contrary to this, rare cases of a dynamin-dependent macropinocytosis have been reported (147, 148, 
289). This was also observed in our studies. Dynasore treatment as well as the overexpression of 
dominant negative dynamin II drastically suppressed the number of internalized nanoparticles (Figure 
16). On a subcellular level, it is known that dynamin participates in the formation of macropinocytic 
protrusions (214). Schlunck and colleagues showed that the disruption of dynamin II leads to an 
altered Rac localization from the cell edges into abnormal dorsal ruffles (214). The consequences of 
this are inhibited cell spreading and the decrease of lamellipodia formation. Taken together, dynamin 
is so far mainly seen as a factor of clathrin and caveolae-mediated endocytosis (Figure 18 and Figure 
19). However, it is more than important to consider the action of dynamin II in macropinocytic 
studies. 
Stimulation of classical macropinocytosis results in a diminished uptake of nanoparticles 
In agreement with the previous results, we concluded that nanoparticles are taken up by an atypical 
macropinocytic pathway. This was underlined by experiments inducing classical macropinocytic 
pathways by EGF or PMA (Figure 17). Both types of stimulation had no boosting effect on the rate of 
internalization. Instead, stimulation of HeLa cells with EGF or PMA resulted in a massive drop of 
internalized SPIOPSN. We postulated that the uptake of nanoparticles after macropinocytic 
stimulation could be limited by their own size or owing to the diameter of the pinocytic ruffle (Figure 
17). During this process, nanomaterials could be excluded from the macropinocytic ruffle. Normally, 
EGF and PMA are known to trigger classical signaling cascades of macropinocytosis resulting in an 
increase of endogenous fluid phase material as we have shown with dextran (Figure 17) (94, 290).  
4.2.4 Changes in cholesterol homeostasis suppress the uptake of SPIOPSN  
So far we discussed how the internalization of SPIOPSN depends on different kinases and small 




that the depletion of cholesterol by mβCD suppressed the uptake ratio of SPIOPSN (Figure 21). In 
general, cholesterol is an important membrane organizer in mammalian cells (291). The disturbance of 
cholesterol homeostasis can have profound effects on cellular functions resulting in lipid-associated 
disorders such as Niemann-Pick disease type C or Tangier disease (292). It further causes the 
deregulation of macropinocytic signaling (138, 293, 294). So far it is known that several membrane 
proteins prefer to interact with distinct lipids forming highly organized lipid rafts (295). Especially, in 
macropinocytic signaling, the subcellular localization of important membrane proteins such as Rac1 
depends on an intact cholesterol homeostasis. Grimmer and colleagues demonstrated that the depletion 
of cholesterol prevents the localization of Rac1 to the plasma membrane in A431 cells (138). Further 
on, the authors showed that the reorganization of the actin cytoskeleton and consequently the 
membrane ruffling can be influenced by membraneous cholesterol (138, 296). In a particular study 
with human embryonic kidney cells it has been demonstrated that the reduction of membranous 
cholesterol decreases the length of actin-dependent protrusions (297).  
Disturbance of the endolysosomal cholesterol homeostasis influences the uptake of nanoparticles 
During this study, we further demonstrated that not only the depletion of membraneous cholesterol but 
also the disturbance of endolysosomal cholesterol homeostasis had an effect on the uptake of 
SPIOPSN (Figure 21). U18666A triggered a Niemann-Pick disease type C by accumulating 
cholesterol and other lipids in the membrane of the endolysosomal system (Figure 21) (298). Inside 
these NPC-like HeLa cells, the uptake rate of dextran and SPIOPSN was drastically decreased 
assuming that NPC proteins might be associated with SPIOPSN-containing vesicles. Indeed, NPC1 
and NPC2 were identified by mass spectrometry in the magnetically enriched fraction (Supplementary 
Table S2). NPC1 and NPC2 are necessary proteins for the efflux of cholesterol and other lipids from 
late endosomal compartments (298). When these proteins are nonfunctional, lipids accumulate inside 
the endolysosomal system. Therefore, we investigated whether a siRNA-mediated knockdown of 
NPC1 could induce such a phenotype. In previous studies, it was observed that siRNA-mediated 
knockdown of NPC1 is sufficient for a deregulation of cholesterol inside the endolysosomal system 
(299). Despite of comparable knockdown rates, we did not observe any significant effects on the 
nanoparticle uptake rate after NPC1 downregulation. Therefore, we concluded that this method is 
insufficient to study the effect of NPC1 on the uptake of nanoparticles. Notabily, other reports used a 
more efficient technique to study the impact of NPC1 on the intracellular transport of nanoparticles 
(83). The authors used NPC1-deficient MEFs and demonstrated that cells with nonfunctional NPC1 
have a disturbed rate of exosome formation resulting in an increased retention of the nanomaterial 
inside the endolysosomal system (83). This study shows the relevance of cholesterol and its 




4.2.5 Flotillin-1 and CD81 knockdown as well as the overexpression of dominant 
negative ARF1 suppresses SPIOPSN entry 
Flotillins are organized as punctuate membrane domains enriched in cholesterol and sphingomyelin 
(300, 301). The subcellular localization of flotillins depends on cholesterol (131). Furthermore, 
flotillin microdomains have been implied to modulate the actin cytoskeleton (302). It was shown that 
flotillin microdomains specifically interact with the cytoskeletal myosin IIa and spectrin (303). 
Experiments with flotillin-1 knockout mice revealed that flotillin-1 is compromising myosin IIa 
activity, thereby implicating a role for flotillins in the modulation of the actin cytoskeleton (303). 
Taking the cholesterol dependence of flotillin and the role in actin modulation into account, one could 
assume a direct link between flotillins and macropinocytic uptake mechanisms (304). To our 
knowledge, this has not been observed in detail. However, Glebov et al. published a role for flotillin in 
a clathrin-independent pathway showing that flotillin-1 mediates the transport of the GPI-anchored 
CD59 and cholera toxin B subunit (88). Considering the investigated cargo molecules, this pathway 
resembles the CLIC/GEEC pathway, which is also known to mediate the uptake of fluids (90). 
In this study we detected a significant drop of internalized nanoparticles in flotillin-1-siRNA-treated 
cells but observed no colocalization with ctxB (Figure 20; data not shown). Together, this implies an 
indirect association of flotillin (88) with the uptake mechanism of the investigated nanoparticles. 
Notably, we identified flotillin-1, flotillin-2 and the GPI-anchored protein CD59 in the magnetic 
fraction by the mass spectrometry analysis of SPIOPSN-containing vesicles (Supplementary Table S2, 
Supplementary Table S4). We propose an accumulation of flotillin-1, flotillin-2 and CD59 after the 
fusion of other endocytic vesicles with SPIOPSN-containing vesicles (305, 306). Furthermore, we 
assume that the uptake of nanoparticles is indirectly influenced by flotillin-1, since we did not observe 
a colocalization with ctxB. Altogether, this shows that endocytic proteins and pathways are not strictly 
separated from each other and could overlap in special cases.  
Tetraspanins 
Besides flotillin microdomains, tetraspanin-enriched microdomains (TEM) were investigated to study 
their impact on the uptake of SPIOPSN (Figure 20). In previous works, tetraspanins have been 
considered as proteins that laterally organize cellular membranes via their interactions with integrins 
(307). These TEMs consist of the tetraspanins CD9, CD81, CD82 and CD63 which partially interact 
with each other on the plasma membrane of HeLa cells (307). It has been shown that 
TEMs/tetraspanins are important receptors for the infection process of HIV-1 and HCV (307, 308). 
Spoden and colleagues showed that the downregulation or inhibition of several tetraspanins lead to a 
diminished infection rate of HPV16 (308). We also observed an association of tetraspanins with 
SPIOPSN-containing vesicles by mass spectrometry (Supplementary Table S2). Therefore, we 




this in more detail, we suppressed CD9, CD81, CD82 and CD63 by a siRNA-mediated approach 
(Figure 20). We observed no influence on SPIOPSN uptake after the knockdown of CD9, CD82 and 
CD63 but detected a suppressed rate of uptake after CD81 knockdown. Interestingly, CD81 was 
previously identified as a binding partner for the small macropinocytic GTPase Rac (309). Tejera et al. 
showed that the knockdown of CD81 resulted in significant alterations of focal adhesion and Rac 
activation (309). In dendritic cells, CD81 influences the formation of lamellipodia indicating an 
impact on the actin cytoskeleton (310). All of these data highlight a potential association of CD81 with 
the macropinocytic uptake of SPIOPSN and lays the foundation for further investigations to study the 
effects of tetraspanins on nanoparticle entry.  
The inhibition of ARF1 results in a decreased uptake of nanoparticles 
Previously, Kumari et al. demonstrated that ARF1 is directly associated with the internalization of 
ctxB and dextran (90). Consequently, they defined ARF1 as a player of the CLIC/GEEC pathway (90). 
A second study of Hasegawa and colleagues showed that a mutation of ARF1 causes a significant 
decrease of internalized dextran during a PDGF-triggered macropinocytosis in NIH3T3 cells (220). 
The overexpression of dominant negative ARF1 T31N was shown to induce an incomplete closure of 
the circular dorsal ruffles mediated by actin (220). The authors resumed that the macropinocytic 
uptake mechanism is blocked by ARF1 (220). Taken together, both groups reported different functions 
of ARF1 in two distinct pathways.  
In this study, we identified four signs indicating a pivotal role of ARF1 in the entry mechanism of 
SPIOPSN (Figure 22). The first evidence was supplied by the detection of ARF1 in the vesicular 
fraction of the magnetically purified pellet (Supplementary Table S3). Secondy, we observed a direct 
interaction between nanoparticles and ARF1 T31N by confocal microscopy (Figure 22). We have 
demonstrated that the overexpression of ARF1 T31N resulted in a massive decrease of internalized 
SPIOPSN highlighting the significant effect of ARF1 on nanoparticle endocytosis (Figure 22). We 
further found that pharmacological inhibiton of ARF1 suppressed the uptake of SPIOPSN (Figure 22). 
Therefore, we concluded that ARF1 is directly involved in a macropinocytic-like uptake of 
nanoparticles. By following the definition of Kumari et al., one could describe this entry mechanism 
as a dynamin-independent CLIC/GEEC pathway (90). However, since we have identified dynamin as 
an important factor during SPIOPSN entry (Figure 16), we considered this uptake mechanism as a 
macropinocytic-like one. This was also supported by cryo-TEM images, where we did not identify any 
tubular endosomal structures that are characteristic for CLIC/GEEC endocytosis (Figure 12). Anyway, 
the classical structures of the CLIC/GEEC pathway have a diameter of about 40 nm, which are to 






Crosstalk between distinct endocytic pathways 
It seems that several endocytic mechanisms have significant functional and morphological overlaps 
hampering the classification of a single pathway. For instance, the CLIC/GEEC pathway is seen as a 
clathrin-independent pathway (96). However, a crosstalk between both pathways has been observed 
(85). Disturbance of the CLIC/GEEC pathway triggers a compensation of GPI-linked protein uptake 
by clathrin-mediated endocytosis (128). Another example of a crosstalk was published by Naslavsky 
et al. (311). The authors showed that the GPI-linked protein CD59 and MHCI are internalized by a 
non-CLIC-GEEC pathway. This pathway is clathrin-and dynamin independent and utilizes ARF6-
positive endosomes (311). As previously mentioned, also the flotillin-mediated pathway and the 
CLIC/GEEC pathway was reported to mediate the internalization of CD59 (88). The CLIC/GEEC 
pathway also resembles macropinocytic-like pathways as shown for adeno-associated virus 2 (AAV2) 
(95). Internalization of AAV2 depends on factors such as cdc42, ARF1, GRAF1 and EIPA but is 
insensitive to Rac1 or other macropinocytic inhibitors (95). The resume of the authors was that AAV2 
is internalized via a pleiomorphic CLIC/GEEC pathway. Taking all of this into account, it is 
challenging to identify model cargoes that can be specifically assigned to a single pathway. This 
shows the close relationship between several entry mechanisms massively depending on cell type and 
investigated cargo.  
4.3 Intracellular trafficking of nanoparticles 
So far we discussed the mechanisms how cells internalize superparamagnetic iron oxide polystyrene 
nanoparticles. We have demonstrated that the entry of SPIOPSN is mediated by an atypical type of 
macropinocytosis mainly depending on cholesterol, kinases and typical small GTPases of several 
closely related endocytic mechanisms. To understand the intracellular trafficking of nanoparticles after 
macropinocytic uptake, we investigated the intracellular trafficking routes of these SPIOPSN (Figure 
24-37). This question becomes especially exciting since several endocytic membrane proteins are also 
located inside the endolysosomal system (307). The reason for this originates in the functionality of 
the endolysosomal system. Notably, it is responsible for the renewal and recycling of plasma 
membrane proteins and membrane lipids by internalizing them (312).  
As a result, the investigation of intracellular trafficking is a challenging field due to the high turnover 
rates of the participating proteins (312). Vesicles that bud off from the membrane are consequently 
able to fuse with other endocytic vesicles afterwards forming a complete novel vesicle with a distinct 
protein composition (181). Further on, it is well accepted that e. g. the maturation of early endosomes 
to late endosomes is accompanied by a rapid exchange of important markers (e. g. Rab proteins). This 
impedes the detection of high rates of colocalization with nanoparticles especially under the 




Early endocytic markers  
Since we have proposed an uptake of SPIOPSN via macropinosome-like vesicles, we first checked for 
the early endocytic marker Rab5 (Figure 24) (142). For epithelial cells and fibroblasts it has been 
demonstrated that Rab5 and its effector Rabankyrin-5 are important proteins with a cooperative 
function for the biogenesis of macropinosomes and the endocytic system (142, 230). The authors 
showed that knockdown of Rab5 and Rabankyrin-5 decreases fluid phase uptake in NIH 3T3 cells. 
They found that Rab5 and Rabankyrin-5 colocalize with fluid phase-filled macropinosomes that are 
negative for EEA1 and transferrin (142). In our study, we also observed nanoparticles in fluid phase 
filled macropinosomes (Figure 25). In spite of extensive studies, no significant association of 
SPIOPSN with the classical early endosomal marker EEA1 was observed by confocal imaging (data 
not shown) and by the proteomic analysis of SPIOPSN-containing vesicles. Though, we detected 
SPIOPSN in Rab5
+
 vesicles that were detectable by DIC microscopy (Figure 24). Surprisingly, the 
knockdown of Rab5A (Figure 24) and Rabankyrin-5 (data not shown) did not significantly suppress 
the uptake of SPIOPSN as contrarily demonstrated by other studies (142). From this, one can infer that 
other factors might drive the internalization of nanoparticles in HeLa cells. This might also be in 
accordance with the low rate of colocalization between nanoparticles and Rab5, in spite of the 
significant detection of Rab5A and Rab5C by mass spectrometry. The low number of colocalization of 
Rab5 with nanoparticles was also observed by previous studies, where the authors analyzed the 
colocalization of nanoparticles in the early stages of uptake (151).  
Contrary to the low rate of colocalization of Rab5A with SPIOPSN, we found a higher number of 
SPIOPSN inside RhoB
+
 vesicles. We detected SPIOPSN inside RhoB
+
 vesicles that actively moved 
through the cell (Figure 25). These vesicles were visible by DIC microscopy and resembled fluid 
phase-filled macropinosomes. Besides the vesicular localization of RhoB-GFP, the protein also 
localized to the plasma membrane implying that RhoB plays a role in the early stages of endocytosis 
(313). Indeed, RhoB was detected by mass spectrometry as a protein of the membrane fraction 
(Supplementary Table S4). From literature it is known that RhoB is a small GTPase acting in the 
actin-mediated transport of endocytic vesicles (314). Studies using confocal microscopy detected 
RhoB mainly in early endosomes (315). In this context, RhoB was further shown to influence the entry 
of virions (223). Overexpression of RhoB significantly increased the endogenous levels of ebola virus 
glycoprotein and VSVG pseudotyped vector transduction. No effect was observed for GP pseudotyped 
HIV or adeno-associated virus 2 vector implying a specific role for RhoB during the uptake of viruses 
(223). However, we concluded that SPIOPSN were internalized by RhoB
+







Late markers of endocytosis 
During the life span of an endosome, several fusion and maturation events change the proteomic 
composition of the vesicle (153). It is well accepted that early endosome to late endosome maturation 
can be measured by the steady conversion of Rab5 to Rab7 on the surface of endosomes (153). In our 
experiments, a colocalization of Rab7
+
 vesicles with SPIOPSN has been recorded (Figure 26; 
Supplementary Table S2). These late endosomes contained intraluminal vesicles and are probably 
linked to anterograde and retrograde TGN-transport mechanisms (Figure 28, Figure 29 and Figure 30) 
(154). TGN-to-LE transport delivers lysosomal hydrolases and membranes to the inside of late 
endosomes providing proteins for the hydrolytic milieu of the lysosome (156). Lysosome-associated 
membrane proteins are directly transported by two major pathways. The most prominent pathway is 
orchestrated by the mannose-6-phosphate-receptor (316). Both types of the M6PR, MPRD and MRPI, 
were associated with SPIOPSN-containing vesicles (Supplementary Table S2). A so far unknown 
pathway is M6PR-independent and is mediated by VAMP7 and hVps41 (154). The authors suggest a 
role for VAMP7 in the transport of lysosome-associated membrane protein carriers showing that 
VAMP7 is directly involved in cargo transport from TGN-to-LE (154). VAMP7 is also well 
characterized as an R-SNARE mediating the fusion of late endosomes to lysosomes (192). Notably, 
we detected the R-SNARE VAMP7 on SPIOPSN-containing vesicles in colocalization experiments 
and by mass spectrometry (Figure 27; Supplementary Table S2). We proposed that those vesicles, 
which are SPIOPSN/VAMP7
+
, were recorded during a heterotypic fusion event between late 
endosomes and lysosomes. This assumption was based on the observation that several SPIOPSN 
accumulated inside these organelles. We resumed that such a large number of SPIOPSN was so far 
only observed in lysosomal organelles.  
Another prominent protein on late endosomes is the small GTPase Rab9, which also colocalized with 
SPIOPSN (Figure 26, Supplementary Table S2) (317). The important role of Rab9 on endosomes 
becomes apparent after Rab9 downregulation. The knockdown of Rab9 results in a size increase of 
late endosomes (318). Furthermore, it was demonstrated that Rab9 stimulates the backtransport of 
M6PR from late endosomes to the TGN in a cell free system (317). This is in compliance with a study 
that microscopically demonstrated the fusion of Rab9
+
 late endosomes with the TGN (225). The 
authors assume that the endocytic system uses a vesicle intermediate to communicate between the 
endocytic system and the TGN-network, thereby implying the strong interaction between both systems 
(225).  
Pmel17 and tetraspanins in the trafficking pathways of SPIOPSN  
We know from previous studies that the endocytic uptake of viruses and nanoparticles can depend on 
tetraspanin-enriched microdomains (217, 307). Tetraspanins can act as receptors for HPV16 entry or 




multivesicular bodies (174, 217). In this particular case, the well-studied tetraspanin CD63 facilitates 
the transport of the melanosomal protein Pmel17 into the ILVs of multivesicular bodies in an 
ubiquitin-independent manner (174, 226, 227). To study the association of ubiquitin, CD63 and 
Pmel17 with SPIOPSN-containing vesicles, their colocalization was studied (Figure 28). Interestingly, 
SPIOPSN-containing vesicles lacked the colocalization with ubiquitin (data not shown). Instead, we 
detected a colocalization of CD63 with SPIOPSN (Figure 28). Therefore, we asked the question, 
whether Pmel17 colocalizes with SPIOPSN-containing vesicles. And indeed, we observed a high rate 
of colocalization of the ILV marker Pmel17 with SPIOPSN inside HeLa cells (Figure 28). This is in 
accordance with our TEM pictures displaying the close proximity of SPIOPSN to ILVs (Figure 29 and 
Figure 30). Taking the colocalization of SPIOPSN with CD63 and Pmel17 and the non-colocalization 
with ubiquitin into account, it is important to raise questions about different MVB subtypes (319). For 
early endosomes, the existence of subpopulations has already been shown (161). However, if this is 
also true for multivesicular body has to be investigated in the future.  
Multilamellar lysosomes are the terminal organelle for SPIOPSN 
The disassembly of nanomaterials is a major prerequisite for the release of encapsulated effector 
molecules in drug delivery applications (2). Therefore, it is of great interest to identify the terminal 
subcellular localization of a nanoparticle to gain knowledge about the endolysosomal enzymes that 
could potentially degrade nanomaterials (Figure 36). In pulse experiments with SPIOPSN using 
transmission electron microscopy, we found almost all SPIOPSN after 20 h inside multilamellar 
lysosomes (data not shown). These vesicles contained several multilamellar membranes whorls 
(Figure 29 and Figure 30) (182). In the past, several groups proposed that multilamellar bodies evolve 
from the fusion with autophagosomes (182). Indeed, it is well known that lysosomes fuse with LC3
+
 
autophagosomes (320). However, LC3-II is degraded after autolysosomal fusion challenging the 
detection of a direct interaction between lysosome and autophagosome by LC3-II (321). In our 
experiments, immunostainings for LC3-II revealed no colocalization with SPIOPSN signals indicating 
that nanoparticles are not transported via the autophagosomal pathway (Figure 32). However, we 
found a large number of mitochondrial proteins inside the magnetically enriched fraction 
(Supplementary Table S5). Further on, TEM images showed multilamellar membrane whorls inside 
multilamellar lysosomes. Altogether, this implies that SPIOPSN are stored inside lysosomes, which 
fused with autophagosomes.  
4.3.1 Relevance of SPIOPSN trafficking in vivo – Studying nanoparticulate 
biodistribution 
Especially, metal containing particles such as SPIOs or gold nanoparticles raise concerns about 
biodistribution and toxicity while they can be rapidly cleared from the blood stream entering organs 




depends on their surface modification and size (324, 325). In vitro, we tested our SPIOPSN for 
aggregation in blood and found less morphologically visible aggregation in blood serum. Therefore, 
we considered this system as stable and injected SPIOPSN into NSG mice (Figure 33). NSG mice are 
immunodeficient and lack functional immune cells such as dendritic cells or macrophages. Therefore, 
it is a proper system to study the biodistribution of nanoparticles independently from the immune 
system. After injection, we magnetically isolated the nanoparticle-containing cells from complete 
tissues. We observed an endolysosomal like disposition of SPIOPSN after 24 h mainly in spleen and 
liver cells, while the peripheral blood, kidney and bladder lacked nanoparticles. This is in partial 
compliance with other studies, mainly detecting nanoparticles in liver and kidney (324). With this 
experiment, we could show the endolysosomal SPIOPSN uptake in vivo. Moreover, SPIOPSN were 
proven to be sufficient for the magnetic isolation of cells. This magnetic potential of SPIOPSN was 
subsequently used to study the intracellular trafficking of nanoparticles in more detail (Figure 34).  
4.3.2 Reconstruction of intracellular nanoparticle trafficking displays a detailed 
picture of the proteomic environment of SPIOPSN 
So far we have discussed how nanoparticles traffic along the endocytic route. To understand these 
trafficking pathways in more detail, one has to identify novel factors that are associated with the 
transport of nanoparticles (Figure 35 and Figure 36). Hitherto, these studies of intracellular 
nanoparticle trafficking were always based on the manipulation of the cellular systems (132, 151). 
This could result in drastical changes of the intracellular trafficking machinery. Overexpression or 
knockdown of membrane proteins may significantly alter the trafficking behavior of cells (153, 318). 
Moreover, the recent methods are biased by other cargoes such as viruses and can only analyze a low 
number of proteins at the same time. During this study, we achieved to circumvent such pitfalls by 
generating an unbiased snapshot of intracellular nanoparticle trafficking using mass spectrometry 
(Figure 35). Another advantage of this untampered approach is the option to characterize the 
lysosomal matrix milieu of enzymes (Figure 36). This could provide information for the prospective 
design of nanocarriers achieving a more specific endolysosomal degradation for an efficient release of 
the effector molecules.  
Identification of proteins heavily depends on the method of subcellular fractionation 
Normally, the purification of subcellular compartments is based on the size and the density of the 
organelle (156). This results in a biased analysis of the isolated vesicles, since only physical 
parameters are considered. Most of the researchers use differential centrifugation in a sucrose or 
percoll gradient for these kind of purifications (156, 326, 327). Sometimes, the distribution of distinct 
organelles (e.g. lysosomes and mitochondria) significantly overlap in hyperosmolar sucrose preventing 
an appropriate separation of distinct compartments (156). Using our protocol for the magnetic 




This approach excludes the isolation of endosomes that are not participating in the trafficking of 
magnetic nanoparticles.  
Another great pitfall of all subcellular fractionation methods are unavoidable impurities inside the 
sample. Especially, in case of sensitive MS methods a large number of unwanted proteins are 
detectable (156). In conclusion: The more sensitive the method, the more challenging the subcellular 
fractionation. The proteomic analysis of the endolysosomal system is even more complicated since the 
cell uses the endocytic pathway for the degradation of non-endolysosomal constituents (328). 
Especially, the fusion of autophagosomes with lysosomes may insert impurities of defect organelles 
such as mitochondria or other damaged vesicles (328). To reliably distinguish between positive and 
false positive results, one has to focus on the enrichment of proteins in the purified fraction in 
comparison to the remaining fraction (Table 18). However, potentially positive proteins still can be 
screened by low copy numbers or degradative processes. Here the major drawbacks include the 
detection of low copy number proteins as well as small proteins (e. g. subunits), hydrophobic insoluble 
transmembrane proteins, proteins with posttranslational modifications and loosely attached proteins 
(156). Further on, endogenous fusion events e. g. between different endocytic proteins impedes the 
clear interpretation and the identification of direct effector proteins in the trafficking of SPIOPSN 
(156). Altogether, these factors hamper the interpretation of the data. Nevertheless, the analysis of 
vesicular proteins by MS is a valuable tool to screen for new proteins. However, the relevance of these 
data has to be confirmed by other methods. 
Reconstruction of intracellular trafficking identifies novel promising candidates for prospective 
studies  
The dissection of intracellular nanoparticle trafficking identified a large number of novel proteins that 
have never been associated with nanoparticles before (Figure 35). These include major markers of 
different endocytic compartments such as early endocytic compartmens, multivesicular bodies, 
lysosomes, COP vesicles and lysosomes (Figure 35). Interesting candidates for future applications are 
primarily represented by proteins of the tetraspanin family. The targeting of tetraspanin-enriched 
microdomains could be a novel approach for targeted delivery applications towards the endosomal 
system since these domains are easily accessible to extracellular particles (307).  
However, the identification of several nanoparticle associated proteins gives also room for 
speculations. Especially, the identification of COP proteins raises questions, whether COP vesicles 
directly interact with the endolysosomal vesicles of a nanoparticle. In this context, it is important to 
mention that our mass spectrometry data is in compliance with the study of Aniento et al., where the 
authors identified epsilon COP and beta COP on endosomal membranes (329). Whether this originates 
from a fusion event of endosomes with COP vesicles needs to be elucidated with other methods, 




problem when using standardized methods such as confocal microscopy. This was also shown by 
Sandin et al. (151). Despite of using spinning disc confocal microscopy, only a low number of 
colocalization events were detectable between nanoparticles and the early endosomal marker Rab1A, 
while no colocalization was observed with the COPI coat complex (151). The limitations often 
originate from the high dynamics of intracellular trafficking. Also low expression levels of the target 
protein or limitations in the detection by confocal microscopy might play a major role. During this 
study, we observed that especially the microscopic imaging of magnetic nanoparticles bears 
limitations. The detection of nanoparticles by PMTs rapidly gives rise to false positive signals on a 
very low signaling intensity owing to the high light scattering properties of the nanomaterial. This 
restricts the sensitive detection of markers by immunofluorescence or overexpression of GFP fusion 
proteins to a minimum. Therefore, our mass spectrometry approach is the more sensitive one, but data 
interpretation needs to be carefully performed.  
Identification of lysosomal matrix proteins and their possible effects on the nanoparticulate protein 
corona 
In the future, it will be necessary to study the degradation of internalized nanomaterial in more detail. 
Already a large number of studies consider nanomaterials as biodegradable structures but only less 
provide information about the long-term stability inside the vesicular environment. Even potentially 
biodegradable nanoparticles remain for a long time inside the endolysosomal system without getting 
significantly degraded (Lieberwirth, unpublished data) (33). After the deposition of nanoparticles 
inside lysosomal compartments, the protein corona and the nanomaterial underlies a harsh vesicular 
milieu of several hydrolases, proteases and other degradative enzymes. It has recently been reported 
that parts of the nanoparticulate protein corona are cointernalized with the nanoparticle (330). 
Regularly, ubiquitinylated proteins that are marked for degradation are transported to the lysosome. 
Therefore, it is possible that proteins on the surface of nanoparticles are marked with ubiquitin 
considering them for the degradative lysosomal pathway. Since we have not found ubiquitin in 
nanoparticle containing vesicles at all, we proposed that the transport of nanoparticles to lysosomes is 
a passively directed process. Anyway, the lysosomal milieu seems to degrade the nanoparticulate 
protein corona very efficiently shown in an example using a fluorescently labeled albumin (Figure 39).  
Especially, for albumin it is known that it is degraded into the lysosome of cells (331). A major 
candidate for the degradation of albumin is cathepsin D and cathepsin B (332). Since we observed a 
colocalization of cathepsin D with nanoparticles (Figure 31) and identified cathepsin D/B by mass 
spectrometry, it was proposed that the protein corona of nanoparticles is degraded inside SPIOPSN 
containing lysosomes after a short time. This data is in compliance with the data of Wang et al., where 
protein corona degradation experiments were performed with fluorescently labeled serum showing a 
degradation of the protein corona inside lysosomal structures (330). Taking this into account, one has 




the surface modification and material properties of nanomaterials. We have to keep in mind that this 
might have a crucial impact on the intracellular drug delivery abilities of nanoparticles.  
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5 Summary and conclusions 
This work investigated the drug delivery abilities, the entry mechanisms and the intracellular 
trafficking pathways of different polymeric nanoparticles. We learned that the different types of 
interaction between nanoparticles and cells mainly depend on the used materials. To exploit intelligent 
drug delivery mechanisms, nanoparticulate systems need to be improved and their interaction with 
biological components need to be understood. 
In the first part of the study, we wanted to know whether we can transport an encapsulated 
hydrophobic molecule over a membrane barrier. This is particularly important in drug delivery 
approaches for hardly accessible cells such as B or T lymphocytes. To approach this question, we 
studied nanoparticle-membrane interaction and a subsequent cargo release of the hydrophobic dye 
PMI on the membrane of HeLa cells, hMSCs and Jurkat cells. We observed a rapid staining of 
intracellular lipid droplets and reproduced this delivery mechanism in all three cell lines. We found 
that the transport of the membrane to the interior of the cell mainly depends on the nanoparticulate 
carrier but not on free dye molecules. Finally, we hypothesize that PMI release is largely triggered by 
a temporary nanoparticle-membrane contact. Hydrophobic surfaces of giant vesicles and of plasma 
membranes can trigger nanoparticle cargo release in a typical “kiss-and-run” dependent manner.  
Next, we showed that the uptake of the well-characterized polymeric nanoparticle SPIOPSN is 
mediated by a macropinocytic-like mechanism. The treatment of cells with typical macropinocytic 
inhibitors significantly decreased the uptake of SPIOPSN into cells. However, inhibition of classical 
macropinocytic kinases such as PKC and PLC did not affect the entry of SPIOPSN. Also the 
stimulation of classical macropinocytosis by PMA and EGF decreased the uptake of SPIOPSN. We 
further investigated several proteins such as ARF1, Rac1 and cdc42 and showed their important role 
during the uptake of nanoparticles. Also the knockdown of flotillin-1 as well as the suppression of the 
tetraspanin CD81 decreased the levels of endogenous nanoparticles. Altogether, this implies an 
atypical type of macropinocytic uptake the investigated nanoparticles utilized.  
Finally, we analyzed the intracellular trafficking pathways of a nanoparticle after a macropinocytic-
like entry in HeLa cells. By the proteomic dissection, the intracellular nanoparticle trafficking (INT) 
was reconstructed based on a simple endocytic model. The analysis of SPIOPSN-containing vesicles 
resulted in the detection of proteins that have never been linked to INT before. To confirm the data of 
mass spectrometry, we analyzed several identified key players of intracellular trafficking by confocal 
live cell imaging. By this approach, SPIOPSN were found to be actively transported via 
macropinosomes, late endosomes and lysosomes. We were able to reproduce the colocalization of 
nanoparticles with lysosomal proteins in hMSCs. Strikingly, we identified several lysosomal matrix 
proteins in the enriched magnetic fraction of the nanoparticle-containing vesicles. It was assumed that 
the properties of the lysosomal compartment mediate the degradation of the nanoparticulate protein 
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corona. The degradation of protein corona may give access to the bare surface and the polymeric 
matrix of nanoparticles opening the way for the degradation of the nanomaterial. 
In conclusion, we present a detailed picture of a so far unknown drug delivery mechanism that 
depends on temporary nanoparticle-membrane interactions. This could remarkably shift the paradigm 
of drug delivery mechanisms in the field of nano-bio-interactions. Furthermore, we provide evidence 
that polymeric nanoparticles are mainly internalized via an unspecific atypical macropinocytosis 
mechanism followed by a subsequent transport of nanoparticles to multilamellar lysosomes. This may 
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8 Supplementary data 
This chapter provides additional data of the lable free quantitative mass spectrometry analysis. The full 
data set is further on available on www.proteomexhange.org.  
Supplementary Table S1: Complete DAVID ontology analysis of proteins. Proteins were enriched > 2-fold in the 
magnetic fraction compared to the non-magnetic fraction.  
18 Cluster(s)  Count 
Annotation Cluster 1 Enrichment Score: 42.07  
 GOTERM_CC_FAT envelope 145 
 GOTERM_CC_FAT organelle envelope 144 
 GOTERM_CC_FAT mitochondrial envelope  115 
 GOTERM_CC_FAT mitochondrial membrane 111 
 GOTERM_CC_FAT mitochondrial inner membrane 96 
 GOTERM_CC_FAT organelle inner membrane 99 
Annotation Cluster 2 Enrichment Score: 29.76  
 GOTERM_CC_FAT lysosome  69 
 GOTERM_CC_FAT lytic vacuole 69 
 GOTERM_CC_FAT vacuole 75 
Annotation Cluster 3 Enrichment Score: 16.73  
 GOTERM_CC_FAT vesicle 105 
 GOTERM_CC_FAT membrane-bounded vesicle 93 
 GOTERM_CC_FAT cytoplasmic membrane-bounded vesicle 91 
 GOTERM_CC_FAT cytoplasmic vesicle 100 
Annotation Cluster 4 Enrichment Score: 9.24  
 GOTERM_CC_FAT membrane fraction 99 
 GOTERM_CC_FAT insoluble fraction 101 
 GOTERM_CC_FAT cell fraction 120 
Annotation Cluster 5 Enrichment Score: 7.22  
 GOTERM_CC_FAT outer membrane 26 
 GOTERM_CC_FAT organelle outer membrane 24 
 GOTERM_CC_FAT mitochondrial outer membrane 22 
Annotation Cluster 6 Enrichment Score: 5.93  
 GOTERM_CC_FAT respiratory chain complex I 14 
 GOTERM_CC_FAT mitochondrial respiratory chain complex I 14 
 GOTERM_CC_FAT NADH dehydrogenase complex 14 
Annotation Cluster 7 Enrichment Score: 5.61  
 GOTERM_CC_FAT membrane-enclosed lumen 171 
 GOTERM_CC_FAT organelle lumen 163 
 GOTERM_CC_FAT intracellular organelle lumen 156 
Annotation Cluster 8 Enrichment Score: 3.33  
 GOTERM_CC_FAT actomyosin 9 
 GOTERM_CC_FAT stress fiber 8 
 GOTERM_CC_FAT actin filament bundle 8 
Annotation Cluster 9 Enrichment Score: 2.51  
 GOTERM_CC_FAT cell-substrate junction 17 
 GOTERM_CC_FAT cell-substrate adherens junction 16 




Annotation Cluster 10 Enrichment Score: 2.29  
 GOTERM_CC_FAT clathrin adaptor complex 8 
 GOTERM_CC_FAT AP-type membrane coat adaptor complex 8 
 GOTERM_CC_FAT clathrin coat 9 
 GOTERM_CC_FAT endocytic vesicle membrane 6 
Annotation Cluster 11 Enrichment Score: 2.15  
 GOTERM_CC_FAT AP-2 adaptor complex 4 
 GOTERM_CC_FAT clathrin coat of coated pit 5 
 GOTERM_CC_FAT clathrin-coated endocytic vesicle 5 
 GOTERM_CC_FAT clathrin coat of endocytic vesicle 4 
 GOTERM_CC_FAT clathrin-coated endocytic vesicle membrane 4 
 GOTERM_CC_FAT clathrin vesicle coat 4 
Annotation Cluster 12 Enrichment Score: 2.1  
 GOTERM_CC_FAT microbody part 9 
 GOTERM_CC_FAT peroxisomal part 9 
 GOTERM_CC_FAT microbody membrane 7 
 GOTERM_CC_FAT peroxisomal membrane 7 
Annotation Cluster 13 Enrichment Score: 2.09  
 GOTERM_CC_FAT protein-lipid complex 8 
 GOTERM_CC_FAT plasma lipoprotein particle 8 
 GOTERM_CC_FAT triglyceride-rich lipoprotein particle 6 
 GOTERM_CC_FAT very-low-density lipoprotein particle 6 
 GOTERM_CC_FAT high-density lipoprotein particle 6 
Annotation Cluster 14 Enrichment Score: 1.58  
 GOTERM_CC_FAT tricarboxylic acid cycle enzyme complex 4 
 GOTERM_CC_FAT dihydrolipoyl dehydrogenase complex 3 
 GOTERM_CC_FAT mitochondrial alpha-ketoglutarate 
dehydrogenase complex 
3 
 GOTERM_CC_FAT mitochondrial tricarboxylic acid cycle 
enzyme complex 
3 
Annotation Cluster 15 Enrichment Score: 1.38  
 GOTERM_CC_FAT COPI vesicle coat 4 
 GOTERM_CC_FAT COPI coated vesicle membrane 4 
 GOTERM_CC_FAT COPI-coated vesicle 4 
Annotation Cluster 16 Enrichment Score: 0.97  
 GOTERM_CC_FAT vesicle lumen 7 
 GOTERM_CC_FAT platelet alpha granule lumen 6 
 GOTERM_CC_FAT cytoplasmic membrane-bounded vesicle 
lumen 
6 
Annotation Cluster 17 Enrichment Score: 0.58  
 GOTERM_CC_FAT contractile fiber part 11 
 GOTERM_CC_FAT contractile fiber 11 
 GOTERM_CC_FAT myofibril 9 
Annotation Cluster 18 Enrichment Score: 0.44  
 GOTERM_CC_FAT spectrin 3 
 GOTERM_CC_FAT cortical actin cytoskeleton 3 





Supplementary Table S2: Reconstruction of SPIOPSN trafficking is based on the GOTERM: Lysosome.  
Uniprot_ID Full protein name 
AGAL_HUMAN galactosidase, alpha 
ANAG_HUMAN N-acetylglucosaminidase, alpha- 
AP3M1_HUMAN adaptor-related protein complex 3, mu 1 subunit 
ARL8A_HUMAN ADP-ribosylation factor-like 8A  
ARL8B_HUMAN ADP-ribosylation factor-like 8B  
ARSA_HUMAN arylsulfatase A 
ARSB_HUMAN arylsulfatase B 
ASAH1_HUMAN N-acylsphingosine amidohydrolase (acid ceramidase) 1 
ASM_HUMAN sphingomyelin phosphodiesterase 1, acid lysosomal 
BGAL_HUMAN galactosidase, beta 1 
BGLR_HUMAN glucuronidase, beta 
CATA_HUMAN catalase 
CATB_HUMAN cathepsin B 
CATC_HUMAN cathepsin C 
CATD_HUMAN cathepsin D 
CATL1_HUMAN cathepsin L1 
CATZ_HUMAN cathepsin Z 
CD63_HUMAN CD63 molecule 
CLCN7_HUMAN chloride channel 7 
CLN3_HUMAN ceroid-lipofuscinosis, neuronal 3 
CLN5_HUMAN ceroid-lipofuscinosis, neuronal 5 
DNS2A_HUMAN deoxyribonuclease II, lysosomal 
DPP2_HUMAN dipeptidyl-peptidase 7 
EPDR1_HUMAN ependymin related protein 1 (zebrafish) 
GALNS_HUMAN galactosamine (N-acetyl)-6-sulfate sulfatase 
GGH_HUMAN gamma-glutamyl hydrolase (conjugase, folylpolygammaglutamyl hydrolase) 
GILT_HUMAN interferon, gamma-inducible protein 30 
GLCM_HUMAN glucosidase, beta; acid (includes glucosylceramidase) 
GNS_HUMAN glucosamine (N-acetyl)-6-sulfatase 
HEXA_HUMAN hexosaminidase A (alpha polypeptide) 
HEXB_HUMAN hexosaminidase B (beta polypeptide) 
LAMP1_HUMAN lysosomal-associated membrane protein 1 
LAMP2_HUMAN lysosomal-associated membrane protein 2 
LGMN_HUMAN legumain 
LICH_HUMAN lipase A, lysosomal acid, cholesterol esterase 
LYAG_HUMAN glucosidase, alpha; acid 
MA2B1_HUMAN mannosidase, alpha, class 2B, member 1 
MANBA_HUMAN mannosidase, beta A, lysosomal 
MCLN1_HUMAN mucolipin 1 
MPRD_HUMAN mannose-6-phosphate receptor (cation dependent) 
MPRI_HUMAN insulin-like growth factor 2 receptor 
NAGAB_HUMAN N-acetylgalactosaminidase, alpha- 




NEUR1_HUMAN sialidase 1 (lysosomal sialidase) 
NICA_HUMAN nicastrin 
NPC1_HUMAN Niemann-Pick disease, type C1 
NPC2_HUMAN Niemann-Pick disease, type C2 
PAG15_HUMAN phospholipase A2, group XV 
PCP_HUMAN prolylcarboxypeptidase (angiotensinase C) 
PCYOX_HUMAN prenylcysteine oxidase 1 
PPAL_HUMAN acid phosphatase 2, lysosomal 
PPGB_HUMAN cathepsin A 
PPT1_HUMAN palmitoyl-protein thioesterase 1 
PPT2_HUMAN palmitoyl-protein thioesterase 2 
RAB14_HUMAN RAB14, member RAS oncogene family 
RAB7A_HUMAN RAB7A, member RAS oncogene family 
RAB9A_HUMAN RAB9A, member RAS oncogene family 
RB27A_HUMAN RAB27A, member RAS oncogene family 
S15A4_HUMAN solute carrier family 15, member 4 
SAP_HUMAN prosaposin 
SAP3_HUMAN GM2 ganglioside activator 
SCRB2_HUMAN scavenger receptor class B, member 2 
SPHM_HUMAN N-sulfoglucosamine sulfohydrolase 
STX7_HUMAN syntaxin 7 
STXB2_HUMAN syntaxin binding protein 2 
TM192_HUMAN transmembrane protein 192 
TPP1_HUMAN tripeptidyl peptidase I 
VAMP7_HUMAN vesicle-associated membrane protein 7 
VATG1_HUMAN ATPase, H+ transporting, lysosomal 13kDa, V1 subunit G1 
 
Supplementary Table S3: Reconstruction of SPIOPSN trafficking is based on the GOTERM: Vesicle.*Not considered 
in GOTERM analysis; manually inserted.  
Uniprot ID Full protein name 
A4_HUMAN amyloid beta (A4) precursor protein 
AAAT_HUMAN solute carrier family 1 (neutral amino acid transporter), member 5 
ADA10_HUMAN ADAM metallopeptidase domain 10 
AMPN_HUMAN alanyl (membrane) aminopeptidase 
AP1B1_HUMAN adaptor-related protein complex 1, beta 1 subunit 
AP2A1_HUMAN adaptor-related protein complex 2, alpha 1 subunit 
AP2A2_HUMAN adaptor-related protein complex 2, alpha 2 subunit 
AP2B1_HUMAN adaptor-related protein complex 2, beta 1 subunit 
AP2M1_HUMAN adaptor-related protein complex 2, mu 1 subunit 
AP2S1_HUMAN adaptor-related protein complex 2, sigma 1 subunit 
APOA1_HUMAN apolipoprotein A-I 
ARSA_HUMAN arylsulfatase A 
ASM_HUMAN sphingomyelin phosphodiesterase 1, acid lysosomal 
AT1A1_HUMAN ATPase, Na+/K+ transporting, alpha 1 polypeptide 




BASI_HUMAN basigin (Ok blood group) 
CATB_HUMAN cathepsin B 
CATD_HUMAN cathepsin D 
CAV1_HUMAN caveolin 1, caveolae protein, 22kDa 
CAV2_HUMAN caveolin 2 
CD9_HUMAN CD9 molecule 
CH60_HUMAN heat shock 60kDa protein 1 (chaperonin) pseudogene 5 
CLIC4_HUMAN chloride intracellular channel 4 
CLN3_HUMAN ceroid-lipofuscinosis, neuronal 3 
CLUS_HUMAN clusterin 
COPB_HUMAN coatomer protein complex, subunit beta 1 
COPB2_HUMAN coatomer protein complex, subunit beta 2 (beta prime) 
COPE_HUMAN coatomer protein complex, subunit epsilon 
COPZ1_HUMAN coatomer protein complex, subunit zeta 1 
DAB2_HUMAN disabled homolog 2, mitogen-responsive phosphoprotein (Drosophila) 
DLDH_HUMAN dihydrolipoamide dehydrogenase 
DNJC5_HUMAN DnaJ (Hsp40) homolog, subfamily C, member 5 
DP13A_HUMAN adaptor protein, phosphotyrosine interaction, PH domain and leucine zipper containing 1 
DPP2_HUMAN dipeptidyl-peptidase 7 
ECE1_HUMAN endothelin converting enzyme 1 
EGFR_HUMAN epidermal growth factor receptor 
EHD1_HUMAN EH-domain containing 1 
FIBA_HUMAN fibrinogen alpha chain 
FIBB_HUMAN fibrinogen beta chain 
FIBG_HUMAN fibrinogen gamma chain 
FLOT1_HUMAN flotillin 1 
GANAB_HUMAN glucosidase, alpha; neutral AB 
GGH_HUMAN gamma-glutamyl hydrolase (conjugase, folylpolygammaglutamyl hydrolase) 
GIPC1_HUMAN GIPC PDZ domain containing family, member 1 
GNAI3_HUMAN guanine nucleotide binding protein (G protein), alpha inhibiting activity polypeptide 3 
GNAS2_HUMAN GNAS complex locus 
GPNMB_HUMAN glycoprotein (transmembrane) nmb 
GTR1_HUMAN solute carrier family 2 (facilitated glucose transporter), member 1 
HEXB_HUMAN hexosaminidase B (beta polypeptide) 
ITA1_HUMAN integrin, alpha 1 
ITB1_HUMAN integrin, beta 1 (fibronectin receptor, beta polypeptide) 
LAMP1_HUMAN lysosomal-associated membrane protein 1 
LAMP2_HUMAN lysosomal-associated membrane protein 2 
MPRI_HUMAN insulin-like growth factor 2 receptor 
MYH11_HUMAN myosin, heavy chain 11, smooth muscle 
MYOF_HUMAN myoferlin 
NEUR1_HUMAN sialidase 1 (lysosomal sialidase) 
NICA_HUMAN nicastrin 
P4K2A_HUMAN phosphatidylinositol 4-kinase type 2 alpha 




PICAL_HUMAN phosphatidylinositol binding clathrin assembly protein 
PLD1_HUMAN phospholipase D1, phosphatidylcholine-specific 
PPT1_HUMAN palmitoyl-protein thioesterase 1 
PTN1_HUMAN protein tyrosine phosphatase, non-receptor type 1 
RAB14_HUMAN RAB14, member RAS oncogene family 
RAB21_HUMAN RAB21, member RAS oncogene family 
RAB2A_HUMAN RAB2A, member RAS oncogene family 
RAB35_HUMAN similar to hCG1778032; RAB35, member RAS oncogene family 
RAB3A_HUMAN RAB3A, member RAS oncogene family 
RAB3D_HUMAN RAB3D, member RAS oncogene family 
RAB5A_HUMAN RAB5A, member RAS oncogene family 
RAB5C_HUMAN RAB5C, member RAS oncogene family 
RAB6B_HUMAN RAB6B, member RAS oncogene family 
RAB7A_HUMAN RAB7A, member RAS oncogene family 
RAI3_HUMAN G protein-coupled receptor, family C, group 5, member A 
RB11A_HUMAN RAB11A, member RAS oncogene family 
RB11B_HUMAN RAB11B, member RAS oncogene family 
RB27A_HUMAN RAB27A, member RAS oncogene family 
RPN1_HUMAN ribophorin I 
SATT_HUMAN solute carrier family 1 (glutamate/neutral amino acid transporter), member 4 
SC23A_HUMAN Sec23 homolog A (S. cerevisiae) 
SCFD1_HUMAN sec1 family domain containing 1 
SDCB1_HUMAN syndecan binding protein (syntenin) 
SH3B4_HUMAN SH3-domain binding protein 4 
SNTB2_HUMAN syntrophin, beta 2 (dystrophin-associated protein A1, 59kDa, basic component 2) 
SPG21_HUMAN spastic paraplegia 21 (autosomal recessive, Mast syndrome) 
STOM_HUMAN phosphatidylethanolamine binding protein 1 
STOM_HUMAN stomatin 
STX12_HUMAN syntaxin 12 
STXB1_HUMAN syntaxin binding protein 1 
STXB2_HUMAN syntaxin binding protein 2 
STXB3_HUMAN syntaxin binding protein 3 
SYPL1_HUMAN synaptophysin-like 1 
TFR1_HUMAN transferrin receptor (p90, CD71) 
TMED2_HUMAN transmembrane emp24 domain trafficking protein 2 
TMEDA_HUMAN transmembrane emp24-like trafficking protein 10 (yeast) 
TPP1_HUMAN tripeptidyl peptidase I 
TSP1_HUMAN thrombospondin 1 
VA0D1_HUMAN ATPase, H+ transporting, lysosomal 38kDa, V0 subunit d1 
VAMP7_HUMAN vesicle-associated membrane protein 7 
VAPA_HUMAN VAMP (vesicle-associated membrane protein)-associated protein A, 33kDa 
VATB2_HUMAN ATPase, H+ transporting, lysosomal 56/58kDa, V1 subunit B2 
VATC1_HUMAN ATPase, H+ transporting, lysosomal 42kDa, V1 subunit C1 
VPP1_HUMAN ATPase, H+ transporting, lysosomal V0 subunit a1 





Manually inserted: Uniprot 
ID 
Full protein name 
1B55_HUMAN* HLA class I histocompatibility antigen, B-55 alpha chain 
1C06_HUMAN* HLA class I histocompatibility antigen, Cw-6 alpha chain 
ARF1_HUMAN* ADP-ribosylation factor 1 
ARF4_HUMAN* ADP-ribosylation factor 4 
COPG1_HUMAN* Coatomer subunit gamma-1 
LTOR1_HUMAN* Ragulator complex protein LAMTOR1 
LTOR2_HUMAN* Ragulator complex protein LAMTOR2 
LTOR3_HUMAN* Ragulator complex protein LAMTOR3 
RAB1A_HUMAN* Ras-related protein Rab-1A 
RAP1A_HUMAN* Ras-related protein Rap-1A 
RAP1B_HUMAN* Ras-related protein Rap-1b 
 
Supplementary Table S4: GOTERM: Membrane fraction.  
Uniprot ID Full protein name 
1A68_HUMAN major histocompatibility complex, class I, A 
1B55_HUMAN,  major histocompatibility complex, class I, C; major histocompatibility complex, class I, 
B 
1C06_HUMAN major histocompatibility complex, class I, C; major histocompatibility complex, class I, 
B 
5NTD_HUMAN 5'-nucleotidase, ecto (CD73) 
A4_HUMAN amyloid beta (A4) precursor protein 
AAAT_HUMAN solute carrier family 1 (neutral amino acid transporter), member 5 
ACSL4_HUMAN acyl-CoA synthetase long-chain family member 4 
ADAM9_HUMAN ADAM metallopeptidase domain 9 (meltrin gamma) 
AIP_HUMAN aryl hydrocarbon receptor interacting protein 
ANKH_HUMAN ankylosis, progressive homolog (mouse) 
ANPRC_HUMAN natriuretic peptide receptor C/guanylate cyclase C (atrionatriuretic peptide receptor C) 
APOE_HUMAN hypothetical LOC100129500; apolipoprotein E 
ARF6_HUMAN ADP-ribosylation factor 6 
ARL1_HUMAN ADP-ribosylation factor-like 1 
ARSA_HUMAN arylsulfatase A 
AT12A_HUMAN ATPase, H+/K+ transporting, nongastric, alpha polypeptide 
AT1A1_HUMAN ATPase, Na+/K+ transporting, alpha 1 polypeptide 
AT1A2_HUMAN ATPase, Na+/K+ transporting, alpha 2 (+) polypeptide 
AT1B1_HUMAN ATPase, Na+/K+ transporting, beta 1 polypeptide 
AT2A1_HUMAN ATPase, Ca++ transporting, cardiac muscle, fast twitch 1 
AT2B1_HUMAN ATPase, Ca++ transporting, plasma membrane 1 
AT2B4_HUMAN ATPase, Ca++ transporting, plasma membrane 4 
CADH2_HUMAN cadherin 2, type 1, N-cadherin (neuronal) 
CAV1_HUMAN caveolin 1, caveolae protein, 22kDa 
CAV2_HUMAN caveolin 2 




CD276_HUMAN CD276 molecule 
CD59_HUMAN CD59 molecule, complement regulatory protein 
CD81_HUMAN CD81 molecule 
CD82_HUMAN CD82 molecule 
CDC42_HUMAN cell division cycle 42 (GTP binding protein, 25kDa); cell division cycle 42 pseudogene 2 
CERU_HUMAN ceruloplasmin (ferroxidase) 
CKAP4_HUMAN cytoskeleton-associated protein 4 
CLN3_HUMAN ceroid-lipofuscinosis, neuronal 3 
CNN2_HUMAN calponin 2 
COMT_HUMAN catechol-O-methyltransferase 
CPT1A_HUMAN carnitine palmitoyltransferase 1A (liver) 
CTNA1_HUMAN catenin (cadherin-associated protein), alpha 1, 102kDa 
CTNA2_HUMAN catenin (cadherin-associated protein), alpha 2 
CTNB1_HUMAN catenin (cadherin-associated protein), beta 1, 88kDa 
CTND1_HUMAN catenin (cadherin-associated protein), delta 1 
CTR1_HUMAN solute carrier family 7 (cationic amino acid transporter, y+ system), member 1 
CXAR_HUMAN coxsackie virus and adenovirus receptor 
CYB5B_HUMAN cytochrome b5 type B (outer mitochondrial membrane) 
DAF_HUMAN CD55 molecule, decay accelerating factor for complement (Cromer blood group) 
DD19A_HUMAN DEAD (Asp-Glu-Ala-As) box polypeptide 19A 
DIAP1_HUMAN diaphanous homolog 1 (Drosophila) 
DLG1_HUMAN discs, large homolog 1 (Drosophila) 
DP13A_HUMAN adaptor protein, phosphotyrosine interaction, PH domain and leucine zipper containing 1 
DPM1_HUMAN dolichyl-phosphate mannosyltransferase polypeptide 1, catalytic subunit 
DSG2_HUMAN desmoglein 2 
DYN2_HUMAN dynamin 2 
ECE1_HUMAN endothelin converting enzyme 1 
EGLN_HUMAN endoglin 
EHD2_HUMAN EH-domain containing 2 
EPCR_HUMAN protein C receptor, endothelial (EPCR) 
EPHA2_HUMAN EPH receptor A2 
EPHB2_HUMAN EPH receptor B2 
ERG7_HUMAN lanosterol synthase (2,3-oxidosqualene-lanosterol cyclase) 
ERO1A_HUMAN ERO1-like (S. cerevisiae) 
FACE1_HUMAN zinc metallopeptidase (STE24 homolog, S. cerevisiae) 
FERM2_HUMAN fermitin family homolog 2 (Drosophila) 
FLOT1_HUMAN flotillin 1 
FLOT2_HUMAN flotillin 2 
FOLR1_HUMAN folate receptor 1 (adult) 
GBB1_HUMAN guanine nucleotide binding protein (G protein), beta polypeptide 1 
GBG10_HUMAN DnaJ (Hsp40) homolog, subfamily C 
GBG12_HUMAN guanine nucleotide binding protein (G protein), gamma 12 
GIPC1_HUMAN GIPC PDZ domain containing family, member 1 
GNA11_HUMAN guanine nucleotide binding protein (G protein), alpha 11 (Gq class) 




GNAI3_HUMAN guanine nucleotide binding protein (G protein), alpha inhibiting activity polypeptide 3 
GNAQ_HUMAN guanine nucleotide binding protein (G protein), q polypeptide 
GNAS2_HUMAN GNAS complex locus 
GPR56_HUMAN G protein-coupled receptor 56 
GTR1_HUMAN solute carrier family 2 (facilitated glucose transporter), member 1 
HGS_HUMAN hepatocyte growth factor-regulated tyrosine kinase substrate 
HMOX1_HUMAN heme oxygenase (decycling) 1 
HMOX2_HUMAN heme oxygenase (decycling) 2 
HYEP_HUMAN epoxide hydrolase 1, microsomal (xenobiotic) 
IGHG2_HUMAN immunoglobulin heavy constant gamma 2 (G2m marker) 
IGHG4_HUMAN immunoglobulin heavy constant gamma 4 (G4m marker) 
IL6RB_HUMAN interleukin 6 signal transducer (gp130, oncostatin M receptor) 
ILK_HUMAN integrin-linked kinase 
ITA1_HUMAN integrin, alpha 1 
ITA2_HUMAN integrin, alpha 2 (CD49B, alpha 2 subunit of VLA-2 receptor) 
ITA3_HUMAN integrin, alpha 3 (antigen CD49C, alpha 3 subunit of VLA-3 receptor) 
ITA5_HUMAN integrin, alpha 5 (fibronectin receptor, alpha polypeptide) 
ITA6_HUMAN integrin, alpha 6 
ITB1_HUMAN integrin, beta 1 (fibronectin receptor, beta polypeptide= 
ITB4_HUMAN integrin, beta 4 
ITB5_HUMAN integrin, beta 5 
KAP2_HUMAN protein kinase, cAMP-dependent, regulatory, type II, alpha 
KPCA_HUMAN protein kinase C, alpha 
L1CAM_HUMAN L1 cell adhesion molecule 
LAMP1_HUMAN lysosomal-associated membrane protein 1 
LAMP2_HUMAN lysosomal-associated membrane protein 2 
LAP2_HUMAN erbb2 interacting protein 
LCAP_HUMAN leucyl/cystinyl aminopeptidase 
LFA3_HUMAN CD58 molecule 
LIMA1_HUMAN LIM domain and actin binding 1 
LIN7C_HUMAN lin-7 homolog C (C. elegans) 
LIS1_HUMAN platelet-activating factor acetylhydrolase, isoform Ib, subunit 1 (45kDa) 
LMAN1_HUMAN lectin, mannose-binding, 1 
MET_HUMAN met proto-oncogene (hepatocyte growth factor receptor) 
MOT1_HUMAN solute carrier family 16, member 1 (monocarboxylic acid transporter 1) 
MPRI_HUMAN insulin-like growth factor 2 receptor 
MPZL1_HUMAN myelin protein zero-like 1 
MRP1_HUMAN ATP-binding cassette, sub-family C (CFTR/MRP), member 1 
MYO1C_HUMAN myosin IC 
NCEH1_HUMAN arylacetamide deacetylase-like 1 
NCPR_HUMAN P450 (cytochrome) oxidoreductase 
NEXN_HUMAN nexilin (F actin binding protein) 
NHRF1_HUMAN solute carrier family 9 (sodium/hydrogen exchanger), member 3 regulator 1 





NU155_HUMAN nucleoporin 155kDa 
ODO2_HUMAN dihydrolipoamide S-succinyltransferase 
OST48_HUMAN dolichyl-diphosphooligosaccharide-protein glycosyltransferase 
P4K2A_HUMAN phosphatidylinositol 4-kinase type 2 alpha 
PA24A_HUMAN phospholipase A2, group IVA (cytosolic, calcium-dependent) 
PACN3_HUMAN protein kinase C and casein kinase substrate in neurons 3 
PARVA_HUMAN parvin, alpha 
PARVB_HUMAN parvin, beta 
PGRC1_HUMAN progesterone receptor membrane component 1 
PLAK_HUMAN junction plakoglobin 
PLD1_HUMAN phospholipase D1, phosphatidylcholine-specific 
PODXL_HUMAN podocalyxin-like 
PPAL_HUMAN acid phosphatase 2, lysosomal 
PPIF_HUMAN peptidylprolyl isomerase F 
PPT1_HUMAN palmitoyl-protein thioesterase 1 
PTPRJ_HUMAN protein tyrosine phosphatase, receptor type, J 
PVRL2_HUMAN poliovirus receptor-related 2 (herpesvirus entry mediator B) 
RAB14_HUMAN RAB14, member RAS oncogene family 
RAB18_HUMAN RAB18, member RAS oncogene family 
RAB1B_HUMAN RAB1B, member RAS oncogene family 
RAB31_HUMAN RAB31, member RAS oncogene family 
RAB3A_HUMAN RAB3A, member RAS oncogene family 
RAB5A_HUMAN RAB5A, member RAS oncogene family 
RAGP1_HUMAN Ran GTPase activating protein 1 
RALA_HUMAN v-ral simian leukemia viral oncogene homolog A (ras related) 
RAP2A_HUMAN RAP2A, member of RAS oncogene family 
RAP2B_HUMAN RAP2B, member of RAS oncogene family 
RASN_HUMAN neuroblastoma RAS viral (v-ras) oncogene homolog 
RENR_HUMAN ATPase, H+ transporting, lysosomal accessory protein 2 
RHEB_HUMAN Ras homolog enriched in brain 
RHG17_HUMAN Rho GTPase activating protein 17 
RHOB_HUMAN ras homolog gene family, member B 
RHOG_HUMAN ras homolog gene family, member G (rho G) 
RRAS_HUMAN related RAS viral (r-ras) oncogene homolog 
S12A7_HUMAN solute carrier family 12 (potassium/chloride transporters), member 7 
SCRB1_HUMAN scavenger receptor class B, member 1 
SCRB2_HUMAN scavenger receptor class B, member 2 
SCRIB_HUMAN scribbled homolog (Drosophila) 
SEPT2_HUMAN septin 2 
SNAG_HUMAN N-ethylmaleimide-sensitive factor attachment protein, gamma 
SNTB2_HUMAN syntrophin, beta 2 (dystrophin-associated protein A1, 59kDa, basic component 2) 
SPCS2_HUMAN signal peptidase complex subunit 2 homolog 
SPCS3_HUMAN signal peptidase complex subunit 3 homolog (S. cerevisiae) 
SPTA2_HUMAN spectrin, alpha, non-erythrocytic 1 (alpha-fodrin) 




STOM_HUMAN phosphatidylethanolamine binding protein 1 
THY1_HUMAN Thy-1 cell surface antigen 
TMED2_HUMAN transmembrane emp24 domain trafficking protein 2 
TMEDA_HUMAN transmembrane emp24-like trafficking protein 10 (yeast) 
TMX1_HUMAN thioredoxin-related transmembrane protein 1 
TOM22_HUMAN translocase of outer mitochondrial membrane 22 homolog (yeast) 
TOM40_HUMAN translocase of outer mitochondrial membrane 40 homolog (yeast) 
TPBG_HUMAN trophoblast glycoprotein 
TRIP6_HUMAN thyroid hormone receptor interactor 6 
UFO_HUMAN AXL receptor tyrosine kinase 
USO1_HUMAN USO1 homolog, vesicle docking protein (yeast) 
VA0D1_HUMAN ATPase, H+ transporting, lysosomal 38kDa, V0 subunit d1 
VAPA_HUMAN VAMP (vesicle-associated membrane protein)-associated protein A, 33kDa 
VASP_HUMAN vasodilator-stimulated phosphoprotein 
VATB1_HUMAN ATPase, H+ transporting, lysosomal 56/58kDa, V1 subunit B1 
VATF_HUMAN ATPase, H+ transporting, lysosomal 14kDa, V1 subunit F 
VDAC3_HUMAN voltage-dependent anion channel 3 
VPP3_HUMAN T-cell, immune regulator 1, ATPase, H+ transporting, lysosomal V0 subunit A3 
ZO1_HUMAN tight junction protein 1 (zona occludens 1) 
ZYX_HUMAN zyxin 
 
Supplementary Table S5: GOTERM: Mitochondrial envelope + mitochondria. 
Uniprot ID Full protein name 
3HIDH_HUMAN 3-hydroxyisobutyrate dehydrogenase 
ABCB6_HUMAN ATP-binding cassette, sub-family B (MDR/TAP), member 6 
ABCE1_HUMAN similar to ATP-binding cassette, sub-family E 
ABHDA_HUMAN abhydrolase domain containing 10 
ACADM_HUMAN acyl-Coenzyme A dehydrogenase, C-4 to C-12 straight chain 
ACADV_HUMAN acyl-Coenzyme A dehydrogenase, very long chain 
ACO13_HUMAN acyl-CoA thioesterase 13 
ACON_HUMAN aconitase 2, mitochondrial 
ACOT9_HUMAN acyl-CoA thioesterase 9 
ACOX1_HUMAN acyl-Coenzyme A oxidase 1, palmitoyl 
ACPM_HUMAN NADH dehydrogenase (ubiquinone) 1, alpha/beta subcomplex, 1, 8kDa 
ACSL4_HUMAN acyl-CoA synthetase long-chain family member 4 
ADAS_HUMAN alkylglycerone phosphate synthase 
ADT2_HUMAN solute carrier family 25 (mitochondrial carrier; adenine nucleotide translocator), member 
5; solute carrier family 25 (mitochondrial carrier; adenine nucleotide translocator), 
member 5 pseudogene 8 
ADT3_HUMAN solute carrier family 25 (mitochondrial carrier; adenine nucleotide translocator), member 
6 
AIFM2_HUMAN apoptosis-inducing factor, mitochondrion-associated, 2 
AL1B1_HUMAN aldehyde dehydrogenase 1 family, member B1 




ALDH2_HUMAN aldehyde dehydrogenase 2 family (mitochondrial) 
AMPL_HUMAN leucine aminopeptidase 3 
AT5F1_HUMAN ATP synthase, H+ transporting, mitochondrial F0 complex, subunit B1 
ATP5H_HUMAN ATP synthase, H+ transporting, mitochondrial F0 complex, subunit d 
ATP5I_HUMAN ATP synthase, H+ transporting, mitochondrial F0 complex, subunit E 
ATP5J_HUMAN ATP synthase, H+ transporting, mitochondrial F0 complex, subunit F6 
ATP5L_HUMAN ATP synthase, H+ transporting, mitochondrial F0 complex, subunit G 
ATPA_HUMAN ATP synthase, H+ transporting, mitochondrial F1 complex, alpha subunit 1, cardiac 
muscle 
ATPB_HUMAN ATP synthase, H+ transporting, mitochondrial F1 complex, beta polypeptide 
ATPD_HUMAN ATP synthase, H+ transporting, mitochondrial F1 complex, delta subunit 
ATPG_HUMAN ATP synthase, H+ transporting, mitochondrial F1 complex, gamma polypeptide 1 
ATPK_HUMAN ATP synthase, H+ transporting, mitochondrial F0 complex, subunit F2 
ATPO_HUMAN ATP synthase, H+ transporting, mitochondrial F1 complex, O subunit 
B2L13_HUMAN BCL2-like 13 (apoptosis facilitator) 
BAX_HUMAN BCL2-associated X protein 
BCS1_HUMAN BCS1-like (yeast) 
C1QBP_HUMAN complement component 1, q subcomponent binding protein 
C1TM_HUMAN methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 1-like 
CATA_HUMAN catalase 
CB047_HUMAN chromosome 2 open reading frame 47 
CCHL_HUMAN holocytochrome c synthase (cytochrome c heme-lyase) 
CH60_HUMAN heat shock 60kDa protein 1 (chaperonin) pseudogene 5; heat shock 60kDa protein 1 
(chaperonin) pseudogene 6; heat shock 60kDa protein 1 (chaperonin) pseudogene 1; heat 
shock 60kDa protein 1 (chaperonin) pseudogene 4; heat shock 60kDa protein 1 
(chaperonin) 
CHCH3_HUMAN coiled-coil-helix-coiled-coil-helix domain containing 3 
CISD1_HUMAN CDGSH iron sulfur domain 1 
CISY_HUMAN citrate synthase 
CLPP_HUMAN ClpP caseinolytic peptidase, ATP-dependent, proteolytic subunit homolog (E. coli) 
CLPX_HUMAN ClpX caseinolytic peptidase X homolog (E. coli) 
CMC1_HUMAN solute carrier family 25 (mitochondrial carrier, Aralar), member 12 
CMC2_HUMAN solute carrier family 25, member 13 (citrin) 
COX2_HUMAN Cytochrome c oxidase subunit 2 
COX41_HUMAN cytochrome c oxidase subunit IV isoform 1 
COX5A_HUMAN cytochrome c oxidase subunit Va 
CPSM_HUMAN carbamoyl-phosphate synthetase 1, mitochondrial 
CPT1A_HUMAN carnitine palmitoyltransferase 1A (liver) 
CPT2_HUMAN carnitine palmitoyltransferase 2 
CX4NB_HUMAN COX4 neighbor 
CX7A2_HUMAN cytochrome c oxidase subunit VIIa polypeptide 2 (liver) 
CYB5B_HUMAN cytochrome b5 type B (outer mitochondrial membrane) 
DECR_HUMAN 2,4-dienoyl CoA reductase 1, mitochondrial 
DHB4_HUMAN hydroxysteroid (17-beta) dehydrogenase 4 




DHRS1_HUMAN dehydrogenase/reductase (SDR family) member 1 
DHSA_HUMAN succinate dehydrogenase complex, subunit A, flavoprotein (Fp) 
DHSB_HUMAN succinate dehydrogenase complex, subunit B, iron sulfur (Ip) 
DIC_HUMAN solute carrier family 25 (mitochondrial carrier; dicarboxylate transporter), member 10 
DJC11_HUMAN DnaJ (Hsp40) homolog, subfamily C, member 11 
DNJA3_HUMAN DnaJ (Hsp40) homolog, subfamily A, member 3 
DPYL2_HUMAN dihydropyrimidinase-like 2 
ECH1_HUMAN enoyl Coenzyme A hydratase 1, peroxisomal 
ECHA_HUMAN hydroxyacyl-Coenzyme A dehydrogenase/3-ketoacyl-Coenzyme A thiolase/enoyl-
Coenzyme A hydratase (trifunctional protein), alpha subunit 
ECHB_HUMAN hydroxyacyl-Coenzyme A dehydrogenase/3-ketoacyl-Coenzyme A thiolase/enoyl-
Coenzyme A hydratase (trifunctional protein), beta subunit 
EFGM_HUMAN G elongation factor, mitochondrial 1 
EFTS_HUMAN Ts translation elongation factor, mitochondrial 
EFTU_HUMAN Tu translation elongation factor, mitochondrial 
ES1_HUMAN chromosome 21 open reading frame 33 
ETFA_HUMAN electron-transfer-flavoprotein, alpha polypeptide 
ETFB_HUMAN electron-transfer-flavoprotein, beta polypeptide 
ETHE1_HUMAN ethylmalonic encephalopathy 1 
FAHD1_HUMAN fumarylacetoacetate hydrolase domain containing 1 
FIS1_HUMAN fission 1 (mitochondrial outer membrane) homolog (S. cerevisiae) 
FUMH_HUMAN fumarate hydratase 
GHC1_HUMAN solute carrier family 25 (mitochondrial carrier: glutamate), member 22 
GLSK_HUMAN glutaminase 
GLYM_HUMAN serine hydroxymethyltransferase 2 (mitochondrial) 
GOLP3_HUMAN golgi phosphoprotein 3 (coat-protein) 
GPDM_HUMAN glycerol-3-phosphate dehydrogenase 2 (mitochondrial) 
GRPE1_HUMAN GrpE-like 1, mitochondrial (E. coli) 
GSTK1_HUMAN glutathione S-transferase kappa 1 
HCD2_HUMAN hydroxysteroid (17-beta) dehydrogenase 10 
HCDH_HUMAN hydroxyacyl-Coenzyme A dehydrogenase 
HINT2_HUMAN histidine triad nucleotide binding protein 2 
HMGCL_HUMAN 3-hydroxymethyl-3-methylglutaryl-Coenzyme A lyase 
HSDL2_HUMAN hydroxysteroid dehydrogenase like 2 
IDH3A_HUMAN isocitrate dehydrogenase 3 (NAD+) alpha 
IDH3G_HUMAN isocitrate dehydrogenase 3 (NAD+) gamma 
IMMT_HUMAN inner membrane protein, mitochondrial (mitofilin) 
IPYR2_HUMAN pyrophosphatase (inorganic) 2 
ISOC2_HUMAN isochorismatase domain containing 2 
IVD_HUMAN isovaleryl Coenzyme A dehydrogenase 
KAD2_HUMAN adenylate kinase 2 
KAD3_HUMAN adenylate kinase 3 
LETM1_HUMAN leucine zipper-EF-hand containing transmembrane protein 1 
LPPRC_HUMAN leucine-rich PPR-motif containing 




M2OM_HUMAN solute carrier family 25 (mitochondrial carrier; oxoglutarate carrier), member 11 
MCCB_HUMAN methylcrotonoyl-Coenzyme A carboxylase 2 (beta) 
MDHM_HUMAN malate dehydrogenase 2, NAD (mitochondrial) 
MECR_HUMAN mitochondrial trans-2-enoyl-CoA reductase 
MFF_HUMAN mitochondrial fission factor 
MPCP_HUMAN solute carrier family 25 (mitochondrial carrier; phosphate carrier), member 3 
MPPA_HUMAN peptidase (mitochondrial processing) alpha 
MPPB_HUMAN peptidase (mitochondrial processing) beta 
MTCH2_HUMAN mitochondrial carrier homolog 2 (C. elegans) 
MTDC_HUMAN methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 2, 
methenyltetrahydrofolate cyclohydrolase 
MTX1_HUMAN metaxin 1 
MTX2_HUMAN metaxin 2 
NB5R3_HUMAN cytochrome b5 reductase 3 
NDUA2_HUMAN NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 2, 8kDa 
NDUA4_HUMAN NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 4, 9kDa 
NDUA5_HUMAN NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 5, 13kDa 
NDUAA_HUMAN NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 10, 42kDa 
NDUAB_HUMAN NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 11, 14.7kDa 
NDUAD_HUMAN NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 13 
NDUB3_HUMAN NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 3, 12kDa 
NDUBA_HUMAN NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 10, 22kDa 
NDUF3_HUMAN NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, assembly factor 3 
NDUS1_HUMAN NADH dehydrogenase (ubiquinone) Fe-S protein 1, 75kDa (NADH-coenzyme Q 
reductase) 
NDUS2_HUMAN NADH dehydrogenase (ubiquinone) Fe-S protein 2, 49kDa (NADH-coenzyme Q 
reductase) 
NDUS3_HUMAN NADH dehydrogenase (ubiquinone) Fe-S protein 3, 30kDa (NADH-coenzyme Q 
reductase) 
NDUS8_HUMAN NADH dehydrogenase (ubiquinone) Fe-S protein 8, 23kDa (NADH-coenzyme Q 
reductase) 
NDUV1_HUMAN NADH dehydrogenase (ubiquinone) flavoprotein 1, 51kDa 
NDUV2_HUMAN NADH dehydrogenase (ubiquinone) flavoprotein 2, 24kDa 
NEUL_HUMAN neurolysin (metallopeptidase M3 family) 
NFU1_HUMAN NFU1 iron-sulfur cluster scaffold homolog (S. cerevisiae) 
NIPS1_HUMAN nipsnap homolog 1 (C. elegans) 
NLTP_HUMAN sterol carrier protein 2 
NNTM_HUMAN nicotinamide nucleotide transhydrogenase 
OAT_HUMAN ornithine aminotransferase (gyrate atrophy) 
ODB2_HUMAN dihydrolipoamide branched chain transacylase E2 
ODBB_HUMAN branched chain keto acid dehydrogenase E1, beta polypeptide 
ODO1_HUMAN oxoglutarate (alpha-ketoglutarate) dehydrogenase (lipoamide) 
ODP2_HUMAN dihydrolipoamide S-acetyltransferase 
ODPA_HUMAN pyruvate dehydrogenase (lipoamide) alpha 1 




OPA1_HUMAN optic atrophy 1 (autosomal dominant) 
P4HA1_HUMAN prolyl 4-hydroxylase, alpha polypeptide I 
P5CR1_HUMAN pyrroline-5-carboxylate reductase 1 
P5CR1_HUMAN sirtuin (silent mating type information regulation 2 homolog) 7 (S. cerevisiae) 
P5CS_HUMAN aldehyde dehydrogenase 18 family, member A1 
PCKGM_HUMAN phosphoenolpyruvate carboxykinase 2 (mitochondrial) 
PDIP2_HUMAN polymerase (DNA-directed), delta interacting protein 2 
PGES2_HUMAN prostaglandin E synthase 2 
PHB_HUMAN prohibitin 
PHB2_HUMAN prohibitin 2 
PNPT1_HUMAN polyribonucleotide nucleotidyltransferase 1 
PP1G_HUMAN protein phosphatase 1, catalytic subunit, gamma isoform 
PPIF_HUMAN peptidylprolyl isomerase F 
PRDX3_HUMAN peroxiredoxin 3 
PRDX4_HUMAN peroxiredoxin 4 
PRS6B_HUMAN similar to 26S protease regulatory subunit 6B  
PTCD3_HUMAN Pentatricopeptide repeat domain 3 
PTH2_HUMAN peptidyl-tRNA hydrolase 2 
PYC_HUMAN pyruvate carboxylase 
QCR1_HUMAN ubiquinol-cytochrome c reductase core protein I 
QCR2_HUMAN ubiquinol-cytochrome c reductase core protein II 
QCR7_HUMAN similar to ubiquinol-cytochrome c reductase binding protein; ubiquinol-cytochrome c 
reductase binding protein pseudogene; ubiquinol-cytochrome c reductase binding protein 
RAB32_HUMAN RAB32, member RAS oncogene family 
RM12_HUMAN mitochondrial ribosomal protein L12 
RM19_HUMAN mitochondrial ribosomal protein L19 
RM37_HUMAN mitochondrial ribosomal protein L37 
RM39_HUMAN mitochondrial ribosomal protein L39 
RM44_HUMAN mitochondrial ribosomal protein L44 
RM46_HUMAN mitochondrial ribosomal protein L46 
RM49_HUMAN mitochondrial ribosomal protein L49 
RMD3_HUMAN family with sequence similarity 82, member A2 
RRFM_HUMAN mitochondrial ribosome recycling factor 
RT10_HUMAN mitochondrial ribosomal protein S10 
RT22_HUMAN mitochondrial ribosomal protein S22 
RT23_HUMAN mitochondrial ribosomal protein S23 
RT27_HUMAN mitochondrial ribosomal protein S27 
RT28_HUMAN mitochondrial ribosomal protein S28 
RT29_HUMAN death associated protein 3 
SCMC1_HUMAN solute carrier family 25 (mitochondrial carrier; phosphate carrier), member 24 
SCOT1_HUMAN 3-oxoacid CoA transferase 1 
SDHF2_HUMAN chromosome 11 open reading frame 79 
SFXN3_HUMAN sideroflexin 3 
SLIRP_HUMAN chromosome 14 open reading frame 156 




SSBP_HUMAN single-stranded DNA binding protein 1 
STML2_HUMAN stomatin (EPB72)-like 2 
STOM_HUMAN phosphatidylethanolamine binding protein 1 
SUCB1_HUMAN succinate-CoA ligase, ADP-forming, beta subunit 
SUCB2_HUMAN similar to sucb; succinate-CoA ligase, GDP-forming, beta subunit 
SYDM_HUMAN aspartyl-tRNA synthetase 2, mitochondrial 
SYJ2B_HUMAN synaptojanin 2 binding protein 
SYLM_HUMAN leucyl-tRNA synthetase 2, mitochondrial 
SYTM_HUMAN threonyl-tRNA synthetase 2, mitochondrial (putative) 
THIL_HUMAN acetyl-Coenzyme A acetyltransferase 1 
THIM_HUMAN hypothetical LOC648603; acetyl-Coenzyme A acyltransferase 2 
TIM44_HUMAN translocase of inner mitochondrial membrane 44 homolog (yeast) 
TIM50_HUMAN translocase of inner mitochondrial membrane 50 homolog (S. cerevisiae) 
TOM22_HUMAN translocase of outer mitochondrial membrane 22 homolog (yeast) 
TOM40_HUMAN translocase of outer mitochondrial membrane 40 homolog (yeast) 
TOM70_HUMAN translocase of outer mitochondrial membrane 70 homolog A (S. cerevisiae) 
TRAP1_HUMAN TNF receptor-associated protein 1 
TXTP_HUMAN solute carrier family 25 (mitochondrial carrier; citrate transporter), member 1 
UCRI_HUMAN ubiquinol-cytochrome c reductase, Rieske iron-sulfur polypeptide-like 1; ubiquinol-
cytochrome c reductase, Rieske iron-sulfur polypeptide 1 
USMG5_HUMAN up-regulated during skeletal muscle growth 5 homolog (mouse) 
VATA_HUMAN ATPase, H+ transporting, lysosomal 70kDa, V1 subunit A 
VATE1_HUMAN ATPase, H+ transporting, lysosomal 31kDa, V1 subunit E1 
VDAC1_HUMAN voltage-dependent anion channel 1; similar to voltage-dependent anion channel 1 
VDAC2_HUMAN voltage-dependent anion channel 2 
VDAC3_HUMAN voltage-dependent anion channel 3 
 
Supplementary Table S6: DAVID ontology analysis of the remaining proteins that have been identified. 
 Enrichment Score: 3.53 Count 
Annotation Cluster 1   
 GOTERM_CC_FAT cytoskeletal part 21 
 GOTERM_CC_FAT cytoskeleton 26 
 GOTERM_CC_FAT actin cytoskeleton 11 
 GOTERM_CC_FAT non-membrane-bounded organelle 32 
 GOTERM_CC_FAT intracellular non-membrane-bounded organelle 32 
Annotation Cluster 2 Enrichment Score: 2.12  
 GOTERM_CC_FAT nuclear pore 6 
 GOTERM_CC_FAT pore complex 6 
 GOTERM_CC_FAT endomembrane system 16 
 GOTERM_CC_FAT nuclear envelope 7 
 GOTERM_CC_FAT organelle envelope 7 
 GOTERM_CC_FAT envelope 7 
Annotation Cluster 3 Enrichment Score: 1.81  
 GOTERM_CC_FAT endomembrane system 16 




 GOTERM_CC_FAT endoplasmic reticulum membrane 7 
 GOTERM_CC_FAT nuclear envelope-endoplasmic reticulum network 7 
 GOTERM_CC_FAT endoplasmic reticulum part 7 
 GOTERM_CC_FAT organelle membrane 9 
Annotation Cluster 4 Enrichment Score: 1.77  
 GOTERM_CC_FAT microtubule cytoskeleton 12 
 GOTERM_CC_FAT centrosome 6 
 GOTERM_CC_FAT microtubule organizing center 6 
Annotation Cluster 5 Enrichment Score: 1.34  
 GOTERM_CC_FAT keratin filament 4 
 GOTERM_CC_FAT intermediate filament 5 
 GOTERM_CC_FAT intermediate filament cytoskeleton 5 
Annotation Cluster 6 Enrichment Score: 1.32  
 GOTERM_CC_FAT ribonucleoprotein complex 10 
 GOTERM_CC_FAT cytosolic ribosome 4 
 GOTERM_CC_FAT cytosolic part 5 
 GOTERM_CC_FAT ribosomal subunit 4 
 GOTERM_CC_FAT ribosome 4 
Annotation Cluster 7 Enrichment Score: 1.16  
 GOTERM_CC_FAT dynein complex 3 
 GOTERM_CC_FAT microtubule 6 
 GOTERM_CC_FAT microtubule associated complex 3 
Annotation Cluster 8 Enrichment Score: 0.52  
 GOTERM_CC_FAT kinetochore 3 
 GOTERM_CC_FAT chromosome, centromeric region 3 
 GOTERM_CC_FAT chromosome 5 
 GOTERM_CC_FAT chromosomal part 4 
 
